id	sid	tid	token	lemma	pos
ajlm-1677	1	1	abstract	abstract	ADJ
ajlm-1677	1	2	introduction	introduction	NOUN
ajlm-1677	1	3	methods	method	NOUN
ajlm-1677	1	4	results	result	VERB
ajlm-1677	1	5	discussion	discussion	NOUN
ajlm-1677	1	6	acknowledgements	acknowledgement	NOUN
ajlm-1677	1	7	references	reference	NOUN
ajlm-1677	1	8	about	about	ADP
ajlm-1677	1	9	the	the	DET
ajlm-1677	1	10	author(s	author(s	PROPN
ajlm-1677	1	11	)	)	PUNCT
ajlm-1677	1	12	joseph	joseph	PROPN
ajlm-1677	1	13	anejo	anejo	PROPN
ajlm-1677	1	14	-	-	PUNCT
ajlm-1677	1	15	okopi	okopi	PROPN
ajlm-1677	1	16	department	department	PROPN
ajlm-1677	1	17	of	of	ADP
ajlm-1677	1	18	microbiology	microbiology	NOUN
ajlm-1677	1	19	,	,	PUNCT
ajlm-1677	1	20	university	university	NOUN
ajlm-1677	1	21	of	of	ADP
ajlm-1677	1	22	jos	jos	PROPN
ajlm-1677	1	23	,	,	PUNCT
ajlm-1677	1	24	jos	jos	PROPN
ajlm-1677	1	25	,	,	PUNCT
ajlm-1677	1	26	nigeria	nigeria	PROPN
ajlm-1677	1	27	aids	aids	PROPN
ajlm-1677	1	28	prevention	prevention	PROPN
ajlm-1677	1	29	initiative	initiative	NOUN
ajlm-1677	1	30	in	in	ADP
ajlm-1677	1	31	nigeria	nigeria	PROPN
ajlm-1677	1	32	,	,	PUNCT
ajlm-1677	1	33	jos	jos	PROPN
ajlm-1677	1	34	university	university	PROPN
ajlm-1677	1	35	teaching	teaching	NOUN
ajlm-1677	1	36	hospital	hospital	NOUN
ajlm-1677	1	37	,	,	PUNCT
ajlm-1677	1	38	jos	jos	PROPN
ajlm-1677	1	39	,	,	PUNCT
ajlm-1677	1	40	nigeria	nigeria	PROPN
ajlm-1677	1	41	edith	edith	PROPN
ajlm-1677	1	42	okeke	okeke	PROPN
ajlm-1677	1	43	department	department	PROPN
ajlm-1677	1	44	of	of	ADP
ajlm-1677	1	45	internal	internal	ADJ
ajlm-1677	1	46	medicine	medicine	NOUN
ajlm-1677	1	47	,	,	PUNCT
ajlm-1677	1	48	university	university	NOUN
ajlm-1677	1	49	of	of	ADP
ajlm-1677	1	50	jos	jos	PROPN
ajlm-1677	1	51	,	,	PUNCT
ajlm-1677	1	52	jos	jos	PROPN
ajlm-1677	1	53	university	university	PROPN
ajlm-1677	1	54	teaching	teaching	NOUN
ajlm-1677	1	55	hospital	hospital	NOUN
ajlm-1677	1	56	,	,	PUNCT
ajlm-1677	1	57	jos	jos	PROPN
ajlm-1677	1	58	,	,	PUNCT
ajlm-1677	1	59	nigeria	nigeria	PROPN
ajlm-1677	1	60	pantong	pantong	VERB
ajlm-1677	1	61	m.	m.	NOUN
ajlm-1677	1	62	davwar	davwar	PROPN
ajlm-1677	1	63	department	department	PROPN
ajlm-1677	1	64	of	of	ADP
ajlm-1677	1	65	internal	internal	ADJ
ajlm-1677	1	66	medicine	medicine	NOUN
ajlm-1677	1	67	,	,	PUNCT
ajlm-1677	1	68	university	university	NOUN
ajlm-1677	1	69	of	of	ADP
ajlm-1677	1	70	jos	jos	PROPN
ajlm-1677	1	71	,	,	PUNCT
ajlm-1677	1	72	jos	jos	PROPN
ajlm-1677	1	73	university	university	PROPN
ajlm-1677	1	74	teaching	teaching	NOUN
ajlm-1677	1	75	hospital	hospital	NOUN
ajlm-1677	1	76	,	,	PUNCT
ajlm-1677	1	77	jos	jos	PROPN
ajlm-1677	1	78	,	,	PUNCT
ajlm-1677	1	79	nigeria	nigeria	PROPN
ajlm-1677	1	80	chika	chika	PROPN
ajlm-1677	1	81	onwuamah	onwuamah	PROPN
ajlm-1677	1	82	center	center	PROPN
ajlm-1677	1	83	for	for	ADP
ajlm-1677	1	84	human	human	ADJ
ajlm-1677	1	85	virology	virology	NOUN
ajlm-1677	1	86	and	and	CCONJ
ajlm-1677	1	87	genomics	genomics	PROPN
ajlm-1677	1	88	nigeria	nigeria	PROPN
ajlm-1677	1	89	institute	institute	PROPN
ajlm-1677	1	90	of	of	ADP
ajlm-1677	1	91	medical	medical	ADJ
ajlm-1677	1	92	research	research	NOUN
ajlm-1677	1	93	,	,	PUNCT
ajlm-1677	1	94	lagos	lagos	PROPN
ajlm-1677	1	95	,	,	PUNCT
ajlm-1677	1	96	nigeria	nigeria	PROPN
ajlm-1677	1	97	harris	harris	PROPN
ajlm-1677	1	98	onywera	onywera	PROPN
ajlm-1677	1	99	institute	institute	PROPN
ajlm-1677	1	100	of	of	ADP
ajlm-1677	1	101	infectious	infectious	ADJ
ajlm-1677	1	102	disease	disease	NOUN
ajlm-1677	1	103	and	and	CCONJ
ajlm-1677	1	104	molecular	molecular	ADJ
ajlm-1677	1	105	medicine	medicine	NOUN
ajlm-1677	1	106	,	,	PUNCT
ajlm-1677	1	107	university	university	NOUN
ajlm-1677	1	108	of	of	ADP
ajlm-1677	1	109	cape	cape	PROPN
ajlm-1677	1	110	town	town	NOUN
ajlm-1677	1	111	,	,	PUNCT
ajlm-1677	1	112	cape	cape	NOUN
ajlm-1677	1	113	town	town	NOUN
ajlm-1677	1	114	,	,	PUNCT
ajlm-1677	1	115	south	south	PROPN
ajlm-1677	1	116	africa	africa	PROPN
ajlm-1677	1	117	division	division	NOUN
ajlm-1677	1	118	of	of	ADP
ajlm-1677	1	119	medical	medical	ADJ
ajlm-1677	1	120	virology	virology	NOUN
ajlm-1677	1	121	,	,	PUNCT
ajlm-1677	1	122	department	department	NOUN
ajlm-1677	1	123	of	of	ADP
ajlm-1677	1	124	pathology	pathology	PROPN
ajlm-1677	1	125	,	,	PUNCT
ajlm-1677	1	126	university	university	PROPN
ajlm-1677	1	127	of	of	ADP
ajlm-1677	1	128	cape	cape	PROPN
ajlm-1677	1	129	town	town	NOUN
ajlm-1677	1	130	,	,	PUNCT
ajlm-1677	1	131	cape	cape	NOUN
ajlm-1677	1	132	town	town	NOUN
ajlm-1677	1	133	,	,	PUNCT
ajlm-1677	1	134	south	south	PROPN
ajlm-1677	1	135	africa	africa	PROPN
ajlm-1677	1	136	research	research	PROPN
ajlm-1677	1	137	,	,	PUNCT
ajlm-1677	1	138	innovations	innovation	NOUN
ajlm-1677	1	139	,	,	PUNCT
ajlm-1677	1	140	and	and	CCONJ
ajlm-1677	1	141	academics	academic	NOUN
ajlm-1677	1	142	unit	unit	NOUN
ajlm-1677	1	143	,	,	PUNCT
ajlm-1677	1	144	tunacare	tunacare	NOUN
ajlm-1677	1	145	services	service	NOUN
ajlm-1677	1	146	health	health	NOUN
ajlm-1677	1	147	providers	provider	NOUN
ajlm-1677	1	148	limited	limit	VERB
ajlm-1677	1	149	,	,	PUNCT
ajlm-1677	1	150	nairobi	nairobi	PROPN
ajlm-1677	1	151	,	,	PUNCT
ajlm-1677	1	152	kenya	kenya	PROPN
ajlm-1677	1	153	patience	patience	PROPN
ajlm-1677	1	154	omaiye	omaiye	VERB
ajlm-1677	1	155	department	department	PROPN
ajlm-1677	1	156	of	of	ADP
ajlm-1677	1	157	internal	internal	ADJ
ajlm-1677	1	158	medicine	medicine	NOUN
ajlm-1677	1	159	,	,	PUNCT
ajlm-1677	1	160	university	university	NOUN
ajlm-1677	1	161	of	of	ADP
ajlm-1677	1	162	jos	jos	PROPN
ajlm-1677	1	163	,	,	PUNCT
ajlm-1677	1	164	jos	jos	PROPN
ajlm-1677	1	165	university	university	PROPN
ajlm-1677	1	166	teaching	teaching	NOUN
ajlm-1677	1	167	hospital	hospital	NOUN
ajlm-1677	1	168	,	,	PUNCT
ajlm-1677	1	169	jos	jos	PROPN
ajlm-1677	1	170	,	,	PUNCT
ajlm-1677	1	171	nigeria	nigeria	PROPN
ajlm-1677	1	172	mary	mary	PROPN
ajlm-1677	1	173	duguru	duguru	PROPN
ajlm-1677	1	174	department	department	PROPN
ajlm-1677	1	175	of	of	ADP
ajlm-1677	1	176	internal	internal	ADJ
ajlm-1677	1	177	medicine	medicine	NOUN
ajlm-1677	1	178	,	,	PUNCT
ajlm-1677	1	179	university	university	NOUN
ajlm-1677	1	180	of	of	ADP
ajlm-1677	1	181	jos	jos	PROPN
ajlm-1677	1	182	,	,	PUNCT
ajlm-1677	1	183	jos	jos	PROPN
ajlm-1677	1	184	university	university	PROPN
ajlm-1677	1	185	teaching	teaching	NOUN
ajlm-1677	1	186	hospital	hospital	NOUN
ajlm-1677	1	187	,	,	PUNCT
ajlm-1677	1	188	jos	jos	PROPN
ajlm-1677	1	189	,	,	PUNCT
ajlm-1677	1	190	nigeria	nigeria	PROPN
ajlm-1677	1	191	ocheme	ocheme	PROPN
ajlm-1677	1	192	j.	j.	PROPN
ajlm-1677	1	193	okojokwu	okojokwu	PROPN
ajlm-1677	1	194	department	department	PROPN
ajlm-1677	1	195	of	of	ADP
ajlm-1677	1	196	microbiology	microbiology	NOUN
ajlm-1677	1	197	,	,	PUNCT
ajlm-1677	1	198	university	university	NOUN
ajlm-1677	1	199	of	of	ADP
ajlm-1677	1	200	jos	jos	PROPN
ajlm-1677	1	201	,	,	PUNCT
ajlm-1677	1	202	jos	jos	PROPN
ajlm-1677	1	203	,	,	PUNCT
ajlm-1677	1	204	nigeria	nigeria	PROPN
ajlm-1677	1	205	otobo	otobo	PROPN
ajlm-1677	1	206	i.	i.	PROPN
ajlm-1677	1	207	ujah	ujah	PROPN
ajlm-1677	1	208	department	department	PROPN
ajlm-1677	1	209	of	of	ADP
ajlm-1677	1	210	community	community	NOUN
ajlm-1677	1	211	and	and	CCONJ
ajlm-1677	1	212	family	family	NOUN
ajlm-1677	1	213	health	health	NOUN
ajlm-1677	1	214	,	,	PUNCT
ajlm-1677	1	215	college	college	NOUN
ajlm-1677	1	216	of	of	ADP
ajlm-1677	1	217	public	public	ADJ
ajlm-1677	1	218	health	health	NOUN
ajlm-1677	1	219	,	,	PUNCT
ajlm-1677	1	220	university	university	NOUN
ajlm-1677	1	221	of	of	ADP
ajlm-1677	1	222	south	south	PROPN
ajlm-1677	1	223	florida	florida	PROPN
ajlm-1677	1	224	,	,	PUNCT
ajlm-1677	1	225	tampa	tampa	PROPN
ajlm-1677	1	226	,	,	PUNCT
ajlm-1677	1	227	florida	florida	PROPN
ajlm-1677	1	228	,	,	PUNCT
ajlm-1677	1	229	united	united	PROPN
ajlm-1677	1	230	states	states	PROPN
ajlm-1677	1	231	bulus	bulus	PROPN
ajlm-1677	1	232	jonathan	jonathan	PROPN
ajlm-1677	1	233	department	department	PROPN
ajlm-1677	1	234	of	of	ADP
ajlm-1677	1	235	family	family	NOUN
ajlm-1677	1	236	medicine	medicine	NOUN
ajlm-1677	1	237	,	,	PUNCT
ajlm-1677	1	238	plateau	plateau	NOUN
ajlm-1677	1	239	state	state	NOUN
ajlm-1677	1	240	specialist	specialist	NOUN
ajlm-1677	1	241	hospital	hospital	NOUN
ajlm-1677	1	242	,	,	PUNCT
ajlm-1677	1	243	jos	jos	PROPN
ajlm-1677	1	244	,	,	PUNCT
ajlm-1677	1	245	nigeria	nigeria	PROPN
ajlm-1677	1	246	chima	chima	PROPN
ajlm-1677	1	247	a.	a.	PROPN
ajlm-1677	1	248	george	george	PROPN
ajlm-1677	1	249	department	department	PROPN
ajlm-1677	1	250	of	of	ADP
ajlm-1677	1	251	family	family	NOUN
ajlm-1677	1	252	medicine	medicine	NOUN
ajlm-1677	1	253	,	,	PUNCT
ajlm-1677	1	254	bingham	bingham	PROPN
ajlm-1677	1	255	university	university	PROPN
ajlm-1677	1	256	teaching	teaching	NOUN
ajlm-1677	1	257	hospital	hospital	NOUN
ajlm-1677	1	258	,	,	PUNCT
ajlm-1677	1	259	jos	jos	PROPN
ajlm-1677	1	260	,	,	PUNCT
ajlm-1677	1	261	nigeria	nigeria	PROPN
ajlm-1677	1	262	ramyil	ramyil	VERB
ajlm-1677	1	263	s.	s.	PROPN
ajlm-1677	1	264	crown	crown	PROPN
ajlm-1677	1	265	department	department	PROPN
ajlm-1677	1	266	of	of	ADP
ajlm-1677	1	267	medical	medical	ADJ
ajlm-1677	1	268	microbiology	microbiology	NOUN
ajlm-1677	1	269	and	and	CCONJ
ajlm-1677	1	270	parasitology	parasitology	NOUN
ajlm-1677	1	271	,	,	PUNCT
ajlm-1677	1	272	bingham	bingham	PROPN
ajlm-1677	1	273	university	university	PROPN
ajlm-1677	1	274	teaching	teaching	NOUN
ajlm-1677	1	275	hospital	hospital	NOUN
ajlm-1677	1	276	,	,	PUNCT
ajlm-1677	1	277	jos	jos	PROPN
ajlm-1677	1	278	,	,	PUNCT
ajlm-1677	1	279	nigeria	nigeria	PROPN
ajlm-1677	1	280	fiyaktu	fiyaktu	PROPN
ajlm-1677	1	281	b.	b.	PROPN
ajlm-1677	1	282	yakubu	yakubu	PROPN
ajlm-1677	1	283	department	department	PROPN
ajlm-1677	1	284	of	of	ADP
ajlm-1677	1	285	chemical	chemical	PROPN
ajlm-1677	1	286	pathology	pathology	PROPN
ajlm-1677	1	287	,	,	PUNCT
ajlm-1677	1	288	jos	jos	PROPN
ajlm-1677	1	289	university	university	PROPN
ajlm-1677	1	290	teaching	teaching	NOUN
ajlm-1677	1	291	hospital	hospital	NOUN
ajlm-1677	1	292	,	,	PUNCT
ajlm-1677	1	293	jos	jos	PROPN
ajlm-1677	1	294	,	,	PUNCT
ajlm-1677	1	295	nigeria	nigeria	PROPN
ajlm-1677	1	296	judith	judith	PROPN
ajlm-1677	1	297	o.	o.	PROPN
ajlm-1677	1	298	sokei	sokei	PROPN
ajlm-1677	1	299	center	center	PROPN
ajlm-1677	1	300	for	for	ADP
ajlm-1677	1	301	human	human	ADJ
ajlm-1677	1	302	virology	virology	NOUN
ajlm-1677	1	303	and	and	CCONJ
ajlm-1677	1	304	genomics	genomics	PROPN
ajlm-1677	1	305	nigeria	nigeria	PROPN
ajlm-1677	1	306	institute	institute	PROPN
ajlm-1677	1	307	of	of	ADP
ajlm-1677	1	308	medical	medical	ADJ
ajlm-1677	1	309	research	research	NOUN
ajlm-1677	1	310	,	,	PUNCT
ajlm-1677	1	311	lagos	lagos	PROPN
ajlm-1677	1	312	,	,	PUNCT
ajlm-1677	1	313	nigeria	nigeria	PROPN
ajlm-1677	1	314	leona	leona	PROPN
ajlm-1677	1	315	c.	c.	PROPN
ajlm-1677	1	316	okoli	okoli	PROPN
ajlm-1677	1	317	center	center	PROPN
ajlm-1677	1	318	for	for	ADP
ajlm-1677	1	319	human	human	ADJ
ajlm-1677	1	320	virology	virology	NOUN
ajlm-1677	1	321	and	and	CCONJ
ajlm-1677	1	322	genomics	genomics	PROPN
ajlm-1677	1	323	nigeria	nigeria	PROPN
ajlm-1677	1	324	institute	institute	PROPN
ajlm-1677	1	325	of	of	ADP
ajlm-1677	1	326	medical	medical	ADJ
ajlm-1677	1	327	research	research	NOUN
ajlm-1677	1	328	,	,	PUNCT
ajlm-1677	1	329	lagos	lagos	PROPN
ajlm-1677	1	330	,	,	PUNCT
ajlm-1677	1	331	nigeria	nigeria	PROPN
ajlm-1677	1	332	onyemocho	onyemocho	ADJ
ajlm-1677	1	333	audu	audu	PROPN
ajlm-1677	1	334	department	department	NOUN
ajlm-1677	1	335	of	of	ADP
ajlm-1677	1	336	epidemiology	epidemiology	NOUN
ajlm-1677	1	337	and	and	CCONJ
ajlm-1677	1	338	community	community	NOUN
ajlm-1677	1	339	health	health	NOUN
ajlm-1677	1	340	,	,	PUNCT
ajlm-1677	1	341	benue	benue	VERB
ajlm-1677	1	342	state	state	NOUN
ajlm-1677	1	343	university	university	PROPN
ajlm-1677	1	344	,	,	PUNCT
ajlm-1677	1	345	makurdi	makurdi	PROPN
ajlm-1677	1	346	,	,	PUNCT
ajlm-1677	1	347	nigeria	nigeria	PROPN
ajlm-1677	1	348	seth	seth	PROPN
ajlm-1677	1	349	c.	c.	PROPN
ajlm-1677	1	350	inzaule	inzaule	PROPN
ajlm-1677	1	351	department	department	PROPN
ajlm-1677	1	352	of	of	ADP
ajlm-1677	1	353	hiv	hiv	PROPN
ajlm-1677	1	354	and	and	CCONJ
ajlm-1677	1	355	global	global	ADJ
ajlm-1677	1	356	hepatitis	hepatitis	PROPN
ajlm-1677	1	357	program	program	NOUN
ajlm-1677	1	358	,	,	PUNCT
ajlm-1677	1	359	world	world	NOUN
ajlm-1677	1	360	health	health	NOUN
ajlm-1677	1	361	organization	organization	PROPN
ajlm-1677	1	362	,	,	PUNCT
ajlm-1677	1	363	geneva	geneva	PROPN
ajlm-1677	1	364	,	,	PUNCT
ajlm-1677	1	365	switzerland	switzerland	PROPN
ajlm-1677	1	366	isaac	isaac	PROPN
ajlm-1677	1	367	o.	o.	PROPN
ajlm-1677	1	368	abah	abah	PROPN
ajlm-1677	1	369	department	department	PROPN
ajlm-1677	1	370	of	of	ADP
ajlm-1677	1	371	pharmacology	pharmacology	NOUN
ajlm-1677	1	372	,	,	PUNCT
ajlm-1677	1	373	university	university	PROPN
ajlm-1677	1	374	of	of	ADP
ajlm-1677	1	375	jos	jos	PROPN
ajlm-1677	1	376	,	,	PUNCT
ajlm-1677	1	377	jos	jos	PROPN
ajlm-1677	1	378	university	university	PROPN
ajlm-1677	1	379	teaching	teaching	NOUN
ajlm-1677	1	380	hospital	hospital	NOUN
ajlm-1677	1	381	,	,	PUNCT
ajlm-1677	1	382	jos	jos	PROPN
ajlm-1677	1	383	,	,	PUNCT
ajlm-1677	1	384	nigeria	nigeria	PROPN
ajlm-1677	1	385	patricia	patricia	PROPN
ajlm-1677	1	386	agaba	agaba	PROPN
ajlm-1677	1	387	aids	aids	PROPN
ajlm-1677	1	388	prevention	prevention	PROPN
ajlm-1677	1	389	initiative	initiative	NOUN
ajlm-1677	1	390	in	in	ADP
ajlm-1677	1	391	nigeria	nigeria	PROPN
ajlm-1677	1	392	,	,	PUNCT
ajlm-1677	1	393	jos	jos	PROPN
ajlm-1677	1	394	university	university	PROPN
ajlm-1677	1	395	teaching	teaching	NOUN
ajlm-1677	1	396	hospital	hospital	NOUN
ajlm-1677	1	397	,	,	PUNCT
ajlm-1677	1	398	jos	jos	PROPN
ajlm-1677	1	399	,	,	PUNCT
ajlm-1677	1	400	nigeria	nigeria	PROPN
ajlm-1677	1	401	department	department	PROPN
ajlm-1677	1	402	of	of	ADP
ajlm-1677	1	403	family	family	NOUN
ajlm-1677	1	404	medicine	medicine	NOUN
ajlm-1677	1	405	,	,	PUNCT
ajlm-1677	1	406	university	university	NOUN
ajlm-1677	1	407	of	of	ADP
ajlm-1677	1	408	jos	jos	PROPN
ajlm-1677	1	409	,	,	PUNCT
ajlm-1677	1	410	jos	jos	PROPN
ajlm-1677	1	411	university	university	PROPN
ajlm-1677	1	412	teaching	teaching	NOUN
ajlm-1677	1	413	hospital	hospital	NOUN
ajlm-1677	1	414	,	,	PUNCT
ajlm-1677	1	415	jos	jos	PROPN
ajlm-1677	1	416	,	,	PUNCT
ajlm-1677	1	417	nigeria	nigeria	PROPN
ajlm-1677	2	1	oche	oche	PROPN
ajlm-1677	2	2	o.	o.	PROPN
ajlm-1677	2	3	agbaji	agbaji	PROPN
ajlm-1677	2	4	department	department	PROPN
ajlm-1677	2	5	of	of	ADP
ajlm-1677	2	6	internal	internal	ADJ
ajlm-1677	2	7	medicine	medicine	NOUN
ajlm-1677	2	8	,	,	PUNCT
ajlm-1677	2	9	university	university	NOUN
ajlm-1677	2	10	of	of	ADP
ajlm-1677	2	11	jos	jos	PROPN
ajlm-1677	2	12	,	,	PUNCT
ajlm-1677	2	13	jos	jos	PROPN
ajlm-1677	2	14	university	university	PROPN
ajlm-1677	2	15	teaching	teaching	NOUN
ajlm-1677	2	16	hospital	hospital	NOUN
ajlm-1677	2	17	,	,	PUNCT
ajlm-1677	2	18	jos	jos	PROPN
ajlm-1677	2	19	,	,	PUNCT
ajlm-1677	2	20	nigeria	nigeria	PROPN
ajlm-1677	3	1	atiene	atiene	PROPN
ajlm-1677	3	2	s.	s.	PROPN
ajlm-1677	3	3	sagay	sagay	PROPN
ajlm-1677	3	4	department	department	PROPN
ajlm-1677	3	5	of	of	ADP
ajlm-1677	3	6	obstetrics	obstetric	NOUN
ajlm-1677	3	7	and	and	CCONJ
ajlm-1677	3	8	gynaecology	gynaecology	NOUN
ajlm-1677	3	9	,	,	PUNCT
ajlm-1677	3	10	university	university	NOUN
ajlm-1677	3	11	of	of	ADP
ajlm-1677	3	12	jos	jos	PROPN
ajlm-1677	3	13	,	,	PUNCT
ajlm-1677	3	14	jos	jos	PROPN
ajlm-1677	3	15	university	university	PROPN
ajlm-1677	3	16	teaching	teaching	NOUN
ajlm-1677	3	17	hospital	hospital	NOUN
ajlm-1677	3	18	,	,	PUNCT
ajlm-1677	3	19	jos	jos	PROPN
ajlm-1677	3	20	,	,	PUNCT
ajlm-1677	3	21	nigeria	nigeria	PROPN
ajlm-1677	3	22	claudia	claudia	PROPN
ajlm-1677	3	23	hawkins	hawkins	PROPN
ajlm-1677	3	24	department	department	PROPN
ajlm-1677	3	25	of	of	ADP
ajlm-1677	3	26	medicine	medicine	NOUN
ajlm-1677	3	27	,	,	PUNCT
ajlm-1677	3	28	feinberg	feinberg	PROPN
ajlm-1677	3	29	school	school	PROPN
ajlm-1677	3	30	of	of	ADP
ajlm-1677	3	31	medicine	medicine	NOUN
ajlm-1677	3	32	,	,	PUNCT
ajlm-1677	3	33	northwestern	northwestern	ADJ
ajlm-1677	3	34	university	university	NOUN
ajlm-1677	3	35	,	,	PUNCT
ajlm-1677	3	36	chicago	chicago	PROPN
ajlm-1677	3	37	,	,	PUNCT
ajlm-1677	3	38	illinois	illinois	PROPN
ajlm-1677	3	39	,	,	PUNCT
ajlm-1677	3	40	united	united	PROPN
ajlm-1677	3	41	states	states	PROPN
ajlm-1677	3	42	citation	citation	PROPN
ajlm-1677	3	43	anejo	anejo	PROPN
ajlm-1677	3	44	-	-	PUNCT
ajlm-1677	3	45	okopi	okopi	PROPN
ajlm-1677	3	46	j	j	PROPN
ajlm-1677	3	47	,	,	PUNCT
ajlm-1677	3	48	okeke	okeke	VERB
ajlm-1677	3	49	e	e	NOUN
ajlm-1677	3	50	,	,	PUNCT
ajlm-1677	3	51	davwar	davwar	ADJ
ajlm-1677	3	52	pm	pm	NOUN
ajlm-1677	3	53	,	,	PUNCT
ajlm-1677	3	54	et	et	PROPN
ajlm-1677	3	55	al	al	PROPN
ajlm-1677	3	56	.	.	PUNCT
ajlm-1677	4	1	molecular	molecular	ADJ
ajlm-1677	4	2	detection	detection	NOUN
ajlm-1677	4	3	of	of	ADP
ajlm-1677	4	4	hepatitis	hepatitis	PROPN
ajlm-1677	4	5	b	b	PROPN
ajlm-1677	4	6	virus	virus	NOUN
ajlm-1677	4	7	genotype	genotype	NOUN
ajlm-1677	4	8	e	e	NOUN
ajlm-1677	4	9	with	with	ADP
ajlm-1677	4	10	immune	immune	ADJ
ajlm-1677	4	11	escape	escape	NOUN
ajlm-1677	4	12	mutations	mutation	NOUN
ajlm-1677	4	13	in	in	ADP
ajlm-1677	4	14	chronic	chronic	ADJ
ajlm-1677	4	15	hepatitis	hepatitis	PROPN
ajlm-1677	4	16	b	b	PROPN
ajlm-1677	4	17	patients	patient	NOUN
ajlm-1677	4	18	on	on	ADP
ajlm-1677	4	19	long	long	ADJ
ajlm-1677	4	20	-	-	PUNCT
ajlm-1677	4	21	term	term	NOUN
ajlm-1677	4	22	antiviral	antiviral	ADJ
ajlm-1677	4	23	therapy	therapy	NOUN
ajlm-1677	4	24	in	in	ADP
ajlm-1677	4	25	jos	jos	PROPN
ajlm-1677	4	26	,	,	PUNCT
ajlm-1677	4	27	nigeria	nigeria	PROPN
ajlm-1677	4	28	.	.	PUNCT
ajlm-1677	5	1	afr	afr	PROPN
ajlm-1677	5	2	j	j	PROPN
ajlm-1677	5	3	lab	lab	PROPN
ajlm-1677	5	4	med	med	PROPN
ajlm-1677	5	5	.	.	PUNCT
ajlm-1677	6	1	2022;11(1	2022;11(1	NUM
ajlm-1677	6	2	)	)	PUNCT
ajlm-1677	7	1	,	,	PUNCT
ajlm-1677	7	2	a1677	a1677	PROPN
ajlm-1677	7	3	.	.	PUNCT
ajlm-1677	7	4	https://doi.org/10.4102/ajlm.v11i1.1677	https://doi.org/10.4102/ajlm.v11i1.1677	PROPN
ajlm-1677	7	5	original	original	ADJ
ajlm-1677	7	6	research	research	NOUN
ajlm-1677	7	7	molecular	molecular	ADJ
ajlm-1677	7	8	detection	detection	NOUN
ajlm-1677	7	9	of	of	ADP
ajlm-1677	7	10	hepatitis	hepatitis	PROPN
ajlm-1677	7	11	b	b	PROPN
ajlm-1677	7	12	virus	virus	NOUN
ajlm-1677	7	13	genotype	genotype	NOUN
ajlm-1677	7	14	e	e	NOUN
ajlm-1677	7	15	with	with	ADP
ajlm-1677	7	16	immune	immune	ADJ
ajlm-1677	7	17	escape	escape	NOUN
ajlm-1677	7	18	mutations	mutation	NOUN
ajlm-1677	7	19	in	in	ADP
ajlm-1677	7	20	chronic	chronic	ADJ
ajlm-1677	7	21	hepatitis	hepatitis	PROPN
ajlm-1677	7	22	b	b	PROPN
ajlm-1677	7	23	patients	patient	NOUN
ajlm-1677	7	24	on	on	ADP
ajlm-1677	7	25	long	long	ADJ
ajlm-1677	7	26	-	-	PUNCT
ajlm-1677	7	27	term	term	NOUN
ajlm-1677	7	28	antiviral	antiviral	ADJ
ajlm-1677	7	29	therapy	therapy	NOUN
ajlm-1677	7	30	in	in	ADP
ajlm-1677	7	31	jos	jos	PROPN
ajlm-1677	7	32	,	,	PUNCT
ajlm-1677	7	33	nigeria	nigeria	PROPN
ajlm-1677	7	34	joseph	joseph	PROPN
ajlm-1677	7	35	anejo	anejo	PROPN
ajlm-1677	7	36	-	-	PUNCT
ajlm-1677	7	37	okopi	okopi	NOUN
ajlm-1677	7	38	,	,	PUNCT
ajlm-1677	7	39	edith	edith	PROPN
ajlm-1677	7	40	okeke	okeke	PROPN
ajlm-1677	7	41	,	,	PUNCT
ajlm-1677	7	42	pantong	pantong	ADJ
ajlm-1677	7	43	m.	m.	NOUN
ajlm-1677	7	44	davwar	davwar	PROPN
ajlm-1677	7	45	,	,	PUNCT
ajlm-1677	7	46	chika	chika	PROPN
ajlm-1677	7	47	onwuamah	onwuamah	PROPN
ajlm-1677	7	48	,	,	PUNCT
ajlm-1677	7	49	harris	harris	PROPN
ajlm-1677	7	50	onywera	onywera	PROPN
ajlm-1677	7	51	,	,	PUNCT
ajlm-1677	7	52	patience	patience	NOUN
ajlm-1677	7	53	omaiye	omaiye	PROPN
ajlm-1677	7	54	,	,	PUNCT
ajlm-1677	7	55	mary	mary	PROPN
ajlm-1677	7	56	duguru	duguru	PROPN
ajlm-1677	7	57	,	,	PUNCT
ajlm-1677	7	58	ocheme	ocheme	NOUN
ajlm-1677	7	59	j.	j.	PROPN
ajlm-1677	7	60	okojokwu	okojokwu	PROPN
ajlm-1677	7	61	,	,	PUNCT
ajlm-1677	7	62	otobo	otobo	PROPN
ajlm-1677	7	63	i.	i.	PROPN
ajlm-1677	7	64	ujah	ujah	PROPN
ajlm-1677	7	65	,	,	PUNCT
ajlm-1677	7	66	bulus	bulus	PROPN
ajlm-1677	7	67	jonathan	jonathan	PROPN
ajlm-1677	7	68	,	,	PUNCT
ajlm-1677	7	69	chima	chima	PROPN
ajlm-1677	7	70	a.	a.	PROPN
ajlm-1677	7	71	george	george	PROPN
ajlm-1677	7	72	,	,	PUNCT
ajlm-1677	7	73	ramyil	ramyil	VERB
ajlm-1677	7	74	s.	s.	PROPN
ajlm-1677	7	75	crown	crown	PROPN
ajlm-1677	7	76	,	,	PUNCT
ajlm-1677	7	77	fiyaktu	fiyaktu	PROPN
ajlm-1677	7	78	b.	b.	PROPN
ajlm-1677	7	79	yakubu	yakubu	PROPN
ajlm-1677	7	80	,	,	PUNCT
ajlm-1677	7	81	judith	judith	PROPN
ajlm-1677	7	82	o.	o.	PROPN
ajlm-1677	7	83	sokei	sokei	PROPN
ajlm-1677	7	84	,	,	PUNCT
ajlm-1677	7	85	leona	leona	PROPN
ajlm-1677	7	86	c.	c.	PROPN
ajlm-1677	7	87	okoli	okoli	PROPN
ajlm-1677	7	88	,	,	PUNCT
ajlm-1677	7	89	onyemocho	onyemocho	ADJ
ajlm-1677	7	90	audu	audu	NOUN
ajlm-1677	7	91	,	,	PUNCT
ajlm-1677	7	92	seth	seth	PROPN
ajlm-1677	7	93	c.	c.	PROPN
ajlm-1677	7	94	inzaule	inzaule	PROPN
ajlm-1677	7	95	,	,	PUNCT
ajlm-1677	7	96	isaac	isaac	PROPN
ajlm-1677	7	97	o.	o.	PROPN
ajlm-1677	7	98	abah	abah	PROPN
ajlm-1677	7	99	,	,	PUNCT
ajlm-1677	7	100	patricia	patricia	PROPN
ajlm-1677	7	101	agaba	agaba	PROPN
ajlm-1677	7	102	,	,	PUNCT
ajlm-1677	7	103	oche	oche	PROPN
ajlm-1677	7	104	o.	o.	PROPN
ajlm-1677	7	105	agbaji	agbaji	PROPN
ajlm-1677	7	106	,	,	PUNCT
ajlm-1677	7	107	atiene	atiene	PROPN
ajlm-1677	7	108	s.	s.	PROPN
ajlm-1677	7	109	sagay	sagay	PROPN
ajlm-1677	7	110	,	,	PUNCT
ajlm-1677	7	111	claudia	claudia	PROPN
ajlm-1677	7	112	hawkins	hawkins	PROPN
ajlm-1677	7	113	received	receive	VERB
ajlm-1677	7	114	:	:	PUNCT
ajlm-1677	7	115	19	19	NUM
ajlm-1677	7	116	july	july	PROPN
ajlm-1677	7	117	2021	2021	NUM
ajlm-1677	7	118	;	;	PUNCT
ajlm-1677	7	119	accepted	accept	VERB
ajlm-1677	7	120	:	:	PUNCT
ajlm-1677	7	121	28	28	NUM
ajlm-1677	7	122	apr	apr	NOUN
ajlm-1677	7	123	.	.	PUNCT
ajlm-1677	7	124	2022	2022	NUM
ajlm-1677	7	125	;	;	PUNCT
ajlm-1677	7	126	published	publish	VERB
ajlm-1677	7	127	:	:	PUNCT
ajlm-1677	7	128	18	18	NUM
ajlm-1677	7	129	oct	oct	NOUN
ajlm-1677	7	130	.	.	PROPN
ajlm-1677	8	1	2022	2022	NUM
ajlm-1677	8	2	copyright	copyright	NOUN
ajlm-1677	8	3	:	:	PUNCT
ajlm-1677	8	4	©	©	PROPN
ajlm-1677	8	5	2022	2022	NUM
ajlm-1677	8	6	.	.	PUNCT
ajlm-1677	9	1	the	the	DET
ajlm-1677	9	2	author(s	author(s	PROPN
ajlm-1677	9	3	)	)	PUNCT
ajlm-1677	9	4	.	.	PUNCT
ajlm-1677	10	1	licensee	licensee	NOUN
ajlm-1677	10	2	:	:	PUNCT
ajlm-1677	10	3	aosis	aosis	NOUN
ajlm-1677	10	4	.	.	PUNCT
ajlm-1677	11	1	this	this	PRON
ajlm-1677	11	2	is	be	AUX
ajlm-1677	11	3	an	an	DET
ajlm-1677	11	4	open	open	ADJ
ajlm-1677	11	5	access	access	NOUN
ajlm-1677	11	6	article	article	NOUN
ajlm-1677	11	7	distributed	distribute	VERB
ajlm-1677	11	8	under	under	ADP
ajlm-1677	11	9	the	the	DET
ajlm-1677	11	10	terms	term	NOUN
ajlm-1677	11	11	of	of	ADP
ajlm-1677	11	12	the	the	DET
ajlm-1677	11	13	creative	creative	ADJ
ajlm-1677	11	14	commons	common	NOUN
ajlm-1677	11	15	attribution	attribution	NOUN
ajlm-1677	11	16	license	license	NOUN
ajlm-1677	11	17	,	,	PUNCT
ajlm-1677	11	18	which	which	PRON
ajlm-1677	11	19	permits	permit	VERB
ajlm-1677	11	20	unrestricted	unrestricted	ADJ
ajlm-1677	11	21	use	use	NOUN
ajlm-1677	11	22	,	,	PUNCT
ajlm-1677	11	23	distribution	distribution	NOUN
ajlm-1677	11	24	,	,	PUNCT
ajlm-1677	11	25	and	and	CCONJ
ajlm-1677	11	26	reproduction	reproduction	NOUN
ajlm-1677	11	27	in	in	ADP
ajlm-1677	11	28	any	any	DET
ajlm-1677	11	29	medium	medium	NOUN
ajlm-1677	11	30	,	,	PUNCT
ajlm-1677	11	31	provided	provide	VERB
ajlm-1677	11	32	the	the	DET
ajlm-1677	11	33	original	original	ADJ
ajlm-1677	11	34	work	work	NOUN
ajlm-1677	11	35	is	be	AUX
ajlm-1677	11	36	properly	properly	ADV
ajlm-1677	11	37	cited	cite	VERB
ajlm-1677	11	38	.	.	PUNCT
ajlm-1677	12	1	abstract	abstract	ADJ
ajlm-1677	12	2	background	background	NOUN
ajlm-1677	12	3	:	:	PUNCT
ajlm-1677	12	4	previous	previous	ADJ
ajlm-1677	12	5	studies	study	NOUN
ajlm-1677	12	6	in	in	ADP
ajlm-1677	12	7	nigeria	nigeria	PROPN
ajlm-1677	12	8	have	have	AUX
ajlm-1677	12	9	reported	report	VERB
ajlm-1677	12	10	the	the	DET
ajlm-1677	12	11	presence	presence	NOUN
ajlm-1677	12	12	of	of	ADP
ajlm-1677	12	13	hepatitis	hepatitis	PROPN
ajlm-1677	12	14	b	b	PROPN
ajlm-1677	12	15	virus	virus	NOUN
ajlm-1677	12	16	(	(	PUNCT
ajlm-1677	12	17	hbv	hbv	NOUN
ajlm-1677	12	18	)	)	PUNCT
ajlm-1677	12	19	genotype	genotype	NOUN
ajlm-1677	12	20	e	e	NOUN
ajlm-1677	12	21	and	and	CCONJ
ajlm-1677	12	22	the	the	DET
ajlm-1677	12	23	availability	availability	NOUN
ajlm-1677	12	24	of	of	ADP
ajlm-1677	12	25	immune	immune	ADJ
ajlm-1677	12	26	escape	escape	NOUN
ajlm-1677	12	27	mutants	mutant	NOUN
ajlm-1677	12	28	.	.	PUNCT
ajlm-1677	13	1	there	there	PRON
ajlm-1677	13	2	is	be	VERB
ajlm-1677	13	3	a	a	DET
ajlm-1677	13	4	paucity	paucity	NOUN
ajlm-1677	13	5	of	of	ADP
ajlm-1677	13	6	data	datum	NOUN
ajlm-1677	13	7	on	on	ADP
ajlm-1677	13	8	chronic	chronic	ADJ
ajlm-1677	13	9	patients	patient	NOUN
ajlm-1677	13	10	on	on	ADP
ajlm-1677	13	11	long	long	ADJ
ajlm-1677	13	12	-	-	PUNCT
ajlm-1677	13	13	term	term	NOUN
ajlm-1677	13	14	antiviral	antiviral	ADJ
ajlm-1677	13	15	therapy	therapy	NOUN
ajlm-1677	13	16	for	for	ADP
ajlm-1677	13	17	hbv	hbv	NOUN
ajlm-1677	13	18	infection	infection	NOUN
ajlm-1677	13	19	.	.	PUNCT
ajlm-1677	14	1	objective	objective	NOUN
ajlm-1677	14	2	:	:	PUNCT
ajlm-1677	14	3	this	this	DET
ajlm-1677	14	4	study	study	NOUN
ajlm-1677	14	5	assessed	assess	VERB
ajlm-1677	14	6	hbv	hbv	NOUN
ajlm-1677	14	7	genotypes	genotype	NOUN
ajlm-1677	14	8	and	and	CCONJ
ajlm-1677	14	9	drug	drug	NOUN
ajlm-1677	14	10	resistance	resistance	NOUN
ajlm-1677	14	11	variants	variant	NOUN
ajlm-1677	14	12	among	among	ADP
ajlm-1677	14	13	patients	patient	NOUN
ajlm-1677	14	14	with	with	ADP
ajlm-1677	14	15	chronic	chronic	ADJ
ajlm-1677	14	16	hbv	hbv	NOUN
ajlm-1677	14	17	infection	infection	NOUN
ajlm-1677	14	18	receiving	receive	VERB
ajlm-1677	14	19	tenofovir	tenofovir	NOUN
ajlm-1677	14	20	in	in	ADP
ajlm-1677	14	21	jos	jos	PROPN
ajlm-1677	14	22	,	,	PUNCT
ajlm-1677	14	23	nigeria	nigeria	PROPN
ajlm-1677	14	24	.	.	PUNCT
ajlm-1677	15	1	methods	method	NOUN
ajlm-1677	15	2	:	:	PUNCT
ajlm-1677	15	3	this	this	DET
ajlm-1677	15	4	cross	cross	ADJ
ajlm-1677	15	5	-	-	ADJ
ajlm-1677	15	6	sectional	sectional	ADJ
ajlm-1677	15	7	study	study	NOUN
ajlm-1677	15	8	consecutively	consecutively	ADV
ajlm-1677	15	9	enrolled	enrol	VERB
ajlm-1677	15	10	101	101	NUM
ajlm-1677	15	11	patients	patient	NOUN
ajlm-1677	15	12	(	(	PUNCT
ajlm-1677	15	13	51	51	NUM
ajlm-1677	15	14	with	with	ADP
ajlm-1677	15	15	hiv	hiv	PROPN
ajlm-1677	15	16	/	/	SYM
ajlm-1677	15	17	hbv	hbv	PROPN
ajlm-1677	15	18	co	co	NOUN
ajlm-1677	15	19	-	-	NOUN
ajlm-1677	15	20	infection	infection	NOUN
ajlm-1677	15	21	and	and	CCONJ
ajlm-1677	15	22	50	50	NUM
ajlm-1677	15	23	with	with	ADP
ajlm-1677	15	24	hbv	hbv	NOUN
ajlm-1677	15	25	infection	infection	NOUN
ajlm-1677	15	26	only	only	ADV
ajlm-1677	15	27	)	)	PUNCT
ajlm-1677	15	28	on	on	ADP
ajlm-1677	15	29	antiviral	antiviral	ADJ
ajlm-1677	15	30	therapy	therapy	NOUN
ajlm-1677	15	31	from	from	ADP
ajlm-1677	15	32	february	february	PROPN
ajlm-1677	15	33	2018	2018	NUM
ajlm-1677	15	34	to	to	ADP
ajlm-1677	15	35	may	may	PROPN
ajlm-1677	15	36	2019	2019	NUM
ajlm-1677	15	37	at	at	ADP
ajlm-1677	15	38	four	four	NUM
ajlm-1677	15	39	hospitals	hospital	NOUN
ajlm-1677	15	40	in	in	ADP
ajlm-1677	15	41	jos	jos	PROPN
ajlm-1677	15	42	,	,	PUNCT
ajlm-1677	15	43	nigeria	nigeria	PROPN
ajlm-1677	15	44	.	.	PUNCT
ajlm-1677	16	1	dna	dna	PROPN
ajlm-1677	16	2	quantification	quantification	NOUN
ajlm-1677	16	3	of	of	ADP
ajlm-1677	16	4	hbv	hbv	NOUN
ajlm-1677	16	5	was	be	AUX
ajlm-1677	16	6	performed	perform	VERB
ajlm-1677	16	7	on	on	ADP
ajlm-1677	16	8	all	all	DET
ajlm-1677	16	9	samples	sample	NOUN
ajlm-1677	16	10	;	;	PUNCT
ajlm-1677	16	11	30	30	NUM
ajlm-1677	16	12	samples	sample	NOUN
ajlm-1677	16	13	with	with	ADP
ajlm-1677	16	14	detectable	detectable	ADJ
ajlm-1677	16	15	viral	viral	ADJ
ajlm-1677	16	16	load	load	NOUN
ajlm-1677	16	17	were	be	AUX
ajlm-1677	16	18	selected	select	VERB
ajlm-1677	16	19	for	for	ADP
ajlm-1677	16	20	genotyping	genotype	VERB
ajlm-1677	16	21	using	use	VERB
ajlm-1677	16	22	sanger	sanger	PROPN
ajlm-1677	16	23	sequencing	sequence	VERB
ajlm-1677	16	24	by	by	ADP
ajlm-1677	16	25	targeting	target	VERB
ajlm-1677	16	26	the	the	DET
ajlm-1677	16	27	full	full	ADJ
ajlm-1677	16	28	-	-	PUNCT
ajlm-1677	16	29	length	length	NOUN
ajlm-1677	16	30	sequences	sequence	NOUN
ajlm-1677	16	31	of	of	ADP
ajlm-1677	16	32	reverse	reverse	ADJ
ajlm-1677	16	33	transcriptase	transcriptase	NOUN
ajlm-1677	16	34	gene	gene	NOUN
ajlm-1677	16	35	of	of	ADP
ajlm-1677	16	36	the	the	DET
ajlm-1677	16	37	hbv	hbv	NOUN
ajlm-1677	16	38	genome	genome	NOUN
ajlm-1677	16	39	.	.	PUNCT
ajlm-1677	17	1	phylogenetic	phylogenetic	ADJ
ajlm-1677	17	2	analysis	analysis	NOUN
ajlm-1677	17	3	was	be	AUX
ajlm-1677	17	4	performed	perform	VERB
ajlm-1677	17	5	with	with	ADP
ajlm-1677	17	6	reference	reference	NOUN
ajlm-1677	17	7	sequences	sequence	NOUN
ajlm-1677	17	8	from	from	ADP
ajlm-1677	17	9	genbank	genbank	PROPN
ajlm-1677	17	10	.	.	PUNCT
ajlm-1677	18	1	escape	escape	NOUN
ajlm-1677	18	2	mutant	mutant	NOUN
ajlm-1677	18	3	and	and	CCONJ
ajlm-1677	18	4	drug	drug	NOUN
ajlm-1677	18	5	resistance	resistance	NOUN
ajlm-1677	18	6	analysis	analysis	NOUN
ajlm-1677	18	7	were	be	AUX
ajlm-1677	18	8	performed	perform	VERB
ajlm-1677	18	9	using	use	VERB
ajlm-1677	18	10	hbv	hbv	NOUN
ajlm-1677	18	11	drug	drug	NOUN
ajlm-1677	18	12	resistance	resistance	NOUN
ajlm-1677	18	13	interpretation	interpretation	NOUN
ajlm-1677	18	14	and	and	CCONJ
ajlm-1677	18	15	geno2pheno	geno2pheno	PROPN
ajlm-1677	18	16	.	.	PUNCT
ajlm-1677	19	1	results	result	NOUN
ajlm-1677	19	2	:	:	PUNCT
ajlm-1677	19	3	only	only	ADV
ajlm-1677	19	4	30	30	NUM
ajlm-1677	19	5	(	(	PUNCT
ajlm-1677	19	6	29.7	29.7	NUM
ajlm-1677	19	7	%	%	NOUN
ajlm-1677	19	8	)	)	PUNCT
ajlm-1677	19	9	of	of	ADP
ajlm-1677	19	10	the	the	DET
ajlm-1677	19	11	101	101	NUM
ajlm-1677	19	12	study	study	NOUN
ajlm-1677	19	13	participants	participant	NOUN
ajlm-1677	19	14	had	have	AUX
ajlm-1677	19	15	detectable	detectable	ADJ
ajlm-1677	19	16	hbv	hbv	NOUN
ajlm-1677	19	17	dna	dna	PROPN
ajlm-1677	19	18	.	.	PUNCT
ajlm-1677	20	1	of	of	ADP
ajlm-1677	20	2	these	these	PRON
ajlm-1677	20	3	,	,	PUNCT
ajlm-1677	20	4	six	six	NUM
ajlm-1677	20	5	(	(	PUNCT
ajlm-1677	20	6	20.0	20.0	NUM
ajlm-1677	20	7	%	%	NOUN
ajlm-1677	20	8	)	)	PUNCT
ajlm-1677	20	9	isolates	isolate	NOUN
ajlm-1677	20	10	were	be	AUX
ajlm-1677	20	11	successfully	successfully	ADV
ajlm-1677	20	12	amplified	amplify	VERB
ajlm-1677	20	13	and	and	CCONJ
ajlm-1677	20	14	sequenced	sequence	VERB
ajlm-1677	20	15	.	.	PUNCT
ajlm-1677	21	1	the	the	DET
ajlm-1677	21	2	identified	identify	VERB
ajlm-1677	21	3	genotype	genotype	NOUN
ajlm-1677	21	4	was	be	AUX
ajlm-1677	21	5	e	e	NOUN
ajlm-1677	21	6	,	,	PUNCT
ajlm-1677	21	7	including	include	VERB
ajlm-1677	21	8	escape	escape	NOUN
ajlm-1677	21	9	mutations	mutation	NOUN
ajlm-1677	21	10	l127r	l127r	NOUN
ajlm-1677	21	11	(	(	PUNCT
ajlm-1677	21	12	16.7	16.7	NUM
ajlm-1677	21	13	%	%	NOUN
ajlm-1677	21	14	)	)	PUNCT
ajlm-1677	21	15	and	and	CCONJ
ajlm-1677	21	16	g145a	g145a	ADV
ajlm-1677	21	17	(	(	PUNCT
ajlm-1677	21	18	16.7	16.7	NUM
ajlm-1677	21	19	%	%	NOUN
ajlm-1677	21	20	)	)	PUNCT
ajlm-1677	21	21	.	.	PUNCT
ajlm-1677	22	1	conclusion	conclusion	NOUN
ajlm-1677	22	2	:	:	PUNCT
ajlm-1677	22	3	this	this	DET
ajlm-1677	22	4	study	study	NOUN
ajlm-1677	22	5	revealed	reveal	VERB
ajlm-1677	22	6	exclusive	exclusive	ADJ
ajlm-1677	22	7	dominance	dominance	NOUN
ajlm-1677	22	8	of	of	ADP
ajlm-1677	22	9	genotype	genotype	NOUN
ajlm-1677	22	10	e	e	PROPN
ajlm-1677	22	11	in	in	ADP
ajlm-1677	22	12	nigeria	nigeria	PROPN
ajlm-1677	22	13	.	.	PUNCT
ajlm-1677	23	1	the	the	DET
ajlm-1677	23	2	s	s	NOUN
ajlm-1677	23	3	gene	gene	NOUN
ajlm-1677	23	4	mutations	mutation	NOUN
ajlm-1677	23	5	g145a	g145a	ADV
ajlm-1677	23	6	and	and	CCONJ
ajlm-1677	23	7	l271r	l271r	PROPN
ajlm-1677	23	8	are	be	AUX
ajlm-1677	23	9	known	know	VERB
ajlm-1677	23	10	to	to	PART
ajlm-1677	23	11	be	be	AUX
ajlm-1677	23	12	associated	associate	VERB
ajlm-1677	23	13	with	with	ADP
ajlm-1677	23	14	modified	modify	VERB
ajlm-1677	23	15	antigenicity	antigenicity	NOUN
ajlm-1677	23	16	and	and	CCONJ
ajlm-1677	23	17	impaired	impair	VERB
ajlm-1677	23	18	serologic	serologic	ADJ
ajlm-1677	23	19	assays	assay	NOUN
ajlm-1677	23	20	,	,	PUNCT
ajlm-1677	23	21	which	which	PRON
ajlm-1677	23	22	may	may	AUX
ajlm-1677	23	23	cause	cause	VERB
ajlm-1677	23	24	false	false	ADJ
ajlm-1677	23	25	negatives	negative	NOUN
ajlm-1677	23	26	in	in	ADP
ajlm-1677	23	27	the	the	DET
ajlm-1677	23	28	detection	detection	NOUN
ajlm-1677	23	29	of	of	ADP
ajlm-1677	23	30	anti	anti	ADJ
ajlm-1677	23	31	-	-	ADJ
ajlm-1677	23	32	hbv	hbv	ADJ
ajlm-1677	23	33	surface	surface	NOUN
ajlm-1677	23	34	antigen	antigen	ADV
ajlm-1677	23	35	.	.	PUNCT
ajlm-1677	24	1	the	the	DET
ajlm-1677	24	2	presence	presence	NOUN
ajlm-1677	24	3	of	of	ADP
ajlm-1677	24	4	mutants	mutant	NOUN
ajlm-1677	24	5	that	that	PRON
ajlm-1677	24	6	are	be	AUX
ajlm-1677	24	7	associated	associate	VERB
ajlm-1677	24	8	with	with	ADP
ajlm-1677	24	9	vaccine	vaccine	NOUN
ajlm-1677	24	10	immune	immune	ADJ
ajlm-1677	24	11	escape	escape	NOUN
ajlm-1677	24	12	may	may	AUX
ajlm-1677	24	13	also	also	ADV
ajlm-1677	24	14	have	have	VERB
ajlm-1677	24	15	diagnostic	diagnostic	ADJ
ajlm-1677	24	16	and	and	CCONJ
ajlm-1677	24	17	vaccine	vaccine	NOUN
ajlm-1677	24	18	immune	immune	ADJ
ajlm-1677	24	19	response	response	NOUN
ajlm-1677	24	20	implications	implication	NOUN
ajlm-1677	24	21	.	.	PUNCT
ajlm-1677	25	1	keywords	keyword	NOUN
ajlm-1677	25	2	:	:	PUNCT
ajlm-1677	25	3	hepatitis	hepatitis	PROPN
ajlm-1677	25	4	b	b	PROPN
ajlm-1677	25	5	virus	virus	NOUN
ajlm-1677	25	6	(	(	PUNCT
ajlm-1677	25	7	hbv	hbv	NOUN
ajlm-1677	25	8	)	)	PUNCT
ajlm-1677	25	9	;	;	PUNCT
ajlm-1677	25	10	genotyping	genotyping	NOUN
ajlm-1677	25	11	;	;	PUNCT
ajlm-1677	25	12	antiviral	antiviral	ADJ
ajlm-1677	25	13	drug	drug	NOUN
ajlm-1677	25	14	resistance	resistance	NOUN
ajlm-1677	25	15	;	;	PUNCT
ajlm-1677	25	16	chronic	chronic	ADJ
ajlm-1677	25	17	hepatitis	hepatitis	PROPN
ajlm-1677	25	18	b.	b.	PROPN
ajlm-1677	25	19	introduction	introduction	NOUN
ajlm-1677	25	20	hepatitis	hepatitis	PROPN
ajlm-1677	25	21	b	b	PROPN
ajlm-1677	25	22	virus	virus	NOUN
ajlm-1677	25	23	(	(	PUNCT
ajlm-1677	25	24	hbv	hbv	NOUN
ajlm-1677	25	25	)	)	PUNCT
ajlm-1677	25	26	infection	infection	NOUN
ajlm-1677	25	27	is	be	AUX
ajlm-1677	25	28	a	a	DET
ajlm-1677	25	29	public	public	ADJ
ajlm-1677	25	30	health	health	NOUN
ajlm-1677	25	31	problem	problem	NOUN
ajlm-1677	25	32	worldwide	worldwide	ADV
ajlm-1677	25	33	,	,	PUNCT
ajlm-1677	25	34	with	with	ADP
ajlm-1677	25	35	an	an	DET
ajlm-1677	25	36	estimated	estimate	VERB
ajlm-1677	25	37	global	global	ADJ
ajlm-1677	25	38	infection	infection	NOUN
ajlm-1677	25	39	of	of	ADP
ajlm-1677	25	40	2	2	NUM
ajlm-1677	25	41	billion	billion	NUM
ajlm-1677	25	42	,	,	PUNCT
ajlm-1677	25	43	257	257	NUM
ajlm-1677	25	44	million	million	NUM
ajlm-1677	25	45	of	of	ADP
ajlm-1677	25	46	whom	whom	PRON
ajlm-1677	25	47	are	be	AUX
ajlm-1677	25	48	chronically	chronically	ADV
ajlm-1677	25	49	infected.1,2	infected.1,2	NUM
ajlm-1677	25	50	hepatitis	hepatitis	NOUN
ajlm-1677	25	51	b	b	PROPN
ajlm-1677	25	52	virus	virus	NOUN
ajlm-1677	25	53	infection	infection	NOUN
ajlm-1677	25	54	causes	cause	VERB
ajlm-1677	25	55	about	about	ADP
ajlm-1677	25	56	880	880	NUM
ajlm-1677	25	57	000	000	NUM
ajlm-1677	25	58	deaths	death	NOUN
ajlm-1677	25	59	yearly	yearly	ADV
ajlm-1677	25	60	due	due	ADP
ajlm-1677	25	61	to	to	ADP
ajlm-1677	25	62	cirrhosis	cirrhosis	NOUN
ajlm-1677	25	63	and	and	CCONJ
ajlm-1677	25	64	hepatocellular	hepatocellular	ADJ
ajlm-1677	25	65	carcinoma	carcinoma	NOUN
ajlm-1677	25	66	(	(	PUNCT
ajlm-1677	25	67	hcc).3	hcc).3	ADV
ajlm-1677	25	68	the	the	DET
ajlm-1677	25	69	prevalence	prevalence	NOUN
ajlm-1677	25	70	of	of	ADP
ajlm-1677	25	71	hcc	hcc	PROPN
ajlm-1677	25	72	is	be	AUX
ajlm-1677	25	73	rapidly	rapidly	ADV
ajlm-1677	25	74	increasing	increase	VERB
ajlm-1677	25	75	with	with	ADP
ajlm-1677	25	76	most	most	ADJ
ajlm-1677	25	77	cases	case	NOUN
ajlm-1677	25	78	being	be	AUX
ajlm-1677	25	79	attributable	attributable	ADJ
ajlm-1677	25	80	to	to	ADP
ajlm-1677	25	81	chronic	chronic	ADJ
ajlm-1677	25	82	hepatitis	hepatitis	PROPN
ajlm-1677	25	83	b.	b.	PROPN
ajlm-1677	26	1	the	the	DET
ajlm-1677	26	2	disease	disease	NOUN
ajlm-1677	26	3	is	be	AUX
ajlm-1677	26	4	endemic	endemic	ADJ
ajlm-1677	26	5	in	in	ADP
ajlm-1677	26	6	sub	sub	ADJ
ajlm-1677	26	7	-	-	ADJ
ajlm-1677	26	8	saharan	saharan	ADJ
ajlm-1677	26	9	africa	africa	PROPN
ajlm-1677	26	10	,	,	PUNCT
ajlm-1677	26	11	affecting	affect	VERB
ajlm-1677	26	12	more	more	ADJ
ajlm-1677	26	13	than	than	ADP
ajlm-1677	26	14	8.0	8.0	NUM
ajlm-1677	26	15	%	%	NOUN
ajlm-1677	26	16	of	of	ADP
ajlm-1677	26	17	the	the	DET
ajlm-1677	26	18	population	population	NOUN
ajlm-1677	26	19	,	,	PUNCT
ajlm-1677	26	20	most	most	ADJ
ajlm-1677	26	21	of	of	ADP
ajlm-1677	26	22	whom	whom	PRON
ajlm-1677	26	23	are	be	AUX
ajlm-1677	26	24	infected	infect	VERB
ajlm-1677	26	25	in	in	ADP
ajlm-1677	26	26	early	early	ADJ
ajlm-1677	26	27	childhood.3	childhood.3	NOUN
ajlm-1677	26	28	individual	individual	ADJ
ajlm-1677	26	29	infections	infection	NOUN
ajlm-1677	26	30	may	may	AUX
ajlm-1677	26	31	resolve	resolve	VERB
ajlm-1677	26	32	,	,	PUNCT
ajlm-1677	26	33	become	become	VERB
ajlm-1677	26	34	sub	sub	ADJ
ajlm-1677	26	35	-	-	ADJ
ajlm-1677	26	36	clinical	clinical	ADJ
ajlm-1677	26	37	,	,	PUNCT
ajlm-1677	26	38	chronic	chronic	ADJ
ajlm-1677	26	39	or	or	CCONJ
ajlm-1677	26	40	result	result	VERB
ajlm-1677	26	41	in	in	ADP
ajlm-1677	26	42	liver	liver	NOUN
ajlm-1677	26	43	damage	damage	NOUN
ajlm-1677	26	44	.	.	PUNCT
ajlm-1677	27	1	sub	sub	ADJ
ajlm-1677	27	2	-	-	ADJ
ajlm-1677	27	3	saharan	saharan	ADJ
ajlm-1677	27	4	africa	africa	PROPN
ajlm-1677	27	5	has	have	VERB
ajlm-1677	27	6	one	one	NUM
ajlm-1677	27	7	of	of	ADP
ajlm-1677	27	8	the	the	DET
ajlm-1677	27	9	highest	high	ADJ
ajlm-1677	27	10	hbv	hbv	NOUN
ajlm-1677	27	11	-	-	PUNCT
ajlm-1677	27	12	related	relate	VERB
ajlm-1677	27	13	liver	liver	NOUN
ajlm-1677	27	14	cancer	cancer	NOUN
ajlm-1677	27	15	rates	rate	NOUN
ajlm-1677	27	16	in	in	ADP
ajlm-1677	27	17	the	the	DET
ajlm-1677	27	18	world.4,5	world.4,5	PROPN
ajlm-1677	27	19	hepatitis	hepatitis	PROPN
ajlm-1677	27	20	b	b	PROPN
ajlm-1677	27	21	virus	virus	NOUN
ajlm-1677	27	22	infection	infection	NOUN
ajlm-1677	27	23	increases	increase	VERB
ajlm-1677	27	24	the	the	DET
ajlm-1677	27	25	risk	risk	NOUN
ajlm-1677	27	26	of	of	ADP
ajlm-1677	27	27	developing	develop	VERB
ajlm-1677	27	28	liver	liver	NOUN
ajlm-1677	27	29	cirrhosis	cirrhosis	NOUN
ajlm-1677	27	30	and	and	CCONJ
ajlm-1677	27	31	hcc	hcc	PROPN
ajlm-1677	27	32	by	by	ADP
ajlm-1677	27	33	25.0	25.0	NUM
ajlm-1677	27	34	%	%	NOUN
ajlm-1677	27	35	to	to	ADP
ajlm-1677	27	36	40.0%.6	40.0%.6	NUM
ajlm-1677	27	37	hepatitis	hepatitis	PROPN
ajlm-1677	27	38	b	b	PROPN
ajlm-1677	27	39	virus	virus	NOUN
ajlm-1677	27	40	prevalence	prevalence	NOUN
ajlm-1677	27	41	in	in	ADP
ajlm-1677	27	42	nigeria	nigeria	PROPN
ajlm-1677	27	43	varies	vary	VERB
ajlm-1677	27	44	among	among	ADP
ajlm-1677	27	45	different	different	ADJ
ajlm-1677	27	46	populations	population	NOUN
ajlm-1677	27	47	(	(	PUNCT
ajlm-1677	27	48	ranging	range	VERB
ajlm-1677	27	49	between	between	ADP
ajlm-1677	27	50	9.2	9.2	NUM
ajlm-1677	27	51	%	%	NOUN
ajlm-1677	27	52	and	and	CCONJ
ajlm-1677	27	53	18.0	18.0	NUM
ajlm-1677	27	54	%	%	NOUN
ajlm-1677	27	55	)	)	PUNCT
ajlm-1677	27	56	,	,	PUNCT
ajlm-1677	27	57	including	include	VERB
ajlm-1677	27	58	hbv	hbv	PROPN
ajlm-1677	27	59	/	/	SYM
ajlm-1677	27	60	hiv	hiv	PROPN
ajlm-1677	27	61	co	co	VERB
ajlm-1677	27	62	-	-	ADJ
ajlm-1677	27	63	infected	infected	ADJ
ajlm-1677	27	64	population.7,8,9	population.7,8,9	NOUN
ajlm-1677	27	65	there	there	PRON
ajlm-1677	27	66	is	be	VERB
ajlm-1677	27	67	mounting	mount	VERB
ajlm-1677	27	68	evidence	evidence	NOUN
ajlm-1677	27	69	for	for	ADP
ajlm-1677	27	70	heterogeneity	heterogeneity	NOUN
ajlm-1677	27	71	of	of	ADP
ajlm-1677	27	72	hbv	hbv	NOUN
ajlm-1677	27	73	treatment	treatment	NOUN
ajlm-1677	27	74	outcomes	outcome	NOUN
ajlm-1677	27	75	and	and	CCONJ
ajlm-1677	27	76	vaccination	vaccination	NOUN
ajlm-1677	27	77	efficacy	efficacy	NOUN
ajlm-1677	27	78	attributed	attribute	VERB
ajlm-1677	27	79	to	to	ADP
ajlm-1677	27	80	the	the	DET
ajlm-1677	27	81	variations	variation	NOUN
ajlm-1677	27	82	in	in	ADP
ajlm-1677	27	83	the	the	DET
ajlm-1677	27	84	distribution	distribution	NOUN
ajlm-1677	27	85	of	of	ADP
ajlm-1677	27	86	hbv	hbv	NOUN
ajlm-1677	27	87	genotypes.10	genotypes.10	PROPN
ajlm-1677	27	88	hepatitis	hepatitis	PROPN
ajlm-1677	27	89	b	b	PROPN
ajlm-1677	27	90	virus	virus	NOUN
ajlm-1677	28	1	has	have	AUX
ajlm-1677	28	2	been	be	AUX
ajlm-1677	28	3	characterised	characterise	VERB
ajlm-1677	28	4	into	into	ADP
ajlm-1677	28	5	10	10	NUM
ajlm-1677	28	6	genotypes	genotype	NOUN
ajlm-1677	28	7	:	:	PUNCT
ajlm-1677	28	8	a	a	DET
ajlm-1677	28	9	–	–	PUNCT
ajlm-1677	28	10	i4,11	i4,11	NOUN
ajlm-1677	28	11	and	and	CCONJ
ajlm-1677	28	12	j	j	NOUN
ajlm-1677	28	13	which	which	PRON
ajlm-1677	28	14	was	be	AUX
ajlm-1677	28	15	recently	recently	ADV
ajlm-1677	28	16	identified	identify	VERB
ajlm-1677	28	17	in	in	ADP
ajlm-1677	28	18	a	a	DET
ajlm-1677	28	19	single	single	ADJ
ajlm-1677	28	20	case	case	NOUN
ajlm-1677	28	21	in	in	ADP
ajlm-1677	28	22	japan.12	japan.12	NOUN
ajlm-1677	28	23	genotypes	genotype	NOUN
ajlm-1677	28	24	a	a	PRON
ajlm-1677	28	25	,	,	PUNCT
ajlm-1677	28	26	d	d	NOUN
ajlm-1677	28	27	and	and	CCONJ
ajlm-1677	28	28	e	e	PROPN
ajlm-1677	28	29	circulate	circulate	VERB
ajlm-1677	28	30	in	in	ADP
ajlm-1677	28	31	africa	africa	PROPN
ajlm-1677	28	32	,	,	PUNCT
ajlm-1677	28	33	with	with	ADP
ajlm-1677	28	34	the	the	DET
ajlm-1677	28	35	latter	latter	ADJ
ajlm-1677	28	36	genotype	genotype	NOUN
ajlm-1677	28	37	prevailing	prevail	VERB
ajlm-1677	28	38	in	in	ADP
ajlm-1677	28	39	western	western	ADJ
ajlm-1677	28	40	africa,4,13	africa,4,13	PROPN
ajlm-1677	28	41	including	include	VERB
ajlm-1677	28	42	nigeria.14,15,16,17,18	nigeria.14,15,16,17,18	PROPN
ajlm-1677	28	43	looking	look	VERB
ajlm-1677	28	44	at	at	ADP
ajlm-1677	28	45	nigeria	nigeria	PROPN
ajlm-1677	28	46	’s	’s	PART
ajlm-1677	28	47	huge	huge	ADJ
ajlm-1677	28	48	population	population	NOUN
ajlm-1677	28	49	and	and	CCONJ
ajlm-1677	28	50	cross	cross	ADJ
ajlm-1677	28	51	-	-	ADJ
ajlm-1677	28	52	border	border	ADJ
ajlm-1677	28	53	movement	movement	NOUN
ajlm-1677	28	54	,	,	PUNCT
ajlm-1677	28	55	it	it	PRON
ajlm-1677	28	56	is	be	AUX
ajlm-1677	28	57	important	important	ADJ
ajlm-1677	28	58	that	that	SCONJ
ajlm-1677	28	59	the	the	DET
ajlm-1677	28	60	molecular	molecular	ADJ
ajlm-1677	28	61	characterisation	characterisation	NOUN
ajlm-1677	28	62	of	of	ADP
ajlm-1677	28	63	hbv	hbv	NOUN
ajlm-1677	28	64	genotypes	genotype	NOUN
ajlm-1677	28	65	and	and	CCONJ
ajlm-1677	28	66	prevalence	prevalence	NOUN
ajlm-1677	28	67	of	of	ADP
ajlm-1677	28	68	drug	drug	NOUN
ajlm-1677	28	69	resistance	resistance	NOUN
ajlm-1677	28	70	mutations	mutation	NOUN
ajlm-1677	28	71	is	be	AUX
ajlm-1677	28	72	determined	determine	VERB
ajlm-1677	28	73	for	for	ADP
ajlm-1677	28	74	better	well	ADJ
ajlm-1677	28	75	management	management	NOUN
ajlm-1677	28	76	and	and	CCONJ
ajlm-1677	28	77	epidemiological	epidemiological	ADJ
ajlm-1677	28	78	purposes	purpose	NOUN
ajlm-1677	28	79	.	.	PUNCT
ajlm-1677	29	1	the	the	DET
ajlm-1677	29	2	investigation	investigation	NOUN
ajlm-1677	29	3	of	of	ADP
ajlm-1677	29	4	hbv	hbv	NOUN
ajlm-1677	29	5	genotype	genotype	NOUN
ajlm-1677	29	6	is	be	AUX
ajlm-1677	29	7	becoming	become	VERB
ajlm-1677	29	8	more	more	ADV
ajlm-1677	29	9	important	important	ADJ
ajlm-1677	29	10	due	due	ADP
ajlm-1677	29	11	to	to	ADP
ajlm-1677	29	12	its	its	PRON
ajlm-1677	29	13	role	role	NOUN
ajlm-1677	29	14	in	in	ADP
ajlm-1677	29	15	the	the	DET
ajlm-1677	29	16	pathogenesis	pathogenesis	NOUN
ajlm-1677	29	17	and	and	CCONJ
ajlm-1677	29	18	treatment	treatment	NOUN
ajlm-1677	29	19	response	response	NOUN
ajlm-1677	29	20	in	in	ADP
ajlm-1677	29	21	both	both	DET
ajlm-1677	29	22	hbv	hbv	NOUN
ajlm-1677	29	23	-	-	PUNCT
ajlm-1677	29	24	mono	mono	NOUN
ajlm-1677	29	25	and	and	CCONJ
ajlm-1677	29	26	hbv	hbv	PROPN
ajlm-1677	29	27	/	/	SYM
ajlm-1677	29	28	hiv	hiv	PROPN
ajlm-1677	29	29	co	co	VERB
ajlm-1677	29	30	-	-	ADJ
ajlm-1677	29	31	infected	infected	ADJ
ajlm-1677	29	32	patients	patient	NOUN
ajlm-1677	29	33	and	and	CCONJ
ajlm-1677	29	34	the	the	DET
ajlm-1677	29	35	wide	wide	ADJ
ajlm-1677	29	36	availability	availability	NOUN
ajlm-1677	29	37	of	of	ADP
ajlm-1677	29	38	antiviral	antiviral	ADJ
ajlm-1677	29	39	therapy.19	therapy.19	NOUN
ajlm-1677	29	40	equally	equally	ADV
ajlm-1677	29	41	,	,	PUNCT
ajlm-1677	29	42	drug	drug	NOUN
ajlm-1677	29	43	resistance	resistance	NOUN
ajlm-1677	29	44	is	be	AUX
ajlm-1677	29	45	a	a	DET
ajlm-1677	29	46	major	major	ADJ
ajlm-1677	29	47	clinical	clinical	ADJ
ajlm-1677	29	48	concern	concern	NOUN
ajlm-1677	29	49	impacting	impact	VERB
ajlm-1677	29	50	clinical	clinical	ADJ
ajlm-1677	29	51	outcomes	outcome	NOUN
ajlm-1677	29	52	.	.	PUNCT
ajlm-1677	30	1	studies	study	NOUN
ajlm-1677	30	2	have	have	AUX
ajlm-1677	30	3	reported	report	VERB
ajlm-1677	30	4	the	the	DET
ajlm-1677	30	5	impact	impact	NOUN
ajlm-1677	30	6	of	of	ADP
ajlm-1677	30	7	some	some	DET
ajlm-1677	30	8	mutations	mutation	NOUN
ajlm-1677	30	9	that	that	PRON
ajlm-1677	30	10	showed	show	VERB
ajlm-1677	30	11	significant	significant	ADJ
ajlm-1677	30	12	role	role	NOUN
ajlm-1677	30	13	of	of	ADP
ajlm-1677	30	14	viral	viral	ADJ
ajlm-1677	30	15	persistence	persistence	NOUN
ajlm-1677	30	16	on	on	ADP
ajlm-1677	30	17	liver	liver	NOUN
ajlm-1677	30	18	disease	disease	NOUN
ajlm-1677	30	19	,	,	PUNCT
ajlm-1677	30	20	immune	immune	ADJ
ajlm-1677	30	21	escape	escape	NOUN
ajlm-1677	30	22	and	and	CCONJ
ajlm-1677	30	23	resistance	resistance	NOUN
ajlm-1677	30	24	to	to	ADP
ajlm-1677	30	25	antiviral	antiviral	ADJ
ajlm-1677	30	26	therapy.20,21	therapy.20,21	NOUN
ajlm-1677	30	27	the	the	DET
ajlm-1677	30	28	reverse	reverse	ADJ
ajlm-1677	30	29	transcriptase	transcriptase	NOUN
ajlm-1677	30	30	encoded	encode	VERB
ajlm-1677	30	31	by	by	ADP
ajlm-1677	30	32	the	the	DET
ajlm-1677	30	33	pol	pol	PROPN
ajlm-1677	30	34	gene	gene	NOUN
ajlm-1677	30	35	lacks	lack	VERB
ajlm-1677	30	36	effective	effective	ADJ
ajlm-1677	30	37	proofreading	proofreading	NOUN
ajlm-1677	30	38	ability	ability	NOUN
ajlm-1677	30	39	,	,	PUNCT
ajlm-1677	30	40	which	which	PRON
ajlm-1677	30	41	has	have	VERB
ajlm-1677	30	42	implications	implication	NOUN
ajlm-1677	30	43	in	in	ADP
ajlm-1677	30	44	hbv	hbv	NOUN
ajlm-1677	30	45	therapy.22	therapy.22	NOUN
ajlm-1677	30	46	however	however	ADV
ajlm-1677	30	47	,	,	PUNCT
ajlm-1677	30	48	the	the	DET
ajlm-1677	30	49	use	use	NOUN
ajlm-1677	30	50	of	of	ADP
ajlm-1677	30	51	low	low	ADJ
ajlm-1677	30	52	genetic	genetic	ADJ
ajlm-1677	30	53	barrier	barrier	NOUN
ajlm-1677	30	54	drugs	drug	NOUN
ajlm-1677	30	55	such	such	ADJ
ajlm-1677	30	56	as	as	ADP
ajlm-1677	30	57	lamivudine	lamivudine	NOUN
ajlm-1677	30	58	has	have	AUX
ajlm-1677	30	59	contributed	contribute	VERB
ajlm-1677	30	60	to	to	ADP
ajlm-1677	30	61	the	the	DET
ajlm-1677	30	62	development	development	NOUN
ajlm-1677	30	63	of	of	ADP
ajlm-1677	30	64	a	a	DET
ajlm-1677	30	65	drug	drug	NOUN
ajlm-1677	30	66	-	-	PUNCT
ajlm-1677	30	67	associated	associate	VERB
ajlm-1677	30	68	vaccine	vaccine	NOUN
ajlm-1677	30	69	-	-	PUNCT
ajlm-1677	30	70	escape	escape	NOUN
ajlm-1677	30	71	mutant	mutant	NOUN
ajlm-1677	30	72	which	which	PRON
ajlm-1677	30	73	is	be	AUX
ajlm-1677	30	74	becoming	become	VERB
ajlm-1677	30	75	a	a	DET
ajlm-1677	30	76	growing	grow	VERB
ajlm-1677	30	77	health	health	NOUN
ajlm-1677	30	78	concern	concern	NOUN
ajlm-1677	30	79	.	.	PUNCT
ajlm-1677	31	1	this	this	DET
ajlm-1677	31	2	mutant	mutant	NOUN
ajlm-1677	31	3	alters	alter	VERB
ajlm-1677	31	4	envelope	envelope	NOUN
ajlm-1677	31	5	antigen	antigen	NOUN
ajlm-1677	31	6	that	that	PRON
ajlm-1677	31	7	permits	permit	VERB
ajlm-1677	31	8	the	the	DET
ajlm-1677	31	9	virus	virus	NOUN
ajlm-1677	31	10	to	to	PART
ajlm-1677	31	11	escape	escape	VERB
ajlm-1677	31	12	the	the	DET
ajlm-1677	31	13	neutralisation	neutralisation	NOUN
ajlm-1677	31	14	antibody	antibody	NOUN
ajlm-1677	31	15	to	to	ADP
ajlm-1677	31	16	hepatitis	hepatitis	PROPN
ajlm-1677	31	17	b	b	PROPN
ajlm-1677	31	18	surface	surface	NOUN
ajlm-1677	31	19	antigen.21	antigen.21	NOUN
ajlm-1677	31	20	this	this	PRON
ajlm-1677	31	21	called	call	VERB
ajlm-1677	31	22	for	for	ADP
ajlm-1677	31	23	the	the	DET
ajlm-1677	31	24	need	need	NOUN
ajlm-1677	31	25	of	of	ADP
ajlm-1677	31	26	drugs	drug	NOUN
ajlm-1677	31	27	with	with	ADP
ajlm-1677	31	28	higher	high	ADJ
ajlm-1677	31	29	genetic	genetic	ADJ
ajlm-1677	31	30	barriers	barrier	NOUN
ajlm-1677	31	31	to	to	ADP
ajlm-1677	31	32	resistance	resistance	NOUN
ajlm-1677	31	33	than	than	ADP
ajlm-1677	31	34	lamivudine	lamivudine	NOUN
ajlm-1677	31	35	or	or	CCONJ
ajlm-1677	31	36	telbivudine.19	telbivudine.19	NOUN
ajlm-1677	31	37	however	however	ADV
ajlm-1677	31	38	,	,	PUNCT
ajlm-1677	31	39	there	there	PRON
ajlm-1677	31	40	is	be	VERB
ajlm-1677	31	41	a	a	DET
ajlm-1677	31	42	paucity	paucity	NOUN
ajlm-1677	31	43	of	of	ADP
ajlm-1677	31	44	knowledge	knowledge	NOUN
ajlm-1677	31	45	regarding	regard	VERB
ajlm-1677	31	46	the	the	DET
ajlm-1677	31	47	hbv	hbv	NOUN
ajlm-1677	31	48	genotypes	genotype	NOUN
ajlm-1677	31	49	and	and	CCONJ
ajlm-1677	31	50	resistant	resistant	ADJ
ajlm-1677	31	51	strains	strain	NOUN
ajlm-1677	31	52	in	in	ADP
ajlm-1677	31	53	chronic	chronic	ADJ
ajlm-1677	31	54	adult	adult	NOUN
ajlm-1677	31	55	patients	patient	NOUN
ajlm-1677	31	56	on	on	ADP
ajlm-1677	31	57	long	long	ADJ
ajlm-1677	31	58	-	-	PUNCT
ajlm-1677	31	59	term	term	NOUN
ajlm-1677	31	60	antiviral	antiviral	ADJ
ajlm-1677	31	61	therapy	therapy	NOUN
ajlm-1677	31	62	.	.	PUNCT
ajlm-1677	32	1	we	we	PRON
ajlm-1677	32	2	therefore	therefore	ADV
ajlm-1677	32	3	characterised	characterise	VERB
ajlm-1677	32	4	hbv	hbv	NOUN
ajlm-1677	32	5	in	in	ADP
ajlm-1677	32	6	chronic	chronic	ADJ
ajlm-1677	32	7	patients	patient	NOUN
ajlm-1677	32	8	on	on	ADP
ajlm-1677	32	9	tenofovir	tenofovir	NOUN
ajlm-1677	32	10	to	to	PART
ajlm-1677	32	11	identify	identify	VERB
ajlm-1677	32	12	circulating	circulate	VERB
ajlm-1677	32	13	genotypes	genotype	NOUN
ajlm-1677	32	14	and	and	CCONJ
ajlm-1677	32	15	drug	drug	NOUN
ajlm-1677	32	16	resistance	resistance	NOUN
ajlm-1677	32	17	variants	variant	NOUN
ajlm-1677	32	18	in	in	ADP
ajlm-1677	32	19	nigeria	nigeria	PROPN
ajlm-1677	32	20	.	.	PUNCT
ajlm-1677	33	1	methods	method	NOUN
ajlm-1677	33	2	ethical	ethical	ADJ
ajlm-1677	33	3	considerations	consideration	NOUN
ajlm-1677	33	4	the	the	DET
ajlm-1677	33	5	study	study	NOUN
ajlm-1677	33	6	protocol	protocol	NOUN
ajlm-1677	33	7	was	be	AUX
ajlm-1677	33	8	approved	approve	VERB
ajlm-1677	33	9	by	by	ADP
ajlm-1677	33	10	the	the	DET
ajlm-1677	33	11	four	four	NUM
ajlm-1677	33	12	study	study	NOUN
ajlm-1677	33	13	sites	site	NOUN
ajlm-1677	33	14	research	research	NOUN
ajlm-1677	33	15	ethics	ethic	NOUN
ajlm-1677	33	16	committees	committee	NOUN
ajlm-1677	33	17	,	,	PUNCT
ajlm-1677	33	18	namely	namely	ADV
ajlm-1677	33	19	:	:	PUNCT
ajlm-1677	33	20	jos	jos	PROPN
ajlm-1677	33	21	university	university	PROPN
ajlm-1677	33	22	teaching	teaching	NOUN
ajlm-1677	33	23	hospital	hospital	NOUN
ajlm-1677	33	24	,	,	PUNCT
ajlm-1677	33	25	faith	faith	NOUN
ajlm-1677	33	26	alive	alive	ADJ
ajlm-1677	33	27	foundation	foundation	PROPN
ajlm-1677	33	28	,	,	PUNCT
ajlm-1677	33	29	bingham	bingham	PROPN
ajlm-1677	33	30	university	university	PROPN
ajlm-1677	33	31	teaching	teaching	NOUN
ajlm-1677	33	32	hospital	hospital	NOUN
ajlm-1677	33	33	and	and	CCONJ
ajlm-1677	33	34	plateau	plateau	NOUN
ajlm-1677	33	35	state	state	NOUN
ajlm-1677	33	36	specialist	specialist	NOUN
ajlm-1677	33	37	hospital	hospital	NOUN
ajlm-1677	33	38	(	(	PUNCT
ajlm-1677	33	39	study	study	NOUN
ajlm-1677	33	40	approval	approval	NOUN
ajlm-1677	33	41	numbers	number	NOUN
ajlm-1677	33	42	:	:	PUNCT
ajlm-1677	33	43	juth	juth	PROPN
ajlm-1677	33	44	/	/	SYM
ajlm-1677	33	45	adm/11/0517	adm/11/0517	PROPN
ajlm-1677	33	46	,	,	PUNCT
ajlm-1677	33	47	fa/0112f	fa/0112f	NOUN
ajlm-1677	33	48	,	,	PUNCT
ajlm-1677	33	49	buth	buth	ADJ
ajlm-1677	33	50	/	/	SYM
ajlm-1677	33	51	ec/01	ec/01	PROPN
ajlm-1677	33	52	-	-	PUNCT
ajlm-1677	33	53	25	25	NUM
ajlm-1677	33	54	-	-	PUNCT
ajlm-1677	33	55	18b	18b	NOUN
ajlm-1677	33	56	and	and	CCONJ
ajlm-1677	33	57	plashrec/12018	plashrec/12018	NOUN
ajlm-1677	33	58	)	)	PUNCT
ajlm-1677	33	59	.	.	PUNCT
ajlm-1677	34	1	after	after	ADP
ajlm-1677	34	2	explaining	explain	VERB
ajlm-1677	34	3	the	the	DET
ajlm-1677	34	4	study	study	NOUN
ajlm-1677	34	5	objectives	objective	NOUN
ajlm-1677	34	6	and	and	CCONJ
ajlm-1677	34	7	procedures	procedure	NOUN
ajlm-1677	34	8	to	to	ADP
ajlm-1677	34	9	the	the	DET
ajlm-1677	34	10	participants	participant	NOUN
ajlm-1677	34	11	,	,	PUNCT
ajlm-1677	34	12	a	a	DET
ajlm-1677	34	13	written	write	VERB
ajlm-1677	34	14	informed	inform	VERB
ajlm-1677	34	15	consent	consent	NOUN
ajlm-1677	34	16	was	be	AUX
ajlm-1677	34	17	obtained	obtain	VERB
ajlm-1677	34	18	from	from	ADP
ajlm-1677	34	19	each	each	DET
ajlm-1677	34	20	patient	patient	NOUN
ajlm-1677	34	21	before	before	ADP
ajlm-1677	34	22	data	datum	NOUN
ajlm-1677	34	23	and	and	CCONJ
ajlm-1677	34	24	sample	sample	NOUN
ajlm-1677	34	25	collection	collection	NOUN
ajlm-1677	34	26	.	.	PUNCT
ajlm-1677	35	1	the	the	DET
ajlm-1677	35	2	patients	patient	NOUN
ajlm-1677	35	3	’	’	PART
ajlm-1677	35	4	data	datum	NOUN
ajlm-1677	35	5	were	be	AUX
ajlm-1677	35	6	coded	code	VERB
ajlm-1677	35	7	and	and	CCONJ
ajlm-1677	35	8	reported	report	VERB
ajlm-1677	35	9	without	without	ADP
ajlm-1677	35	10	divulging	divulge	VERB
ajlm-1677	35	11	personal	personal	ADJ
ajlm-1677	35	12	health	health	NOUN
ajlm-1677	35	13	information	information	NOUN
ajlm-1677	35	14	.	.	PUNCT
ajlm-1677	36	1	all	all	DET
ajlm-1677	36	2	other	other	ADJ
ajlm-1677	36	3	aspects	aspect	NOUN
ajlm-1677	36	4	of	of	ADP
ajlm-1677	36	5	the	the	DET
ajlm-1677	36	6	study	study	NOUN
ajlm-1677	36	7	were	be	AUX
ajlm-1677	36	8	conducted	conduct	VERB
ajlm-1677	36	9	in	in	ADP
ajlm-1677	36	10	accordance	accordance	NOUN
ajlm-1677	36	11	with	with	ADP
ajlm-1677	36	12	the	the	DET
ajlm-1677	36	13	ethical	ethical	ADJ
ajlm-1677	36	14	standards	standard	NOUN
ajlm-1677	36	15	of	of	ADP
ajlm-1677	36	16	the	the	DET
ajlm-1677	36	17	helsinki	helsinki	PROPN
ajlm-1677	36	18	declaration	declaration	PROPN
ajlm-1677	36	19	.	.	PUNCT
ajlm-1677	37	1	study	study	NOUN
ajlm-1677	37	2	design	design	NOUN
ajlm-1677	37	3	and	and	CCONJ
ajlm-1677	37	4	population	population	NOUN
ajlm-1677	37	5	we	we	PRON
ajlm-1677	37	6	conducted	conduct	VERB
ajlm-1677	37	7	a	a	DET
ajlm-1677	37	8	cross	cross	ADJ
ajlm-1677	37	9	-	-	ADJ
ajlm-1677	37	10	sectional	sectional	ADJ
ajlm-1677	37	11	study	study	NOUN
ajlm-1677	37	12	between	between	ADP
ajlm-1677	37	13	february	february	PROPN
ajlm-1677	37	14	2018	2018	NUM
ajlm-1677	37	15	and	and	CCONJ
ajlm-1677	37	16	may	may	AUX
ajlm-1677	37	17	2019	2019	NUM
ajlm-1677	37	18	at	at	ADP
ajlm-1677	37	19	jos	jos	PROPN
ajlm-1677	37	20	university	university	PROPN
ajlm-1677	37	21	teaching	teaching	NOUN
ajlm-1677	37	22	hospital	hospital	NOUN
ajlm-1677	37	23	,	,	PUNCT
ajlm-1677	37	24	plateau	plateau	NOUN
ajlm-1677	37	25	state	state	NOUN
ajlm-1677	37	26	specialist	specialist	NOUN
ajlm-1677	37	27	hospital	hospital	NOUN
ajlm-1677	37	28	,	,	PUNCT
ajlm-1677	37	29	faith	faith	NOUN
ajlm-1677	37	30	alive	alive	ADJ
ajlm-1677	37	31	foundation	foundation	PROPN
ajlm-1677	37	32	and	and	CCONJ
ajlm-1677	37	33	bingham	bingham	PROPN
ajlm-1677	37	34	university	university	PROPN
ajlm-1677	37	35	teaching	teaching	NOUN
ajlm-1677	37	36	hospital	hospital	NOUN
ajlm-1677	37	37	,	,	PUNCT
ajlm-1677	37	38	all	all	PRON
ajlm-1677	37	39	in	in	ADP
ajlm-1677	37	40	jos	jos	PROPN
ajlm-1677	37	41	metropolis	metropolis	PROPN
ajlm-1677	37	42	,	,	PUNCT
ajlm-1677	37	43	nigeria	nigeria	PROPN
ajlm-1677	37	44	.	.	PUNCT
ajlm-1677	38	1	the	the	DET
ajlm-1677	38	2	101	101	NUM
ajlm-1677	38	3	consecutively	consecutively	ADV
ajlm-1677	38	4	enrolled	enrol	VERB
ajlm-1677	38	5	adult	adult	NOUN
ajlm-1677	38	6	patients	patient	NOUN
ajlm-1677	38	7	,	,	PUNCT
ajlm-1677	38	8	including	include	VERB
ajlm-1677	38	9	51	51	NUM
ajlm-1677	38	10	patients	patient	NOUN
ajlm-1677	38	11	co	co	VERB
ajlm-1677	38	12	-	-	VERB
ajlm-1677	38	13	infected	infected	ADJ
ajlm-1677	38	14	with	with	ADP
ajlm-1677	38	15	hiv	hiv	PROPN
ajlm-1677	38	16	,	,	PUNCT
ajlm-1677	38	17	were	be	AUX
ajlm-1677	38	18	confirmed	confirm	VERB
ajlm-1677	38	19	to	to	PART
ajlm-1677	38	20	have	have	VERB
ajlm-1677	38	21	chronic	chronic	ADJ
ajlm-1677	38	22	hbv	hbv	NOUN
ajlm-1677	38	23	infection	infection	NOUN
ajlm-1677	38	24	after	after	ADP
ajlm-1677	38	25	testing	test	VERB
ajlm-1677	38	26	positive	positive	ADJ
ajlm-1677	38	27	for	for	ADP
ajlm-1677	38	28	hepatitus	hepatitus	PROPN
ajlm-1677	38	29	b	b	PROPN
ajlm-1677	38	30	surface	surface	NOUN
ajlm-1677	38	31	antigen	antigen	NOUN
ajlm-1677	38	32	antibodies	antibodie	VERB
ajlm-1677	38	33	.	.	PUNCT
ajlm-1677	39	1	for	for	ADP
ajlm-1677	39	2	hbv	hbv	NOUN
ajlm-1677	39	3	sero	sero	NOUN
ajlm-1677	39	4	-	-	PUNCT
ajlm-1677	39	5	diagnosis	diagnosis	NOUN
ajlm-1677	39	6	,	,	PUNCT
ajlm-1677	39	7	5	5	NUM
ajlm-1677	39	8	ml	ml	NOUN
ajlm-1677	39	9	of	of	ADP
ajlm-1677	39	10	blood	blood	NOUN
ajlm-1677	39	11	sample	sample	NOUN
ajlm-1677	39	12	was	be	AUX
ajlm-1677	39	13	collected	collect	VERB
ajlm-1677	39	14	,	,	PUNCT
ajlm-1677	39	15	centrifuged	centrifuge	VERB
ajlm-1677	39	16	at	at	ADP
ajlm-1677	39	17	2500	2500	NUM
ajlm-1677	39	18	revolutions	revolution	NOUN
ajlm-1677	39	19	per	per	ADP
ajlm-1677	39	20	minute	minute	NOUN
ajlm-1677	39	21	for	for	ADP
ajlm-1677	39	22	1	1	NUM
ajlm-1677	39	23	min	min	NOUN
ajlm-1677	39	24	,	,	PUNCT
ajlm-1677	39	25	and	and	CCONJ
ajlm-1677	39	26	1	1	NUM
ajlm-1677	39	27	ml	ml	NOUN
ajlm-1677	39	28	of	of	ADP
ajlm-1677	39	29	plasma	plasma	NOUN
ajlm-1677	39	30	was	be	AUX
ajlm-1677	39	31	used	use	VERB
ajlm-1677	39	32	for	for	ADP
ajlm-1677	39	33	testing	test	VERB
ajlm-1677	39	34	hbsag	hbsag	NOUN
ajlm-1677	39	35	by	by	ADP
ajlm-1677	39	36	third	third	ADJ
ajlm-1677	39	37	-	-	PUNCT
ajlm-1677	39	38	generation	generation	NOUN
ajlm-1677	39	39	enzyme	enzyme	NOUN
ajlm-1677	39	40	-	-	PUNCT
ajlm-1677	39	41	linked	link	VERB
ajlm-1677	39	42	immunosorbent	immunosorbent	NOUN
ajlm-1677	39	43	assay	assay	PROPN
ajlm-1677	39	44	(	(	PUNCT
ajlm-1677	39	45	monolisa	monolisa	NOUN
ajlm-1677	39	46	,	,	PUNCT
ajlm-1677	39	47	bio	bio	NOUN
ajlm-1677	39	48	-	-	PROPN
ajlm-1677	39	49	rad	rad	PROPN
ajlm-1677	39	50	,	,	PUNCT
ajlm-1677	39	51	paris	paris	PROPN
ajlm-1677	39	52	,	,	PUNCT
ajlm-1677	39	53	france	france	PROPN
ajlm-1677	39	54	)	)	PUNCT
ajlm-1677	39	55	according	accord	VERB
ajlm-1677	39	56	to	to	ADP
ajlm-1677	39	57	manufacturer	manufacturer	NOUN
ajlm-1677	39	58	’s	’s	PART
ajlm-1677	39	59	instruction	instruction	NOUN
ajlm-1677	39	60	;	;	PUNCT
ajlm-1677	39	61	a	a	DET
ajlm-1677	39	62	positive	positive	ADJ
ajlm-1677	39	63	hbsag	hbsag	NOUN
ajlm-1677	39	64	result	result	NOUN
ajlm-1677	39	65	indicates	indicate	VERB
ajlm-1677	39	66	current	current	ADJ
ajlm-1677	39	67	infection	infection	NOUN
ajlm-1677	39	68	.	.	PUNCT
ajlm-1677	40	1	all	all	DET
ajlm-1677	40	2	participants	participant	NOUN
ajlm-1677	40	3	were	be	AUX
ajlm-1677	40	4	on	on	ADP
ajlm-1677	40	5	antiviral	antiviral	ADJ
ajlm-1677	40	6	therapy	therapy	NOUN
ajlm-1677	40	7	(	(	PUNCT
ajlm-1677	40	8	hbv	hbv	NOUN
ajlm-1677	40	9	/	/	SYM
ajlm-1677	40	10	hiv	hiv	PROPN
ajlm-1677	40	11	:	:	PUNCT
ajlm-1677	40	12	lamivudine	lamivudine	NOUN
ajlm-1677	40	13	/	/	SYM
ajlm-1677	40	14	tenofovir	tenofovir	PROPN
ajlm-1677	40	15	combination	combination	NOUN
ajlm-1677	40	16	,	,	PUNCT
ajlm-1677	40	17	hbv	hbv	NOUN
ajlm-1677	40	18	-	-	PUNCT
ajlm-1677	40	19	mono	mono	NOUN
ajlm-1677	40	20	:	:	PUNCT
ajlm-1677	40	21	tenofovir	tenofovir	NOUN
ajlm-1677	40	22	alone	alone	ADV
ajlm-1677	40	23	)	)	PUNCT
ajlm-1677	40	24	≥	≥	NOUN
ajlm-1677	40	25	12	12	NUM
ajlm-1677	40	26	months	month	NOUN
ajlm-1677	40	27	.	.	PUNCT
ajlm-1677	41	1	sample	sample	NOUN
ajlm-1677	41	2	preparation	preparation	NOUN
ajlm-1677	41	3	the	the	DET
ajlm-1677	41	4	5	5	NUM
ajlm-1677	41	5	ml	ml	NOUN
ajlm-1677	41	6	of	of	ADP
ajlm-1677	41	7	blood	blood	NOUN
ajlm-1677	41	8	samples	sample	NOUN
ajlm-1677	41	9	collected	collect	VERB
ajlm-1677	41	10	were	be	AUX
ajlm-1677	41	11	centrifuged	centrifuge	VERB
ajlm-1677	41	12	,	,	PUNCT
ajlm-1677	41	13	and	and	CCONJ
ajlm-1677	41	14	the	the	DET
ajlm-1677	41	15	sera	sera	NOUN
ajlm-1677	41	16	separated	separate	VERB
ajlm-1677	41	17	,	,	PUNCT
ajlm-1677	41	18	aliquoted	aliquote	VERB
ajlm-1677	41	19	,	,	PUNCT
ajlm-1677	41	20	and	and	CCONJ
ajlm-1677	41	21	stored	store	VERB
ajlm-1677	41	22	at	at	ADP
ajlm-1677	41	23	–	–	PUNCT
ajlm-1677	41	24	80	80	NUM
ajlm-1677	41	25	°	°	NUM
ajlm-1677	41	26	c	c	NOUN
ajlm-1677	41	27	until	until	ADP
ajlm-1677	41	28	use	use	NOUN
ajlm-1677	41	29	.	.	PUNCT
ajlm-1677	42	1	the	the	DET
ajlm-1677	42	2	hbv	hbv	NOUN
ajlm-1677	42	3	dna	dna	PROPN
ajlm-1677	42	4	detection	detection	NOUN
ajlm-1677	42	5	and	and	CCONJ
ajlm-1677	42	6	quantification	quantification	NOUN
ajlm-1677	42	7	were	be	AUX
ajlm-1677	42	8	performed	perform	VERB
ajlm-1677	42	9	using	use	VERB
ajlm-1677	42	10	automated	automate	VERB
ajlm-1677	42	11	cobas	cobas	ADJ
ajlm-1677	42	12	®	®	NOUN
ajlm-1677	42	13	ampliprep	ampliprep	PROPN
ajlm-1677	42	14	taqman	taqman	NOUN
ajlm-1677	42	15	hbv	hbv	PROPN
ajlm-1677	42	16	test	test	NOUN
ajlm-1677	42	17	version	version	NOUN
ajlm-1677	42	18	2.0	2.0	NUM
ajlm-1677	42	19	(	(	PUNCT
ajlm-1677	42	20	roche	roche	NOUN
ajlm-1677	42	21	diagnostics	diagnostic	NOUN
ajlm-1677	42	22	international	international	PROPN
ajlm-1677	42	23	ag	ag	PROPN
ajlm-1677	42	24	,	,	PUNCT
ajlm-1677	42	25	rotkreuz	rotkreuz	PROPN
ajlm-1677	42	26	,	,	PUNCT
ajlm-1677	42	27	switzerland	switzerland	PROPN
ajlm-1677	42	28	)	)	PUNCT
ajlm-1677	42	29	.	.	PUNCT
ajlm-1677	43	1	a	a	DET
ajlm-1677	43	2	total	total	NOUN
ajlm-1677	43	3	of	of	ADP
ajlm-1677	43	4	30	30	NUM
ajlm-1677	43	5	samples	sample	NOUN
ajlm-1677	43	6	with	with	ADP
ajlm-1677	43	7	detectable	detectable	ADJ
ajlm-1677	43	8	viral	viral	ADJ
ajlm-1677	43	9	load	load	NOUN
ajlm-1677	43	10	were	be	AUX
ajlm-1677	43	11	selected	select	VERB
ajlm-1677	43	12	for	for	ADP
ajlm-1677	43	13	dna	dna	NOUN
ajlm-1677	43	14	sequencing	sequence	VERB
ajlm-1677	43	15	reactions	reaction	NOUN
ajlm-1677	43	16	.	.	PUNCT
ajlm-1677	44	1	hepatitis	hepatitis	PROPN
ajlm-1677	44	2	b	b	PROPN
ajlm-1677	44	3	virus	virus	PROPN
ajlm-1677	44	4	dna	dna	PROPN
ajlm-1677	44	5	extraction	extraction	NOUN
ajlm-1677	44	6	dna	dna	PROPN
ajlm-1677	44	7	extraction	extraction	NOUN
ajlm-1677	44	8	,	,	PUNCT
ajlm-1677	44	9	amplification	amplification	NOUN
ajlm-1677	44	10	and	and	CCONJ
ajlm-1677	44	11	direct	direct	ADJ
ajlm-1677	44	12	sequencing	sequencing	NOUN
ajlm-1677	44	13	of	of	ADP
ajlm-1677	44	14	the	the	DET
ajlm-1677	44	15	full	full	ADJ
ajlm-1677	44	16	-	-	PUNCT
ajlm-1677	44	17	length	length	NOUN
ajlm-1677	44	18	hbsag	hbsag	NOUN
ajlm-1677	44	19	and	and	CCONJ
ajlm-1677	44	20	the	the	DET
ajlm-1677	44	21	reverse	reverse	ADJ
ajlm-1677	44	22	transcriptase	transcriptase	NOUN
ajlm-1677	44	23	genes	gene	NOUN
ajlm-1677	44	24	were	be	AUX
ajlm-1677	44	25	performed	perform	VERB
ajlm-1677	44	26	at	at	ADP
ajlm-1677	44	27	center	center	NOUN
ajlm-1677	44	28	for	for	ADP
ajlm-1677	44	29	human	human	ADJ
ajlm-1677	44	30	virology	virology	NOUN
ajlm-1677	44	31	and	and	CCONJ
ajlm-1677	44	32	genomics	genomic	NOUN
ajlm-1677	44	33	,	,	PUNCT
ajlm-1677	44	34	nigeria	nigeria	PROPN
ajlm-1677	44	35	institute	institute	PROPN
ajlm-1677	44	36	of	of	ADP
ajlm-1677	44	37	medical	medical	ADJ
ajlm-1677	44	38	research	research	NOUN
ajlm-1677	44	39	,	,	PUNCT
ajlm-1677	44	40	lagos	lagos	PROPN
ajlm-1677	44	41	,	,	PUNCT
ajlm-1677	44	42	nigeria	nigeria	PROPN
ajlm-1677	44	43	.	.	PUNCT
ajlm-1677	45	1	viral	viral	ADJ
ajlm-1677	45	2	dna	dna	PROPN
ajlm-1677	45	3	was	be	AUX
ajlm-1677	45	4	extracted	extract	VERB
ajlm-1677	45	5	from	from	ADP
ajlm-1677	45	6	200	200	NUM
ajlm-1677	45	7	µl	µl	NOUN
ajlm-1677	45	8	of	of	ADP
ajlm-1677	45	9	plasma	plasma	NOUN
ajlm-1677	45	10	samples	sample	NOUN
ajlm-1677	45	11	using	use	VERB
ajlm-1677	45	12	the	the	DET
ajlm-1677	45	13	zr	zr	PROPN
ajlm-1677	45	14	viral	viral	ADJ
ajlm-1677	45	15	dna	dna	PROPN
ajlm-1677	45	16	kittm	kittm	NOUN
ajlm-1677	45	17	(	(	PUNCT
ajlm-1677	45	18	zymo	zymo	NOUN
ajlm-1677	45	19	research	research	NOUN
ajlm-1677	45	20	,	,	PUNCT
ajlm-1677	45	21	irvine	irvine	PROPN
ajlm-1677	45	22	,	,	PUNCT
ajlm-1677	45	23	california	california	PROPN
ajlm-1677	45	24	,	,	PUNCT
ajlm-1677	45	25	united	united	PROPN
ajlm-1677	45	26	states	states	PROPN
ajlm-1677	45	27	)	)	PUNCT
ajlm-1677	45	28	,	,	PUNCT
ajlm-1677	45	29	according	accord	VERB
ajlm-1677	45	30	to	to	ADP
ajlm-1677	45	31	the	the	DET
ajlm-1677	45	32	manufacturer	manufacturer	NOUN
ajlm-1677	45	33	’s	’s	PART
ajlm-1677	45	34	protocol	protocol	NOUN
ajlm-1677	45	35	.	.	PUNCT
ajlm-1677	46	1	primers	primer	NOUN
ajlm-1677	46	2	and	and	CCONJ
ajlm-1677	46	3	nested	nest	VERB
ajlm-1677	46	4	polymerase	polymerase	NOUN
ajlm-1677	46	5	chain	chain	NOUN
ajlm-1677	46	6	reaction	reaction	NOUN
ajlm-1677	46	7	universal	universal	ADJ
ajlm-1677	46	8	primers	primer	NOUN
ajlm-1677	46	9	from	from	ADP
ajlm-1677	46	10	previous	previous	ADJ
ajlm-1677	46	11	study	study	NOUN
ajlm-1677	46	12	were	be	AUX
ajlm-1677	46	13	used	use	VERB
ajlm-1677	46	14	for	for	ADP
ajlm-1677	46	15	detection	detection	NOUN
ajlm-1677	46	16	of	of	ADP
ajlm-1677	46	17	hbv	hbv	NOUN
ajlm-1677	46	18	genotypes,23	genotypes,23	PROPN
ajlm-1677	46	19	which	which	PRON
ajlm-1677	46	20	were	be	AUX
ajlm-1677	46	21	synthesised	synthesise	VERB
ajlm-1677	46	22	by	by	ADP
ajlm-1677	46	23	inqaba	inqaba	NOUN
ajlm-1677	46	24	biotech	biotech	NOUN
ajlm-1677	46	25	(	(	PUNCT
ajlm-1677	46	26	pretoria	pretoria	PROPN
ajlm-1677	46	27	,	,	PUNCT
ajlm-1677	46	28	south	south	PROPN
ajlm-1677	46	29	africa	africa	PROPN
ajlm-1677	46	30	)	)	PUNCT
ajlm-1677	46	31	.	.	PUNCT
ajlm-1677	47	1	two	two	NUM
ajlm-1677	47	2	outer	outer	ADJ
ajlm-1677	47	3	primer	primer	NOUN
ajlm-1677	47	4	sets	set	NOUN
ajlm-1677	47	5	were	be	AUX
ajlm-1677	47	6	used	use	VERB
ajlm-1677	47	7	.	.	PUNCT
ajlm-1677	48	1	primer	primer	NOUN
ajlm-1677	48	2	set	set	VERB
ajlm-1677	48	3	251f	251f	NOUN
ajlm-1677	48	4	(	(	PUNCT
ajlm-1677	48	5	5ʹ-gga	5ʹ-gga	NUM
ajlm-1677	48	6	tgt	tgt	PROPN
ajlm-1677	48	7	gtc	gtc	PROPN
ajlm-1677	48	8	tgc	tgc	PROPN
ajlm-1677	48	9	ggc	ggc	PROPN
ajlm-1677	48	10	gtt	gtt	PROPN
ajlm-1677	48	11	t-3ʹ	t-3ʹ	PROPN
ajlm-1677	48	12	)	)	PUNCT
ajlm-1677	48	13	and	and	CCONJ
ajlm-1677	48	14	1797r	1797r	NUM
ajlm-1677	48	15	(	(	PUNCT
ajlm-1677	48	16	5ʹ-gac	5ʹ-gac	NUM
ajlm-1677	48	17	cca	cca	PROPN
ajlm-1677	48	18	caa	caa	PROPN
ajlm-1677	48	19	ttc	ttc	PROPN
ajlm-1677	48	20	ktt	ktt	PROPN
ajlm-1677	48	21	gac	gac	PROPN
ajlm-1677	49	1	ata	ata	PROPN
ajlm-1677	49	2	ctt	ctt	PROPN
ajlm-1677	49	3	tcc-3ʹ	tcc-3ʹ	PROPN
ajlm-1677	49	4	)	)	PUNCT
ajlm-1677	49	5	were	be	AUX
ajlm-1677	49	6	used	use	VERB
ajlm-1677	49	7	for	for	ADP
ajlm-1677	49	8	the	the	DET
ajlm-1677	49	9	initial	initial	ADJ
ajlm-1677	49	10	amplification	amplification	NOUN
ajlm-1677	49	11	,	,	PUNCT
ajlm-1677	49	12	and	and	CCONJ
ajlm-1677	49	13	251f	251f	NOUN
ajlm-1677	49	14	(	(	PUNCT
ajlm-1677	49	15	5ʹ-cga	5ʹ-cga	NUM
ajlm-1677	49	16	acc	acc	PROPN
ajlm-1677	49	17	act	act	PROPN
ajlm-1677	49	18	gaa	gaa	PROPN
ajlm-1677	49	19	caa	caa	PROPN
ajlm-1677	49	20	atg	atg	PROPN
ajlm-1677	49	21	gc-3ʹ	gc-3ʹ	PROPN
ajlm-1677	49	22	)	)	PUNCT
ajlm-1677	49	23	and	and	CCONJ
ajlm-1677	49	24	1190r	1190r	NUM
ajlm-1677	49	25	(	(	PUNCT
ajlm-1677	49	26	5ʹ-tca	5ʹ-tca	NUM
ajlm-1677	49	27	cca	cca	NOUN
ajlm-1677	49	28	tat	tat	NOUN
ajlm-1677	49	29	tct	tct	PROPN
ajlm-1677	49	30	tgg	tgg	PROPN
ajlm-1677	49	31	gaa	gaa	PROPN
ajlm-1677	49	32	caa	caa	PROPN
ajlm-1677	49	33	ga-3ʹ	ga-3ʹ	PROPN
ajlm-1677	49	34	)	)	PUNCT
ajlm-1677	49	35	used	use	VERB
ajlm-1677	49	36	for	for	ADP
ajlm-1677	49	37	the	the	DET
ajlm-1677	49	38	second	second	ADJ
ajlm-1677	49	39	amplification	amplification	NOUN
ajlm-1677	49	40	,	,	PUNCT
ajlm-1677	49	41	as	as	SCONJ
ajlm-1677	49	42	previously	previously	ADV
ajlm-1677	49	43	described.23	described.23	AUX
ajlm-1677	49	44	these	these	DET
ajlm-1677	49	45	primer	primer	NOUN
ajlm-1677	49	46	sets	set	NOUN
ajlm-1677	49	47	were	be	AUX
ajlm-1677	49	48	designed	design	VERB
ajlm-1677	49	49	to	to	PART
ajlm-1677	49	50	generate	generate	VERB
ajlm-1677	49	51	overlapping	overlap	VERB
ajlm-1677	49	52	fragments	fragment	NOUN
ajlm-1677	49	53	,	,	PUNCT
ajlm-1677	49	54	and	and	CCONJ
ajlm-1677	49	55	polymerase	polymerase	NOUN
ajlm-1677	49	56	chain	chain	NOUN
ajlm-1677	49	57	reaction	reaction	NOUN
ajlm-1677	49	58	(	(	PUNCT
ajlm-1677	49	59	pcr	pcr	PROPN
ajlm-1677	49	60	)	)	PUNCT
ajlm-1677	49	61	was	be	AUX
ajlm-1677	49	62	performed	perform	VERB
ajlm-1677	49	63	using	use	VERB
ajlm-1677	49	64	platinum	platinum	NOUN
ajlm-1677	49	65	™	™	ADJ
ajlm-1677	49	66	superfi	superfi	VERB
ajlm-1677	49	67	™	™	ADJ
ajlm-1677	49	68	pcr	pcr	NOUN
ajlm-1677	49	69	master	master	NOUN
ajlm-1677	49	70	mix	mix	NOUN
ajlm-1677	49	71	(	(	PUNCT
ajlm-1677	49	72	thermofisher	thermofisher	PROPN
ajlm-1677	49	73	,	,	PUNCT
ajlm-1677	49	74	waltham	waltham	PROPN
ajlm-1677	49	75	,	,	PUNCT
ajlm-1677	49	76	massachusetts	massachusetts	PROPN
ajlm-1677	49	77	,	,	PUNCT
ajlm-1677	49	78	united	united	PROPN
ajlm-1677	49	79	states	states	PROPN
ajlm-1677	49	80	)	)	PUNCT
ajlm-1677	49	81	.	.	PUNCT
ajlm-1677	50	1	each	each	DET
ajlm-1677	50	2	25.0	25.0	NUM
ajlm-1677	50	3	µl	µl	ADP
ajlm-1677	50	4	reaction	reaction	NOUN
ajlm-1677	50	5	mixture	mixture	NOUN
ajlm-1677	50	6	contained	contain	VERB
ajlm-1677	50	7	12.5	12.5	NUM
ajlm-1677	50	8	µl	µl	NOUN
ajlm-1677	50	9	of	of	ADP
ajlm-1677	50	10	2×	2×	NUM
ajlm-1677	50	11	premix	premix	NOUN
ajlm-1677	50	12	,	,	PUNCT
ajlm-1677	50	13	1.25	1.25	NUM
ajlm-1677	50	14	µl	µl	ADP
ajlm-1677	50	15	of	of	ADP
ajlm-1677	50	16	each	each	DET
ajlm-1677	50	17	10.0	10.0	NUM
ajlm-1677	50	18	µm	µm	NOUN
ajlm-1677	50	19	primer	primer	NOUN
ajlm-1677	50	20	,	,	PUNCT
ajlm-1677	50	21	5.0	5.0	NUM
ajlm-1677	50	22	µl	µl	NOUN
ajlm-1677	50	23	of	of	ADP
ajlm-1677	50	24	pcr	pcr	ADJ
ajlm-1677	50	25	water	water	NOUN
ajlm-1677	50	26	and	and	CCONJ
ajlm-1677	50	27	5.0	5.0	NUM
ajlm-1677	50	28	µl	µl	ADP
ajlm-1677	50	29	dna	dna	PROPN
ajlm-1677	50	30	template	template	NOUN
ajlm-1677	50	31	for	for	ADP
ajlm-1677	50	32	first	first	ADJ
ajlm-1677	50	33	pcr	pcr	NOUN
ajlm-1677	50	34	while	while	SCONJ
ajlm-1677	50	35	for	for	ADP
ajlm-1677	50	36	the	the	DET
ajlm-1677	50	37	second	second	ADJ
ajlm-1677	50	38	pcr	pcr	NOUN
ajlm-1677	50	39	,	,	PUNCT
ajlm-1677	50	40	3.0	3.0	NUM
ajlm-1677	50	41	µl	µl	NOUN
ajlm-1677	50	42	of	of	ADP
ajlm-1677	50	43	first	first	ADJ
ajlm-1677	50	44	pcr	pcr	ADJ
ajlm-1677	50	45	product	product	NOUN
ajlm-1677	50	46	was	be	AUX
ajlm-1677	50	47	used	use	VERB
ajlm-1677	50	48	.	.	PUNCT
ajlm-1677	51	1	both	both	DET
ajlm-1677	51	2	pcr	pcr	NOUN
ajlm-1677	51	3	were	be	AUX
ajlm-1677	51	4	carried	carry	VERB
ajlm-1677	51	5	out	out	ADP
ajlm-1677	51	6	in	in	ADP
ajlm-1677	51	7	applied	apply	VERB
ajlm-1677	51	8	biosystems	biosystems	PROPN
ajlm-1677	51	9	miniamp	miniamp	NOUN
ajlm-1677	51	10	plus	plus	CCONJ
ajlm-1677	51	11	thermal	thermal	ADJ
ajlm-1677	51	12	cycler	cycler	NOUN
ajlm-1677	51	13	(	(	PUNCT
ajlm-1677	51	14	thermofisher	thermofisher	PROPN
ajlm-1677	51	15	,	,	PUNCT
ajlm-1677	51	16	waltham	waltham	PROPN
ajlm-1677	51	17	,	,	PUNCT
ajlm-1677	51	18	massachusetts	massachusetts	PROPN
ajlm-1677	51	19	,	,	PUNCT
ajlm-1677	51	20	united	united	PROPN
ajlm-1677	51	21	states	states	PROPN
ajlm-1677	51	22	)	)	PUNCT
ajlm-1677	51	23	with	with	ADP
ajlm-1677	51	24	the	the	DET
ajlm-1677	51	25	following	follow	VERB
ajlm-1677	51	26	cycling	cycling	NOUN
ajlm-1677	51	27	conditions	condition	NOUN
ajlm-1677	51	28	:	:	PUNCT
ajlm-1677	51	29	95	95	NUM
ajlm-1677	51	30	°	°	NUM
ajlm-1677	51	31	c	c	NOUN
ajlm-1677	51	32	for	for	ADP
ajlm-1677	51	33	3	3	NUM
ajlm-1677	51	34	min	min	NOUN
ajlm-1677	51	35	followed	follow	VERB
ajlm-1677	51	36	by	by	ADP
ajlm-1677	51	37	35	35	NUM
ajlm-1677	51	38	cycles	cycle	NOUN
ajlm-1677	51	39	of	of	ADP
ajlm-1677	51	40	97	97	NUM
ajlm-1677	51	41	°	°	NUM
ajlm-1677	51	42	c	c	NOUN
ajlm-1677	51	43	for	for	ADP
ajlm-1677	51	44	30	30	NUM
ajlm-1677	51	45	s	s	NOUN
ajlm-1677	51	46	,	,	PUNCT
ajlm-1677	51	47	54	54	NUM
ajlm-1677	51	48	°	°	NUM
ajlm-1677	51	49	c	c	NOUN
ajlm-1677	51	50	for	for	ADP
ajlm-1677	51	51	60	60	NUM
ajlm-1677	51	52	s	s	NOUN
ajlm-1677	51	53	and	and	CCONJ
ajlm-1677	51	54	72	72	NUM
ajlm-1677	51	55	°	°	NUM
ajlm-1677	51	56	c	c	NOUN
ajlm-1677	51	57	for	for	ADP
ajlm-1677	51	58	60	60	NUM
ajlm-1677	51	59	s	s	NOUN
ajlm-1677	51	60	for	for	ADP
ajlm-1677	51	61	the	the	DET
ajlm-1677	51	62	first	first	ADJ
ajlm-1677	51	63	round	round	NOUN
ajlm-1677	51	64	of	of	ADP
ajlm-1677	51	65	pcr	pcr	NOUN
ajlm-1677	51	66	while	while	SCONJ
ajlm-1677	51	67	31	31	NUM
ajlm-1677	51	68	cycles	cycle	NOUN
ajlm-1677	51	69	were	be	AUX
ajlm-1677	51	70	done	do	VERB
ajlm-1677	51	71	for	for	ADP
ajlm-1677	51	72	the	the	DET
ajlm-1677	51	73	second	second	ADJ
ajlm-1677	51	74	round	round	NOUN
ajlm-1677	51	75	of	of	ADP
ajlm-1677	51	76	pcr	pcr	NOUN
ajlm-1677	51	77	.	.	PUNCT
ajlm-1677	52	1	each	each	DET
ajlm-1677	52	2	round	round	NOUN
ajlm-1677	52	3	of	of	ADP
ajlm-1677	52	4	pcr	pcr	NOUN
ajlm-1677	52	5	was	be	AUX
ajlm-1677	52	6	followed	follow	VERB
ajlm-1677	52	7	by	by	ADP
ajlm-1677	52	8	a	a	DET
ajlm-1677	52	9	final	final	ADJ
ajlm-1677	52	10	extension	extension	NOUN
ajlm-1677	52	11	of	of	ADP
ajlm-1677	52	12	72	72	NUM
ajlm-1677	52	13	°	°	NOUN
ajlm-1677	52	14	c	c	NOUN
ajlm-1677	52	15	for	for	ADP
ajlm-1677	52	16	10	10	NUM
ajlm-1677	52	17	min	min	NOUN
ajlm-1677	52	18	.	.	PROPN
ajlm-1677	52	19	amplified	amplify	VERB
ajlm-1677	52	20	products	product	NOUN
ajlm-1677	52	21	were	be	AUX
ajlm-1677	52	22	verified	verify	VERB
ajlm-1677	52	23	using	use	VERB
ajlm-1677	52	24	1	1	NUM
ajlm-1677	52	25	%	%	NOUN
ajlm-1677	52	26	agarose	agarose	NOUN
ajlm-1677	52	27	gel	gel	NOUN
ajlm-1677	52	28	stained	stain	VERB
ajlm-1677	52	29	with	with	ADP
ajlm-1677	52	30	gelred	gelre	VERB
ajlm-1677	52	31	®	®	NOUN
ajlm-1677	52	32	(	(	PUNCT
ajlm-1677	52	33	biotium	biotium	PROPN
ajlm-1677	52	34	,	,	PUNCT
ajlm-1677	52	35	fremont	fremont	PROPN
ajlm-1677	52	36	,	,	PUNCT
ajlm-1677	52	37	california	california	PROPN
ajlm-1677	52	38	,	,	PUNCT
ajlm-1677	52	39	united	united	PROPN
ajlm-1677	52	40	states	states	PROPN
ajlm-1677	52	41	)	)	PUNCT
ajlm-1677	52	42	on	on	ADP
ajlm-1677	52	43	a	a	DET
ajlm-1677	52	44	cyfox	cyfox	VERB
ajlm-1677	52	45	gel	gel	NOUN
ajlm-1677	52	46	documentation	documentation	NOUN
ajlm-1677	52	47	system	system	NOUN
ajlm-1677	52	48	(	(	PUNCT
ajlm-1677	52	49	sysmex	sysmex	NOUN
ajlm-1677	52	50	-	-	PUNCT
ajlm-1677	52	51	partec	partec	NOUN
ajlm-1677	52	52	,	,	PUNCT
ajlm-1677	52	53	münster	münster	NOUN
ajlm-1677	52	54	,	,	PUNCT
ajlm-1677	52	55	germany	germany	PROPN
ajlm-1677	52	56	)	)	PUNCT
ajlm-1677	52	57	.	.	PUNCT
ajlm-1677	53	1	the	the	DET
ajlm-1677	53	2	amplified	amplify	VERB
ajlm-1677	53	3	products	product	NOUN
ajlm-1677	53	4	were	be	AUX
ajlm-1677	53	5	purified	purify	VERB
ajlm-1677	53	6	using	use	VERB
ajlm-1677	53	7	exosap	exosap	NOUN
ajlm-1677	53	8	-	-	PUNCT
ajlm-1677	53	9	it	it	PRON
ajlm-1677	53	10	(	(	PUNCT
ajlm-1677	53	11	thermofisher	thermofisher	PROPN
ajlm-1677	53	12	,	,	PUNCT
ajlm-1677	53	13	waltham	waltham	PROPN
ajlm-1677	53	14	,	,	PUNCT
ajlm-1677	53	15	massachusetts	massachusetts	PROPN
ajlm-1677	53	16	,	,	PUNCT
ajlm-1677	53	17	united	united	PROPN
ajlm-1677	53	18	states	states	PROPN
ajlm-1677	53	19	)	)	PUNCT
ajlm-1677	53	20	and	and	CCONJ
ajlm-1677	53	21	quantified	quantify	VERB
ajlm-1677	53	22	using	use	VERB
ajlm-1677	53	23	dsdna	dsdna	ADV
ajlm-1677	53	24	high	high	ADJ
ajlm-1677	53	25	-	-	PUNCT
ajlm-1677	53	26	sensitivity	sensitivity	NOUN
ajlm-1677	53	27	(	(	PUNCT
ajlm-1677	53	28	thermofisher	thermofisher	PROPN
ajlm-1677	53	29	,	,	PUNCT
ajlm-1677	53	30	waltham	waltham	PROPN
ajlm-1677	53	31	,	,	PUNCT
ajlm-1677	53	32	massachusetts	massachusetts	PROPN
ajlm-1677	53	33	,	,	PUNCT
ajlm-1677	53	34	united	united	PROPN
ajlm-1677	53	35	states	states	PROPN
ajlm-1677	53	36	)	)	PUNCT
ajlm-1677	53	37	reagent	reagent	NOUN
ajlm-1677	53	38	on	on	ADP
ajlm-1677	53	39	the	the	DET
ajlm-1677	53	40	qubit-4tm	qubit-4tm	NOUN
ajlm-1677	53	41	(	(	PUNCT
ajlm-1677	53	42	thermofisher	thermofisher	PROPN
ajlm-1677	53	43	,	,	PUNCT
ajlm-1677	53	44	waltham	waltham	PROPN
ajlm-1677	53	45	,	,	PUNCT
ajlm-1677	53	46	massachusetts	massachusetts	PROPN
ajlm-1677	53	47	,	,	PUNCT
ajlm-1677	53	48	united	united	PROPN
ajlm-1677	53	49	states	states	PROPN
ajlm-1677	53	50	)	)	PUNCT
ajlm-1677	53	51	.	.	PUNCT
ajlm-1677	54	1	samples	sample	NOUN
ajlm-1677	54	2	with	with	ADP
ajlm-1677	54	3	dna	dna	PROPN
ajlm-1677	54	4	concentration	concentration	NOUN
ajlm-1677	54	5	≥	≥	NUM
ajlm-1677	54	6	5	5	NUM
ajlm-1677	54	7	ng/µl	ng/µl	NUM
ajlm-1677	54	8	and	and	CCONJ
ajlm-1677	54	9	gel	gel	NOUN
ajlm-1677	54	10	bands	band	NOUN
ajlm-1677	54	11	of	of	ADP
ajlm-1677	54	12	appropriate	appropriate	ADJ
ajlm-1677	54	13	size	size	NOUN
ajlm-1677	54	14	were	be	AUX
ajlm-1677	54	15	selected	select	VERB
ajlm-1677	54	16	for	for	ADP
ajlm-1677	54	17	further	further	ADJ
ajlm-1677	54	18	processing	processing	NOUN
ajlm-1677	54	19	.	.	PUNCT
ajlm-1677	55	1	purification	purification	NOUN
ajlm-1677	55	2	and	and	CCONJ
ajlm-1677	55	3	sanger	sanger	PROPN
ajlm-1677	55	4	sequencing	sequence	VERB
ajlm-1677	55	5	verified	verify	VERB
ajlm-1677	55	6	nested	nested	ADJ
ajlm-1677	55	7	pcr	pcr	ADJ
ajlm-1677	55	8	products	product	NOUN
ajlm-1677	55	9	were	be	AUX
ajlm-1677	55	10	purified	purify	VERB
ajlm-1677	55	11	using	use	VERB
ajlm-1677	55	12	exosap	exosap	NOUN
ajlm-1677	55	13	-	-	PUNCT
ajlm-1677	55	14	ittm	ittm	NOUN
ajlm-1677	55	15	pcr	pcr	NOUN
ajlm-1677	55	16	product	product	NOUN
ajlm-1677	55	17	cleanup	cleanup	NOUN
ajlm-1677	55	18	reagent	reagent	NOUN
ajlm-1677	55	19	(	(	PUNCT
ajlm-1677	55	20	thermofisher	thermofisher	PROPN
ajlm-1677	55	21	,	,	PUNCT
ajlm-1677	55	22	waltham	waltham	PROPN
ajlm-1677	55	23	,	,	PUNCT
ajlm-1677	55	24	massachusetts	massachusetts	PROPN
ajlm-1677	55	25	,	,	PUNCT
ajlm-1677	55	26	united	united	PROPN
ajlm-1677	55	27	states	states	PROPN
ajlm-1677	55	28	)	)	PUNCT
ajlm-1677	55	29	at	at	ADP
ajlm-1677	55	30	37	37	NUM
ajlm-1677	55	31	°	°	ADP
ajlm-1677	55	32	c	c	NOUN
ajlm-1677	55	33	for	for	ADP
ajlm-1677	55	34	15	15	NUM
ajlm-1677	55	35	min	min	NOUN
ajlm-1677	55	36	(	(	PUNCT
ajlm-1677	55	37	to	to	PART
ajlm-1677	55	38	digest	digest	VERB
ajlm-1677	55	39	excess	excess	ADJ
ajlm-1677	55	40	primers	primer	NOUN
ajlm-1677	55	41	and	and	CCONJ
ajlm-1677	55	42	deoxynucleoside	deoxynucleoside	NOUN
ajlm-1677	55	43	triphosphates	triphosphate	NOUN
ajlm-1677	55	44	)	)	PUNCT
ajlm-1677	55	45	,	,	PUNCT
ajlm-1677	55	46	and	and	CCONJ
ajlm-1677	55	47	80	80	NUM
ajlm-1677	55	48	°	°	NUM
ajlm-1677	55	49	c	c	NOUN
ajlm-1677	55	50	for	for	ADP
ajlm-1677	55	51	15	15	NUM
ajlm-1677	55	52	min	min	NOUN
ajlm-1677	55	53	(	(	PUNCT
ajlm-1677	55	54	to	to	PART
ajlm-1677	55	55	inactivate	inactivate	VERB
ajlm-1677	55	56	the	the	DET
ajlm-1677	55	57	enzymes	enzyme	NOUN
ajlm-1677	55	58	)	)	PUNCT
ajlm-1677	55	59	according	accord	VERB
ajlm-1677	55	60	to	to	ADP
ajlm-1677	55	61	manufacturer	manufacturer	PROPN
ajlm-1677	55	62	’s	’s	PART
ajlm-1677	55	63	protocol	protocol	NOUN
ajlm-1677	55	64	.	.	PUNCT
ajlm-1677	56	1	the	the	DET
ajlm-1677	56	2	sequencing	sequence	VERB
ajlm-1677	56	3	reaction	reaction	NOUN
ajlm-1677	56	4	mixture	mixture	NOUN
ajlm-1677	56	5	contained	contain	VERB
ajlm-1677	56	6	1.0	1.0	NUM
ajlm-1677	56	7	µl	µl	NOUN
ajlm-1677	56	8	of	of	ADP
ajlm-1677	56	9	bigdye	bigdye	NOUN
ajlm-1677	56	10	®	®	NOUN
ajlm-1677	56	11	terminator	terminator	NOUN
ajlm-1677	56	12	version	version	PROPN
ajlm-1677	56	13	3.1	3.1	NUM
ajlm-1677	56	14	ready	ready	ADJ
ajlm-1677	56	15	reaction	reaction	NOUN
ajlm-1677	56	16	mix	mix	NOUN
ajlm-1677	56	17	(	(	PUNCT
ajlm-1677	56	18	applied	apply	VERB
ajlm-1677	56	19	biosystems	biosystem	NOUN
ajlm-1677	56	20	,	,	PUNCT
ajlm-1677	56	21	foster	foster	ADJ
ajlm-1677	56	22	city	city	NOUN
ajlm-1677	56	23	,	,	PUNCT
ajlm-1677	56	24	california	california	PROPN
ajlm-1677	56	25	,	,	PUNCT
ajlm-1677	56	26	united	united	PROPN
ajlm-1677	56	27	states	states	PROPN
ajlm-1677	56	28	)	)	PUNCT
ajlm-1677	56	29	,	,	PUNCT
ajlm-1677	56	30	4.0	4.0	NUM
ajlm-1677	56	31	µl	µl	NOUN
ajlm-1677	56	32	of	of	ADP
ajlm-1677	56	33	5×	5×	ADJ
ajlm-1677	56	34	sequencing	sequencing	NOUN
ajlm-1677	56	35	buffer	buffer	NOUN
ajlm-1677	56	36	,	,	PUNCT
ajlm-1677	56	37	2.0	2.0	NUM
ajlm-1677	56	38	µl	µl	NOUN
ajlm-1677	56	39	of	of	ADP
ajlm-1677	56	40	template	template	NOUN
ajlm-1677	56	41	,	,	PUNCT
ajlm-1677	56	42	11.0	11.0	NUM
ajlm-1677	56	43	µl	µl	NOUN
ajlm-1677	56	44	of	of	ADP
ajlm-1677	56	45	double	double	ADJ
ajlm-1677	56	46	distilled	distil	VERB
ajlm-1677	56	47	water	water	NOUN
ajlm-1677	56	48	,	,	PUNCT
ajlm-1677	56	49	and	and	CCONJ
ajlm-1677	56	50	2.0	2.0	NUM
ajlm-1677	56	51	µl	µl	NOUN
ajlm-1677	56	52	of	of	ADP
ajlm-1677	56	53	10.0	10.0	NUM
ajlm-1677	56	54	µm	µm	ADP
ajlm-1677	56	55	251f	251f	NOUN
ajlm-1677	56	56	and	and	CCONJ
ajlm-1677	56	57	1190r	1190r	NUM
ajlm-1677	56	58	primers	primer	NOUN
ajlm-1677	56	59	.	.	PUNCT
ajlm-1677	57	1	cycle	cycle	NOUN
ajlm-1677	57	2	sequencing	sequencing	NOUN
ajlm-1677	57	3	was	be	AUX
ajlm-1677	57	4	performed	perform	VERB
ajlm-1677	57	5	using	use	VERB
ajlm-1677	57	6	251f	251f	NOUN
ajlm-1677	57	7	and	and	CCONJ
ajlm-1677	57	8	1190r	1190r	NUM
ajlm-1677	57	9	primers	primer	NOUN
ajlm-1677	57	10	in	in	ADP
ajlm-1677	57	11	a	a	DET
ajlm-1677	57	12	miniamp	miniamp	NOUN
ajlm-1677	57	13	plus	plus	CCONJ
ajlm-1677	57	14	thermal	thermal	ADJ
ajlm-1677	57	15	cycler	cycler	NOUN
ajlm-1677	57	16	with	with	ADP
ajlm-1677	57	17	the	the	DET
ajlm-1677	57	18	following	follow	VERB
ajlm-1677	57	19	program	program	NOUN
ajlm-1677	57	20	:	:	PUNCT
ajlm-1677	57	21	25	25	NUM
ajlm-1677	57	22	cycles	cycle	NOUN
ajlm-1677	57	23	of	of	ADP
ajlm-1677	57	24	96	96	NUM
ajlm-1677	57	25	°	°	NUM
ajlm-1677	57	26	c	c	NOUN
ajlm-1677	57	27	for	for	ADP
ajlm-1677	57	28	10	10	NUM
ajlm-1677	57	29	s	s	NOUN
ajlm-1677	57	30	,	,	PUNCT
ajlm-1677	57	31	50	50	NUM
ajlm-1677	57	32	°	°	NOUN
ajlm-1677	57	33	c	c	NOUN
ajlm-1677	57	34	for	for	ADP
ajlm-1677	57	35	5	5	NUM
ajlm-1677	57	36	s	s	NOUN
ajlm-1677	57	37	and	and	CCONJ
ajlm-1677	57	38	60	60	NUM
ajlm-1677	57	39	°	°	ADP
ajlm-1677	57	40	c	c	NOUN
ajlm-1677	57	41	for	for	ADP
ajlm-1677	57	42	4	4	NUM
ajlm-1677	57	43	min	min	NOUN
ajlm-1677	57	44	.	.	PUNCT
ajlm-1677	58	1	the	the	DET
ajlm-1677	58	2	cycle	cycle	NOUN
ajlm-1677	58	3	sequencing	sequence	VERB
ajlm-1677	58	4	product	product	NOUN
ajlm-1677	58	5	was	be	AUX
ajlm-1677	58	6	purified	purify	VERB
ajlm-1677	58	7	using	use	VERB
ajlm-1677	58	8	the	the	DET
ajlm-1677	58	9	bigdye	bigdye	NOUN
ajlm-1677	58	10	xterminator	xterminator	NOUN
ajlm-1677	58	11	®	®	NOUN
ajlm-1677	58	12	solution	solution	NOUN
ajlm-1677	58	13	(	(	PUNCT
ajlm-1677	58	14	applied	apply	VERB
ajlm-1677	58	15	biosystems	biosystem	NOUN
ajlm-1677	58	16	,	,	PUNCT
ajlm-1677	58	17	waltham	waltham	PROPN
ajlm-1677	58	18	,	,	PUNCT
ajlm-1677	58	19	massachusetts	massachusetts	PROPN
ajlm-1677	58	20	,	,	PUNCT
ajlm-1677	58	21	united	united	PROPN
ajlm-1677	58	22	states	states	PROPN
ajlm-1677	58	23	)	)	PUNCT
ajlm-1677	58	24	followed	follow	VERB
ajlm-1677	58	25	by	by	ADP
ajlm-1677	58	26	the	the	DET
ajlm-1677	58	27	capillary	capillary	ADJ
ajlm-1677	58	28	electrophoresis	electrophoresis	NOUN
ajlm-1677	58	29	on	on	ADP
ajlm-1677	58	30	the	the	DET
ajlm-1677	58	31	3130xl	3130xl	ADJ
ajlm-1677	58	32	genetic	genetic	ADJ
ajlm-1677	58	33	analyzer	analyzer	NOUN
ajlm-1677	58	34	using	use	VERB
ajlm-1677	58	35	a	a	DET
ajlm-1677	58	36	50	50	NUM
ajlm-1677	58	37	cm	cm	NOUN
ajlm-1677	58	38	capillary	capillary	ADJ
ajlm-1677	58	39	array	array	NOUN
ajlm-1677	58	40	,	,	PUNCT
ajlm-1677	58	41	and	and	CCONJ
ajlm-1677	58	42	pop-7	pop-7	PUNCT
ajlm-1677	58	43	polymer	polymer	NOUN
ajlm-1677	58	44	(	(	PUNCT
ajlm-1677	58	45	applied	apply	VERB
ajlm-1677	58	46	biosystems	biosystem	NOUN
ajlm-1677	58	47	,	,	PUNCT
ajlm-1677	58	48	waltham	waltham	PROPN
ajlm-1677	58	49	,	,	PUNCT
ajlm-1677	58	50	massachusetts	massachusetts	PROPN
ajlm-1677	58	51	,	,	PUNCT
ajlm-1677	58	52	united	united	PROPN
ajlm-1677	58	53	states	states	PROPN
ajlm-1677	58	54	)	)	PUNCT
ajlm-1677	58	55	.	.	PUNCT
ajlm-1677	59	1	all	all	DET
ajlm-1677	59	2	the	the	DET
ajlm-1677	59	3	generated	generate	VERB
ajlm-1677	59	4	sequences	sequence	NOUN
ajlm-1677	59	5	were	be	AUX
ajlm-1677	59	6	analysed	analyse	VERB
ajlm-1677	59	7	and	and	CCONJ
ajlm-1677	59	8	assembled	assemble	VERB
ajlm-1677	59	9	using	use	VERB
ajlm-1677	59	10	clc	clc	PROPN
ajlm-1677	59	11	genomic	genomic	ADJ
ajlm-1677	59	12	workbench	workbench	NOUN
ajlm-1677	59	13	version	version	NOUN
ajlm-1677	59	14	8.0.3	8.0.3	NUM
ajlm-1677	59	15	(	(	PUNCT
ajlm-1677	59	16	clc	clc	PROPN
ajlm-1677	59	17	bio	bio	PROPN
ajlm-1677	59	18	,	,	PUNCT
ajlm-1677	59	19	aarhus	aarhus	PROPN
ajlm-1677	59	20	,	,	PUNCT
ajlm-1677	59	21	denmark	denmark	NOUN
ajlm-1677	59	22	)	)	PUNCT
ajlm-1677	59	23	and	and	CCONJ
ajlm-1677	59	24	then	then	ADV
ajlm-1677	59	25	subjected	subject	VERB
ajlm-1677	59	26	to	to	ADP
ajlm-1677	59	27	ncbi	ncbi	PROPN
ajlm-1677	59	28	nucleotide	nucleotide	PROPN
ajlm-1677	59	29	blast	blast	NOUN
ajlm-1677	59	30	(	(	PUNCT
ajlm-1677	59	31	https://blast.ncbi.nlm.nih.gov/blast.cgi	https://blast.ncbi.nlm.nih.gov/blast.cgi	PROPN
ajlm-1677	59	32	)	)	PUNCT
ajlm-1677	59	33	for	for	ADP
ajlm-1677	59	34	quality	quality	NOUN
ajlm-1677	59	35	check	check	NOUN
ajlm-1677	59	36	.	.	PUNCT
ajlm-1677	60	1	in	in	ADP
ajlm-1677	60	2	this	this	DET
ajlm-1677	60	3	study	study	NOUN
ajlm-1677	60	4	,	,	PUNCT
ajlm-1677	60	5	a	a	DET
ajlm-1677	60	6	chromatogram	chromatogram	NOUN
ajlm-1677	60	7	was	be	AUX
ajlm-1677	60	8	considered	consider	VERB
ajlm-1677	60	9	of	of	ADP
ajlm-1677	60	10	good	good	ADJ
ajlm-1677	60	11	quality	quality	NOUN
ajlm-1677	60	12	if	if	SCONJ
ajlm-1677	60	13	(	(	PUNCT
ajlm-1677	60	14	1	1	X
ajlm-1677	60	15	)	)	PUNCT
ajlm-1677	60	16	at	at	ADV
ajlm-1677	60	17	least	least	ADJ
ajlm-1677	60	18	80	80	NUM
ajlm-1677	60	19	%	%	NOUN
ajlm-1677	60	20	of	of	ADP
ajlm-1677	60	21	total	total	ADJ
ajlm-1677	60	22	amplicon	amplicon	NOUN
ajlm-1677	60	23	length	length	NOUN
ajlm-1677	60	24	was	be	AUX
ajlm-1677	60	25	sequenced	sequence	VERB
ajlm-1677	60	26	and	and	CCONJ
ajlm-1677	60	27	(	(	PUNCT
ajlm-1677	60	28	2	2	X
ajlm-1677	60	29	)	)	PUNCT
ajlm-1677	60	30	the	the	DET
ajlm-1677	60	31	noise	noise	NOUN
ajlm-1677	60	32	-	-	PUNCT
ajlm-1677	60	33	to	to	ADP
ajlm-1677	60	34	-	-	PUNCT
ajlm-1677	60	35	signal	signal	NOUN
ajlm-1677	60	36	ratio	ratio	NOUN
ajlm-1677	60	37	was	be	AUX
ajlm-1677	60	38	estimated	estimate	VERB
ajlm-1677	60	39	to	to	PART
ajlm-1677	60	40	be	be	AUX
ajlm-1677	60	41	<	<	X
ajlm-1677	60	42	5	5	NUM
ajlm-1677	60	43	%	%	NOUN
ajlm-1677	60	44	.	.	PUNCT
ajlm-1677	61	1	phylogenetic	phylogenetic	ADJ
ajlm-1677	61	2	analysis	analysis	NOUN
ajlm-1677	61	3	of	of	ADP
ajlm-1677	61	4	hepatitis	hepatitis	PROPN
ajlm-1677	61	5	b	b	PROPN
ajlm-1677	61	6	virus	virus	NOUN
ajlm-1677	61	7	sequences	sequence	NOUN
ajlm-1677	61	8	to	to	PART
ajlm-1677	61	9	infer	infer	VERB
ajlm-1677	61	10	the	the	DET
ajlm-1677	61	11	evolutionary	evolutionary	ADJ
ajlm-1677	61	12	relationship	relationship	NOUN
ajlm-1677	61	13	between	between	ADP
ajlm-1677	61	14	the	the	DET
ajlm-1677	61	15	six	six	NUM
ajlm-1677	61	16	hbv	hbv	NOUN
ajlm-1677	61	17	nucleotide	nucleotide	NOUN
ajlm-1677	61	18	sequences	sequence	NOUN
ajlm-1677	61	19	in	in	ADP
ajlm-1677	61	20	our	our	PRON
ajlm-1677	61	21	study	study	NOUN
ajlm-1677	61	22	and	and	CCONJ
ajlm-1677	61	23	hbv	hbv	NOUN
ajlm-1677	61	24	sequences	sequence	NOUN
ajlm-1677	61	25	from	from	ADP
ajlm-1677	61	26	different	different	ADJ
ajlm-1677	61	27	parts	part	NOUN
ajlm-1677	61	28	of	of	ADP
ajlm-1677	61	29	the	the	DET
ajlm-1677	61	30	world	world	NOUN
ajlm-1677	61	31	,	,	PUNCT
ajlm-1677	61	32	we	we	PRON
ajlm-1677	61	33	used	use	VERB
ajlm-1677	61	34	molecular	molecular	ADJ
ajlm-1677	61	35	evolutionary	evolutionary	ADJ
ajlm-1677	61	36	genetics	genetic	NOUN
ajlm-1677	61	37	analysis	analysis	NOUN
ajlm-1677	61	38	(	(	PUNCT
ajlm-1677	61	39	mega	mega	NOUN
ajlm-1677	61	40	)	)	PUNCT
ajlm-1677	61	41	x	x	SYM
ajlm-1677	61	42	version	version	NOUN
ajlm-1677	61	43	10.1.7	10.1.7	PROPN
ajlm-1677	62	1	(	(	PUNCT
ajlm-1677	62	2	mega	mega	ADJ
ajlm-1677	62	3	software	software	NOUN
ajlm-1677	62	4	,	,	PUNCT
ajlm-1677	62	5	dortmund	dortmund	PROPN
ajlm-1677	62	6	,	,	PUNCT
ajlm-1677	62	7	germany).24	germany).24	PROPN
ajlm-1677	62	8	first	first	ADV
ajlm-1677	62	9	,	,	PUNCT
ajlm-1677	62	10	a	a	DET
ajlm-1677	62	11	total	total	ADJ
ajlm-1677	62	12	102	102	NUM
ajlm-1677	62	13	sequences	sequence	NOUN
ajlm-1677	62	14	(	(	PUNCT
ajlm-1677	62	15	including	include	VERB
ajlm-1677	62	16	a	a	DET
ajlm-1677	62	17	sequence	sequence	NOUN
ajlm-1677	62	18	from	from	ADP
ajlm-1677	62	19	a	a	DET
ajlm-1677	62	20	chimpanzee	chimpanzee	NOUN
ajlm-1677	62	21	)	)	PUNCT
ajlm-1677	62	22	representing	represent	VERB
ajlm-1677	62	23	the	the	DET
ajlm-1677	62	24	hbv	hbv	NOUN
ajlm-1677	62	25	genotypes	genotype	NOUN
ajlm-1677	62	26	from	from	ADP
ajlm-1677	62	27	different	different	ADJ
ajlm-1677	62	28	parts	part	NOUN
ajlm-1677	62	29	of	of	ADP
ajlm-1677	62	30	the	the	DET
ajlm-1677	62	31	world	world	NOUN
ajlm-1677	62	32	were	be	AUX
ajlm-1677	62	33	mined	mine	VERB
ajlm-1677	62	34	from	from	ADP
ajlm-1677	62	35	the	the	DET
ajlm-1677	62	36	ncbi	ncbi	PROPN
ajlm-1677	62	37	genbank	genbank	PROPN
ajlm-1677	62	38	nucleotide	nucleotide	PROPN
ajlm-1677	62	39	database	database	NOUN
ajlm-1677	62	40	(	(	PUNCT
ajlm-1677	62	41	https://www.ncbi.nlm.nih.gov/nucleotide/	https://www.ncbi.nlm.nih.gov/nucleotide/	X
ajlm-1677	62	42	)	)	PUNCT
ajlm-1677	62	43	.	.	PUNCT
ajlm-1677	63	1	the	the	DET
ajlm-1677	63	2	sequence	sequence	NOUN
ajlm-1677	63	3	from	from	ADP
ajlm-1677	63	4	the	the	DET
ajlm-1677	63	5	chimpanzee	chimpanzee	NOUN
ajlm-1677	63	6	was	be	AUX
ajlm-1677	63	7	used	use	VERB
ajlm-1677	63	8	as	as	ADP
ajlm-1677	63	9	an	an	DET
ajlm-1677	63	10	out	out	ADJ
ajlm-1677	63	11	-	-	PUNCT
ajlm-1677	63	12	group	group	NOUN
ajlm-1677	63	13	.	.	PUNCT
ajlm-1677	64	1	the	the	DET
ajlm-1677	64	2	generated	generate	VERB
ajlm-1677	64	3	nucleotide	nucleotide	NOUN
ajlm-1677	64	4	sequence	sequence	NOUN
ajlm-1677	64	5	data	datum	NOUN
ajlm-1677	64	6	were	be	AUX
ajlm-1677	64	7	deposited	deposit	VERB
ajlm-1677	64	8	in	in	ADP
ajlm-1677	64	9	the	the	DET
ajlm-1677	64	10	genbank	genbank	NOUN
ajlm-1677	64	11	database	database	NOUN
ajlm-1677	64	12	under	under	ADP
ajlm-1677	64	13	the	the	DET
ajlm-1677	64	14	accession	accession	NOUN
ajlm-1677	64	15	numbers	number	NOUN
ajlm-1677	64	16	on236588	on236588	PROPN
ajlm-1677	64	17	–	–	PUNCT
ajlm-1677	64	18	on236593	on236593	ADJ
ajlm-1677	64	19	.	.	PUNCT
ajlm-1677	65	1	these	these	DET
ajlm-1677	65	2	sequences	sequence	NOUN
ajlm-1677	65	3	,	,	PUNCT
ajlm-1677	65	4	together	together	ADV
ajlm-1677	65	5	with	with	ADP
ajlm-1677	65	6	the	the	DET
ajlm-1677	65	7	six	six	NUM
ajlm-1677	65	8	from	from	ADP
ajlm-1677	65	9	our	our	PRON
ajlm-1677	65	10	cohort	cohort	NOUN
ajlm-1677	65	11	,	,	PUNCT
ajlm-1677	65	12	were	be	AUX
ajlm-1677	65	13	aligned	align	VERB
ajlm-1677	65	14	using	use	VERB
ajlm-1677	65	15	multiple	multiple	ADJ
ajlm-1677	65	16	sequence	sequence	NOUN
ajlm-1677	65	17	comparison	comparison	NOUN
ajlm-1677	65	18	by	by	ADP
ajlm-1677	65	19	log	log	NOUN
ajlm-1677	65	20	-	-	PUNCT
ajlm-1677	65	21	expectation	expectation	NOUN
ajlm-1677	65	22	(	(	PUNCT
ajlm-1677	65	23	muscle	muscle	NOUN
ajlm-1677	65	24	)	)	PUNCT
ajlm-1677	65	25	software,25	software,25	NOUN
ajlm-1677	65	26	which	which	PRON
ajlm-1677	65	27	is	be	AUX
ajlm-1677	65	28	a	a	DET
ajlm-1677	65	29	sequence	sequence	NOUN
ajlm-1677	65	30	alignment	alignment	NOUN
ajlm-1677	65	31	option	option	NOUN
ajlm-1677	65	32	in	in	ADP
ajlm-1677	65	33	mega	mega	PROPN
ajlm-1677	65	34	.	.	PUNCT
ajlm-1677	66	1	the	the	DET
ajlm-1677	66	2	multiple	multiple	ADJ
ajlm-1677	66	3	sequence	sequence	NOUN
ajlm-1677	66	4	alignment	alignment	NOUN
ajlm-1677	66	5	was	be	AUX
ajlm-1677	66	6	trimmed	trim	VERB
ajlm-1677	66	7	to	to	ADP
ajlm-1677	66	8	846	846	NUM
ajlm-1677	66	9	-	-	PUNCT
ajlm-1677	66	10	base	base	NOUN
ajlm-1677	66	11	pairs	pair	NOUN
ajlm-1677	66	12	,	,	PUNCT
ajlm-1677	66	13	followed	follow	VERB
ajlm-1677	66	14	by	by	ADP
ajlm-1677	66	15	determination	determination	NOUN
ajlm-1677	66	16	of	of	ADP
ajlm-1677	66	17	the	the	DET
ajlm-1677	66	18	dna	dna	PROPN
ajlm-1677	66	19	model	model	NOUN
ajlm-1677	66	20	that	that	PRON
ajlm-1677	66	21	best	good	ADJ
ajlm-1677	66	22	describes	describe	VERB
ajlm-1677	66	23	the	the	DET
ajlm-1677	66	24	nucleotide	nucleotide	NOUN
ajlm-1677	66	25	substitution	substitution	NOUN
ajlm-1677	66	26	pattern	pattern	NOUN
ajlm-1677	66	27	.	.	PUNCT
ajlm-1677	67	1	this	this	PRON
ajlm-1677	67	2	was	be	AUX
ajlm-1677	67	3	performed	perform	VERB
ajlm-1677	67	4	using	use	VERB
ajlm-1677	67	5	the	the	DET
ajlm-1677	67	6	maximum	maximum	ADJ
ajlm-1677	67	7	likelihood	likelihood	NOUN
ajlm-1677	67	8	(	(	PUNCT
ajlm-1677	67	9	ml	ml	NOUN
ajlm-1677	67	10	)	)	PUNCT
ajlm-1677	67	11	statistical	statistical	ADJ
ajlm-1677	67	12	method	method	NOUN
ajlm-1677	67	13	.	.	PUNCT
ajlm-1677	68	1	the	the	DET
ajlm-1677	68	2	general	general	ADJ
ajlm-1677	68	3	time	time	NOUN
ajlm-1677	68	4	reversible	reversible	ADJ
ajlm-1677	68	5	(	(	PUNCT
ajlm-1677	68	6	gtr	gtr	NOUN
ajlm-1677	68	7	)	)	PUNCT
ajlm-1677	68	8	model	model	NOUN
ajlm-1677	68	9	with	with	ADP
ajlm-1677	68	10	discrete	discrete	ADJ
ajlm-1677	68	11	gamma	gamma	NOUN
ajlm-1677	68	12	distribution	distribution	NOUN
ajlm-1677	68	13	(	(	PUNCT
ajlm-1677	68	14	+	+	NOUN
ajlm-1677	68	15	g	g	NOUN
ajlm-1677	68	16	=	=	SYM
ajlm-1677	68	17	0.51	0.51	NUM
ajlm-1677	68	18	,	,	PUNCT
ajlm-1677	68	19	with	with	ADP
ajlm-1677	68	20	5	5	NUM
ajlm-1677	68	21	rate	rate	NOUN
ajlm-1677	68	22	categories	category	NOUN
ajlm-1677	68	23	)	)	PUNCT
ajlm-1677	68	24	and	and	CCONJ
ajlm-1677	68	25	some	some	DET
ajlm-1677	68	26	invariant	invariant	ADJ
ajlm-1677	68	27	evolutionary	evolutionary	ADJ
ajlm-1677	68	28	sites	site	NOUN
ajlm-1677	68	29	(	(	PUNCT
ajlm-1677	68	30	+	+	NOUN
ajlm-1677	68	31	i	i	NOUN
ajlm-1677	68	32	=	=	SYM
ajlm-1677	68	33	35.51	35.51	NUM
ajlm-1677	68	34	%	%	NOUN
ajlm-1677	68	35	sites	site	NOUN
ajlm-1677	68	36	)	)	PUNCT
ajlm-1677	68	37	was	be	AUX
ajlm-1677	68	38	chosen	choose	VERB
ajlm-1677	68	39	as	as	ADP
ajlm-1677	68	40	the	the	DET
ajlm-1677	68	41	best	good	ADJ
ajlm-1677	68	42	model	model	NOUN
ajlm-1677	68	43	,	,	PUNCT
ajlm-1677	68	44	based	base	VERB
ajlm-1677	68	45	on	on	ADP
ajlm-1677	68	46	its	its	PRON
ajlm-1677	68	47	low	low	ADJ
ajlm-1677	68	48	bayesian	bayesian	NOUN
ajlm-1677	68	49	information	information	NOUN
ajlm-1677	68	50	criterion	criterion	NOUN
ajlm-1677	68	51	score	score	NOUN
ajlm-1677	68	52	(	(	PUNCT
ajlm-1677	68	53	18	18	NUM
ajlm-1677	68	54	980	980	NUM
ajlm-1677	68	55	)	)	PUNCT
ajlm-1677	68	56	.	.	PUNCT
ajlm-1677	69	1	for	for	ADP
ajlm-1677	69	2	the	the	DET
ajlm-1677	69	3	phylogeny	phylogeny	NOUN
ajlm-1677	69	4	reconstruction	reconstruction	NOUN
ajlm-1677	69	5	the	the	DET
ajlm-1677	69	6	ml	ml	NOUN
ajlm-1677	69	7	statistical	statistical	ADJ
ajlm-1677	69	8	method	method	NOUN
ajlm-1677	69	9	was	be	AUX
ajlm-1677	69	10	used	use	VERB
ajlm-1677	69	11	with	with	ADP
ajlm-1677	69	12	a	a	DET
ajlm-1677	69	13	bootstrap	bootstrap	NOUN
ajlm-1677	69	14	of	of	ADP
ajlm-1677	69	15	1000	1000	NUM
ajlm-1677	69	16	replicates	replicate	NOUN
ajlm-1677	69	17	and	and	CCONJ
ajlm-1677	69	18	the	the	DET
ajlm-1677	69	19	sub	sub	NOUN
ajlm-1677	69	20	tree	tree	NOUN
ajlm-1677	69	21	-	-	PUNCT
ajlm-1677	69	22	pruning	prune	VERB
ajlm-1677	69	23	-	-	PUNCT
ajlm-1677	69	24	regrafting	regrafting	NOUN
ajlm-1677	69	25	(	(	PUNCT
ajlm-1677	69	26	extensive	extensive	ADJ
ajlm-1677	69	27	;	;	PUNCT
ajlm-1677	69	28	spr	spr	ADJ
ajlm-1677	69	29	level	level	NOUN
ajlm-1677	69	30	5	5	NUM
ajlm-1677	69	31	)	)	PUNCT
ajlm-1677	69	32	as	as	ADP
ajlm-1677	69	33	the	the	DET
ajlm-1677	69	34	ml	ml	PROPN
ajlm-1677	69	35	heuristic	heuristic	ADJ
ajlm-1677	69	36	method	method	NOUN
ajlm-1677	69	37	.	.	PUNCT
ajlm-1677	70	1	moreover	moreover	ADV
ajlm-1677	70	2	,	,	PUNCT
ajlm-1677	70	3	we	we	PRON
ajlm-1677	70	4	used	use	VERB
ajlm-1677	70	5	the	the	DET
ajlm-1677	70	6	option	option	NOUN
ajlm-1677	70	7	of	of	ADP
ajlm-1677	70	8	‘	'	PUNCT
ajlm-1677	70	9	moderate	moderate	ADJ
ajlm-1677	70	10	branch	branch	NOUN
ajlm-1677	70	11	length	length	NOUN
ajlm-1677	70	12	filter	filter	NOUN
ajlm-1677	70	13	’	'	PUNCT
ajlm-1677	70	14	to	to	PART
ajlm-1677	70	15	enable	enable	VERB
ajlm-1677	70	16	a	a	DET
ajlm-1677	70	17	semi	semi	ADJ
ajlm-1677	70	18	-	-	ADJ
ajlm-1677	70	19	stringent	stringent	ADJ
ajlm-1677	70	20	exhaustive	exhaustive	ADJ
ajlm-1677	70	21	optimisation	optimisation	NOUN
ajlm-1677	70	22	of	of	ADP
ajlm-1677	70	23	the	the	DET
ajlm-1677	70	24	branch	branch	NOUN
ajlm-1677	70	25	lengths	length	NOUN
ajlm-1677	70	26	of	of	ADP
ajlm-1677	70	27	the	the	DET
ajlm-1677	70	28	phylogenetic	phylogenetic	ADJ
ajlm-1677	70	29	trees	tree	NOUN
ajlm-1677	70	30	.	.	PUNCT
ajlm-1677	71	1	initial	initial	ADJ
ajlm-1677	71	2	trees	tree	NOUN
ajlm-1677	71	3	for	for	ADP
ajlm-1677	71	4	the	the	DET
ajlm-1677	71	5	heuristic	heuristic	ADJ
ajlm-1677	71	6	search	search	NOUN
ajlm-1677	71	7	were	be	AUX
ajlm-1677	71	8	generated	generate	VERB
ajlm-1677	71	9	using	use	VERB
ajlm-1677	71	10	neighbor	neighbor	NOUN
ajlm-1677	71	11	-	-	PUNCT
ajlm-1677	71	12	joining	join	VERB
ajlm-1677	71	13	and	and	CCONJ
ajlm-1677	71	14	bionj	bionj	NOUN
ajlm-1677	71	15	algorithms	algorithm	NOUN
ajlm-1677	71	16	and	and	CCONJ
ajlm-1677	71	17	the	the	DET
ajlm-1677	71	18	phylogenetic	phylogenetic	ADJ
ajlm-1677	71	19	tree	tree	NOUN
ajlm-1677	71	20	with	with	ADP
ajlm-1677	71	21	superior	superior	ADJ
ajlm-1677	71	22	log	log	NOUN
ajlm-1677	71	23	likelihood	likelihood	NOUN
ajlm-1677	71	24	value	value	NOUN
ajlm-1677	71	25	selected	select	VERB
ajlm-1677	71	26	.	.	PUNCT
ajlm-1677	72	1	phylogenetic	phylogenetic	ADJ
ajlm-1677	72	2	trees	tree	NOUN
ajlm-1677	72	3	were	be	AUX
ajlm-1677	72	4	produced	produce	VERB
ajlm-1677	72	5	in	in	ADP
ajlm-1677	72	6	newick	newick	NOUN
ajlm-1677	72	7	format	format	NOUN
ajlm-1677	72	8	employing	employ	VERB
ajlm-1677	72	9	interactive	interactive	ADJ
ajlm-1677	72	10	tree	tree	NOUN
ajlm-1677	72	11	of	of	ADP
ajlm-1677	72	12	life	life	NOUN
ajlm-1677	72	13	interface	interface	NOUN
ajlm-1677	72	14	(	(	PUNCT
ajlm-1677	72	15	https://itol.embl.de/tree/	https://itol.embl.de/tree/	PROPN
ajlm-1677	72	16	)	)	PUNCT
ajlm-1677	72	17	.	.	PUNCT
ajlm-1677	73	1	to	to	PART
ajlm-1677	73	2	determine	determine	VERB
ajlm-1677	73	3	the	the	DET
ajlm-1677	73	4	genetic	genetic	ADJ
ajlm-1677	73	5	diversity	diversity	NOUN
ajlm-1677	73	6	of	of	ADP
ajlm-1677	73	7	the	the	DET
ajlm-1677	73	8	six	six	NUM
ajlm-1677	73	9	hbv	hbv	NOUN
ajlm-1677	73	10	sequences	sequence	NOUN
ajlm-1677	73	11	,	,	PUNCT
ajlm-1677	73	12	we	we	PRON
ajlm-1677	73	13	performed	perform	VERB
ajlm-1677	73	14	an	an	DET
ajlm-1677	73	15	alignment	alignment	NOUN
ajlm-1677	73	16	analysis	analysis	NOUN
ajlm-1677	73	17	using	use	VERB
ajlm-1677	73	18	mega.24	mega.24	ADP
ajlm-1677	73	19	the	the	DET
ajlm-1677	73	20	overall	overall	ADJ
ajlm-1677	73	21	mean	mean	NOUN
ajlm-1677	73	22	(	(	PUNCT
ajlm-1677	73	23	average	average	ADJ
ajlm-1677	73	24	)	)	PUNCT
ajlm-1677	73	25	and	and	CCONJ
ajlm-1677	73	26	maximum	maximum	ADJ
ajlm-1677	73	27	distance	distance	NOUN
ajlm-1677	73	28	were	be	AUX
ajlm-1677	73	29	used	use	VERB
ajlm-1677	73	30	as	as	ADP
ajlm-1677	73	31	proxies	proxy	NOUN
ajlm-1677	73	32	for	for	ADP
ajlm-1677	73	33	genetic	genetic	ADJ
ajlm-1677	73	34	diversity	diversity	NOUN
ajlm-1677	73	35	.	.	PUNCT
ajlm-1677	74	1	assessment	assessment	NOUN
ajlm-1677	74	2	of	of	ADP
ajlm-1677	74	3	hepatitis	hepatitis	PROPN
ajlm-1677	74	4	b	b	PROPN
ajlm-1677	74	5	virus	virus	NOUN
ajlm-1677	74	6	drug	drug	NOUN
ajlm-1677	74	7	resistance	resistance	NOUN
ajlm-1677	74	8	mutations	mutation	NOUN
ajlm-1677	74	9	the	the	PRON
ajlm-1677	74	10	obtained	obtain	VERB
ajlm-1677	74	11	sequences	sequence	NOUN
ajlm-1677	74	12	of	of	ADP
ajlm-1677	74	13	overlapping	overlap	VERB
ajlm-1677	74	14	surface	surface	NOUN
ajlm-1677	74	15	(	(	PUNCT
ajlm-1677	74	16	s	s	NOUN
ajlm-1677	74	17	)	)	PUNCT
ajlm-1677	74	18	and	and	CCONJ
ajlm-1677	74	19	pol	pol	NOUN
ajlm-1677	74	20	gene	gene	NOUN
ajlm-1677	74	21	were	be	AUX
ajlm-1677	74	22	translated	translate	VERB
ajlm-1677	74	23	to	to	ADP
ajlm-1677	74	24	the	the	DET
ajlm-1677	74	25	protein	protein	NOUN
ajlm-1677	74	26	sequences	sequence	NOUN
ajlm-1677	74	27	and	and	CCONJ
ajlm-1677	74	28	aligned	align	VERB
ajlm-1677	74	29	with	with	ADP
ajlm-1677	74	30	the	the	DET
ajlm-1677	74	31	references	reference	NOUN
ajlm-1677	74	32	in	in	ADP
ajlm-1677	74	33	bioedit	bioedit	NOUN
ajlm-1677	74	34	version	version	NOUN
ajlm-1677	74	35	7.1.3.0.26	7.1.3.0.26	NUM
ajlm-1677	74	36	escape	escape	NOUN
ajlm-1677	74	37	mutant	mutant	ADJ
ajlm-1677	74	38	analysis	analysis	NOUN
ajlm-1677	74	39	and	and	CCONJ
ajlm-1677	74	40	drug	drug	NOUN
ajlm-1677	74	41	resistance	resistance	NOUN
ajlm-1677	74	42	analysis	analysis	NOUN
ajlm-1677	74	43	were	be	AUX
ajlm-1677	74	44	performed	perform	VERB
ajlm-1677	74	45	using	use	VERB
ajlm-1677	74	46	hbv	hbv	NOUN
ajlm-1677	74	47	drug	drug	NOUN
ajlm-1677	74	48	resistance	resistance	NOUN
ajlm-1677	74	49	interpretation	interpretation	NOUN
ajlm-1677	74	50	and	and	CCONJ
ajlm-1677	74	51	geno2pheno	geno2pheno	PROPN
ajlm-1677	74	52	(	(	PUNCT
ajlm-1677	74	53	hbv	hbv	NOUN
ajlm-1677	74	54	)	)	PUNCT
ajlm-1677	74	55	version	version	NOUN
ajlm-1677	74	56	2.0	2.0	NUM
ajlm-1677	74	57	(	(	PUNCT
ajlm-1677	74	58	https://hbv.geno2pheno.org/index.php	https://hbv.geno2pheno.org/index.php	NUM
ajlm-1677	74	59	)	)	PUNCT
ajlm-1677	74	60	.	.	PUNCT
ajlm-1677	75	1	it	it	PRON
ajlm-1677	75	2	is	be	AUX
ajlm-1677	75	3	a	a	DET
ajlm-1677	75	4	program	program	NOUN
ajlm-1677	75	5	that	that	PRON
ajlm-1677	75	6	searches	search	VERB
ajlm-1677	75	7	for	for	ADP
ajlm-1677	75	8	homology	homology	NOUN
ajlm-1677	75	9	between	between	ADP
ajlm-1677	75	10	the	the	DET
ajlm-1677	75	11	input	input	NOUN
ajlm-1677	75	12	sequence	sequence	NOUN
ajlm-1677	75	13	and	and	CCONJ
ajlm-1677	75	14	other	other	ADJ
ajlm-1677	75	15	dna	dna	PROPN
ajlm-1677	75	16	sequences	sequence	NOUN
ajlm-1677	75	17	in	in	ADP
ajlm-1677	75	18	the	the	DET
ajlm-1677	75	19	existing	exist	VERB
ajlm-1677	75	20	stored	store	VERB
ajlm-1677	75	21	database	database	NOUN
ajlm-1677	75	22	for	for	ADP
ajlm-1677	75	23	drug	drug	NOUN
ajlm-1677	75	24	resistance	resistance	NOUN
ajlm-1677	75	25	and	and	CCONJ
ajlm-1677	75	26	surface	surface	NOUN
ajlm-1677	75	27	gene	gene	NOUN
ajlm-1677	75	28	mutations	mutation	NOUN
ajlm-1677	75	29	.	.	PUNCT
ajlm-1677	76	1	genotype	genotype	NOUN
ajlm-1677	76	2	assignments	assignment	NOUN
ajlm-1677	76	3	were	be	AUX
ajlm-1677	76	4	confirmed	confirm	VERB
ajlm-1677	76	5	using	use	VERB
ajlm-1677	76	6	the	the	DET
ajlm-1677	76	7	genbank	genbank	PROPN
ajlm-1677	76	8	blast	blast	NOUN
ajlm-1677	76	9	and	and	CCONJ
ajlm-1677	76	10	hbvseq	hbvseq	NOUN
ajlm-1677	76	11	tools	tool	NOUN
ajlm-1677	76	12	from	from	ADP
ajlm-1677	76	13	the	the	DET
ajlm-1677	76	14	hiv	hiv	PROPN
ajlm-1677	76	15	drug	drug	PROPN
ajlm-1677	76	16	resistance	resistance	NOUN
ajlm-1677	76	17	database.26,27	database.26,27	VERB
ajlm-1677	76	18	statistical	statistical	ADJ
ajlm-1677	76	19	analysis	analysis	NOUN
ajlm-1677	76	20	the	the	DET
ajlm-1677	76	21	obtained	obtain	VERB
ajlm-1677	76	22	data	datum	NOUN
ajlm-1677	76	23	were	be	AUX
ajlm-1677	76	24	analysed	analyse	VERB
ajlm-1677	76	25	using	use	VERB
ajlm-1677	76	26	statistical	statistical	ADJ
ajlm-1677	76	27	package	package	NOUN
ajlm-1677	76	28	for	for	ADP
ajlm-1677	76	29	social	social	ADJ
ajlm-1677	76	30	science	science	NOUN
ajlm-1677	76	31	software	software	NOUN
ajlm-1677	76	32	(	(	PUNCT
ajlm-1677	76	33	version	version	NOUN
ajlm-1677	76	34	19.0	19.0	NUM
ajlm-1677	76	35	;	;	PUNCT
ajlm-1677	76	36	ibm	ibm	PROPN
ajlm-1677	76	37	corp	corp	PROPN
ajlm-1677	76	38	.	.	PROPN
ajlm-1677	76	39	,	,	PUNCT
ajlm-1677	76	40	armonk	armonk	PROPN
ajlm-1677	76	41	,	,	PUNCT
ajlm-1677	76	42	new	new	PROPN
ajlm-1677	76	43	york	york	PROPN
ajlm-1677	76	44	,	,	PUNCT
ajlm-1677	76	45	united	united	PROPN
ajlm-1677	76	46	states	states	PROPN
ajlm-1677	76	47	)	)	PUNCT
ajlm-1677	76	48	and	and	CCONJ
ajlm-1677	76	49	expressed	express	VERB
ajlm-1677	76	50	as	as	ADP
ajlm-1677	76	51	medians	median	NOUN
ajlm-1677	76	52	(	(	PUNCT
ajlm-1677	76	53	with	with	ADP
ajlm-1677	76	54	interquartile	interquartile	NOUN
ajlm-1677	76	55	ranges	range	VERB
ajlm-1677	76	56	[	[	X
ajlm-1677	76	57	iqr	iqr	NOUN
ajlm-1677	76	58	]	]	X
ajlm-1677	76	59	)	)	PUNCT
ajlm-1677	76	60	for	for	ADP
ajlm-1677	76	61	continuous	continuous	ADJ
ajlm-1677	76	62	variables	variable	NOUN
ajlm-1677	76	63	,	,	PUNCT
ajlm-1677	76	64	and	and	CCONJ
ajlm-1677	76	65	as	as	ADP
ajlm-1677	76	66	counts	count	NOUN
ajlm-1677	76	67	and	and	CCONJ
ajlm-1677	76	68	percentages	percentage	NOUN
ajlm-1677	76	69	for	for	ADP
ajlm-1677	76	70	discrete	discrete	ADJ
ajlm-1677	76	71	variables	variable	NOUN
ajlm-1677	76	72	.	.	PUNCT
ajlm-1677	77	1	chi	chi	ADJ
ajlm-1677	77	2	-	-	PUNCT
ajlm-1677	77	3	squared	square	VERB
ajlm-1677	77	4	test	test	NOUN
ajlm-1677	77	5	was	be	AUX
ajlm-1677	77	6	used	use	VERB
ajlm-1677	77	7	for	for	ADP
ajlm-1677	77	8	discrete	discrete	ADJ
ajlm-1677	77	9	data	datum	NOUN
ajlm-1677	77	10	.	.	PUNCT
ajlm-1677	78	1	results	result	VERB
ajlm-1677	78	2	thirty	thirty	NUM
ajlm-1677	78	3	(	(	PUNCT
ajlm-1677	78	4	29.7	29.7	NUM
ajlm-1677	78	5	%	%	NOUN
ajlm-1677	78	6	)	)	PUNCT
ajlm-1677	78	7	of	of	ADP
ajlm-1677	78	8	the	the	DET
ajlm-1677	78	9	101	101	NUM
ajlm-1677	78	10	had	have	VERB
ajlm-1677	78	11	detectable	detectable	ADJ
ajlm-1677	78	12	hbv	hbv	NOUN
ajlm-1677	78	13	dna	dna	PROPN
ajlm-1677	78	14	.	.	PUNCT
ajlm-1677	79	1	of	of	ADP
ajlm-1677	79	2	the	the	DET
ajlm-1677	79	3	30	30	NUM
ajlm-1677	79	4	patients	patient	NOUN
ajlm-1677	79	5	,	,	PUNCT
ajlm-1677	79	6	11	11	NUM
ajlm-1677	79	7	(	(	PUNCT
ajlm-1677	79	8	36.7	36.7	NUM
ajlm-1677	79	9	%	%	NOUN
ajlm-1677	79	10	)	)	PUNCT
ajlm-1677	79	11	were	be	AUX
ajlm-1677	79	12	co	co	VERB
ajlm-1677	79	13	-	-	VERB
ajlm-1677	79	14	infected	infected	ADJ
ajlm-1677	79	15	with	with	ADP
ajlm-1677	79	16	hiv	hiv	PROPN
ajlm-1677	79	17	while	while	SCONJ
ajlm-1677	79	18	19	19	NUM
ajlm-1677	79	19	(	(	PUNCT
ajlm-1677	79	20	63.3	63.3	NUM
ajlm-1677	79	21	%	%	NOUN
ajlm-1677	79	22	)	)	PUNCT
ajlm-1677	79	23	had	have	VERB
ajlm-1677	79	24	hbv	hbv	NOUN
ajlm-1677	79	25	-	-	PUNCT
ajlm-1677	79	26	mono	mono	NOUN
ajlm-1677	79	27	infection	infection	NOUN
ajlm-1677	79	28	.	.	PUNCT
ajlm-1677	80	1	seventeen	seventeen	NUM
ajlm-1677	80	2	(	(	PUNCT
ajlm-1677	80	3	56.7	56.7	NUM
ajlm-1677	80	4	%	%	NOUN
ajlm-1677	80	5	)	)	PUNCT
ajlm-1677	80	6	were	be	AUX
ajlm-1677	80	7	female	female	ADJ
ajlm-1677	80	8	;	;	PUNCT
ajlm-1677	80	9	the	the	DET
ajlm-1677	80	10	mean	mean	ADJ
ajlm-1677	80	11	age	age	NOUN
ajlm-1677	80	12	was	be	AUX
ajlm-1677	80	13	41	41	NUM
ajlm-1677	80	14	years	year	NOUN
ajlm-1677	80	15	.	.	PUNCT
ajlm-1677	81	1	the	the	DET
ajlm-1677	81	2	proportion	proportion	NOUN
ajlm-1677	81	3	of	of	ADP
ajlm-1677	81	4	patients	patient	NOUN
ajlm-1677	81	5	with	with	ADP
ajlm-1677	81	6	hbv	hbv	PROPN
ajlm-1677	81	7	dna	dna	PROPN
ajlm-1677	81	8	copies	copy	NOUN
ajlm-1677	81	9	/	/	SYM
ajlm-1677	81	10	ml	ml	X
ajlm-1677	81	11	of	of	ADP
ajlm-1677	81	12	<	<	X
ajlm-1677	81	13	20	20	NUM
ajlm-1677	81	14	copies	copy	NOUN
ajlm-1677	81	15	/	/	SYM
ajlm-1677	81	16	ml	ml	PROPN
ajlm-1677	81	17	was	be	AUX
ajlm-1677	81	18	22/30	22/30	NUM
ajlm-1677	81	19	(	(	PUNCT
ajlm-1677	81	20	73.3	73.3	NUM
ajlm-1677	81	21	%	%	NOUN
ajlm-1677	81	22	)	)	PUNCT
ajlm-1677	81	23	;	;	PUNCT
ajlm-1677	81	24	6/19	6/19	NUM
ajlm-1677	81	25	(	(	PUNCT
ajlm-1677	81	26	31.6	31.6	NUM
ajlm-1677	81	27	%	%	NOUN
ajlm-1677	81	28	)	)	PUNCT
ajlm-1677	81	29	of	of	ADP
ajlm-1677	81	30	hbv	hbv	NOUN
ajlm-1677	81	31	-	-	PUNCT
ajlm-1677	81	32	mono	mono	NOUN
ajlm-1677	81	33	and	and	CCONJ
ajlm-1677	81	34	2/11	2/11	NUM
ajlm-1677	81	35	(	(	PUNCT
ajlm-1677	81	36	18.2	18.2	NUM
ajlm-1677	81	37	%	%	NOUN
ajlm-1677	81	38	)	)	PUNCT
ajlm-1677	81	39	of	of	ADP
ajlm-1677	81	40	hiv	hiv	PROPN
ajlm-1677	81	41	/	/	SYM
ajlm-1677	81	42	hbv	hbv	PROPN
ajlm-1677	81	43	had	have	VERB
ajlm-1677	81	44	20	20	NUM
ajlm-1677	81	45	copies	copy	NOUN
ajlm-1677	81	46	/	/	SYM
ajlm-1677	81	47	ml	ml	NUM
ajlm-1677	81	48	–	–	PUNCT
ajlm-1677	81	49	20	20	NUM
ajlm-1677	81	50	000	000	NUM
ajlm-1677	81	51	copies	copy	NOUN
ajlm-1677	81	52	/	/	SYM
ajlm-1677	81	53	ml	ml	NOUN
ajlm-1677	81	54	.	.	PUNCT
ajlm-1677	82	1	median	median	ADJ
ajlm-1677	82	2	aspartate	aspartate	NOUN
ajlm-1677	82	3	aminotransferase	aminotransferase	PROPN
ajlm-1677	82	4	u	u	PROPN
ajlm-1677	82	5	/	/	SYM
ajlm-1677	82	6	l	l	PROPN
ajlm-1677	82	7	was	be	AUX
ajlm-1677	82	8	28	28	NUM
ajlm-1677	82	9	(	(	PUNCT
ajlm-1677	82	10	23.8–36.0	23.8–36.0	NUM
ajlm-1677	82	11	)	)	PUNCT
ajlm-1677	82	12	for	for	ADP
ajlm-1677	82	13	hiv	hiv	PROPN
ajlm-1677	82	14	/	/	SYM
ajlm-1677	82	15	hbv	hbv	PROPN
ajlm-1677	82	16	co	co	VERB
ajlm-1677	82	17	-	-	ADJ
ajlm-1677	82	18	infected	infected	ADJ
ajlm-1677	82	19	patients	patient	NOUN
ajlm-1677	82	20	and	and	CCONJ
ajlm-1677	82	21	27	27	NUM
ajlm-1677	82	22	(	(	PUNCT
ajlm-1677	82	23	iqr	iqr	NOUN
ajlm-1677	82	24	:	:	PUNCT
ajlm-1677	82	25	19–32	19–32	NUM
ajlm-1677	82	26	)	)	PUNCT
ajlm-1677	82	27	for	for	ADP
ajlm-1677	82	28	those	those	PRON
ajlm-1677	82	29	with	with	ADP
ajlm-1677	82	30	hbv	hbv	NOUN
ajlm-1677	82	31	-	-	PUNCT
ajlm-1677	82	32	mono	mono	NOUN
ajlm-1677	82	33	infection	infection	NOUN
ajlm-1677	82	34	.	.	PUNCT
ajlm-1677	83	1	median	median	ADJ
ajlm-1677	83	2	alanine	alanine	NOUN
ajlm-1677	83	3	aminotransferase	aminotransferase	PROPN
ajlm-1677	83	4	was	be	AUX
ajlm-1677	83	5	26.1	26.1	NUM
ajlm-1677	83	6	(	(	PUNCT
ajlm-1677	83	7	iqr	iqr	NOUN
ajlm-1677	83	8	:	:	PUNCT
ajlm-1677	83	9	19.8–35.5	19.8–35.5	NUM
ajlm-1677	83	10	)	)	PUNCT
ajlm-1677	83	11	for	for	ADP
ajlm-1677	83	12	those	those	PRON
ajlm-1677	83	13	with	with	ADP
ajlm-1677	83	14	hiv	hiv	PROPN
ajlm-1677	83	15	/	/	SYM
ajlm-1677	83	16	hbv	hbv	NOUN
ajlm-1677	83	17	dual	dual	ADJ
ajlm-1677	83	18	infection	infection	NOUN
ajlm-1677	83	19	and	and	CCONJ
ajlm-1677	83	20	27	27	NUM
ajlm-1677	83	21	(	(	PUNCT
ajlm-1677	83	22	iqr	iqr	NOUN
ajlm-1677	83	23	:	:	PUNCT
ajlm-1677	83	24	20–41	20–41	NUM
ajlm-1677	83	25	)	)	PUNCT
ajlm-1677	83	26	for	for	ADP
ajlm-1677	83	27	those	those	PRON
ajlm-1677	83	28	with	with	ADP
ajlm-1677	83	29	hbv	hbv	NOUN
ajlm-1677	83	30	-	-	PUNCT
ajlm-1677	83	31	mono	mono	NOUN
ajlm-1677	83	32	infection	infection	NOUN
ajlm-1677	83	33	while	while	SCONJ
ajlm-1677	83	34	platelet	platelet	NOUN
ajlm-1677	83	35	level	level	NOUN
ajlm-1677	83	36	was	be	AUX
ajlm-1677	83	37	259	259	NUM
ajlm-1677	83	38	(	(	PUNCT
ajlm-1677	83	39	iqr	iqr	NOUN
ajlm-1677	83	40	:	:	PUNCT
ajlm-1677	83	41	198.3–298.8	198.3–298.8	NUM
ajlm-1677	83	42	)	)	PUNCT
ajlm-1677	83	43	for	for	ADP
ajlm-1677	83	44	those	those	PRON
ajlm-1677	83	45	with	with	ADP
ajlm-1677	83	46	hiv	hiv	PROPN
ajlm-1677	83	47	/	/	SYM
ajlm-1677	83	48	hbv	hbv	NOUN
ajlm-1677	83	49	dual	dual	ADJ
ajlm-1677	83	50	infection	infection	NOUN
ajlm-1677	83	51	and	and	CCONJ
ajlm-1677	83	52	195	195	NUM
ajlm-1677	83	53	(	(	PUNCT
ajlm-1677	83	54	168–257	168–257	NUM
ajlm-1677	83	55	)	)	PUNCT
ajlm-1677	83	56	for	for	ADP
ajlm-1677	83	57	those	those	PRON
ajlm-1677	83	58	with	with	ADP
ajlm-1677	83	59	hbv	hbv	NOUN
ajlm-1677	83	60	-	-	PUNCT
ajlm-1677	83	61	mono	mono	NOUN
ajlm-1677	83	62	infection	infection	NOUN
ajlm-1677	83	63	.	.	PUNCT
ajlm-1677	84	1	phylogeny	phylogeny	NOUN
ajlm-1677	84	2	and	and	CCONJ
ajlm-1677	84	3	genetic	genetic	ADJ
ajlm-1677	84	4	diversity	diversity	NOUN
ajlm-1677	84	5	of	of	ADP
ajlm-1677	84	6	the	the	DET
ajlm-1677	84	7	hepatitis	hepatitis	PROPN
ajlm-1677	84	8	b	b	PROPN
ajlm-1677	84	9	virus	virus	NOUN
ajlm-1677	84	10	sequences	sequence	VERB
ajlm-1677	84	11	all	all	DET
ajlm-1677	84	12	the	the	DET
ajlm-1677	84	13	generated	generate	VERB
ajlm-1677	84	14	sequences	sequence	NOUN
ajlm-1677	84	15	were	be	AUX
ajlm-1677	84	16	from	from	ADP
ajlm-1677	84	17	the	the	DET
ajlm-1677	84	18	hbv	hbv	NOUN
ajlm-1677	84	19	-	-	PUNCT
ajlm-1677	84	20	mono	mono	NOUN
ajlm-1677	84	21	infected	infect	VERB
ajlm-1677	84	22	patients	patient	NOUN
ajlm-1677	84	23	.	.	PUNCT
ajlm-1677	85	1	the	the	DET
ajlm-1677	85	2	genotypes	genotype	NOUN
ajlm-1677	85	3	of	of	ADP
ajlm-1677	85	4	the	the	DET
ajlm-1677	85	5	six	six	NUM
ajlm-1677	85	6	hbv	hbv	NOUN
ajlm-1677	85	7	nucleotide	nucleotide	NOUN
ajlm-1677	85	8	sequences	sequence	NOUN
ajlm-1677	85	9	were	be	AUX
ajlm-1677	85	10	inferred	infer	VERB
ajlm-1677	85	11	from	from	ADP
ajlm-1677	85	12	the	the	DET
ajlm-1677	85	13	phylogenetic	phylogenetic	ADJ
ajlm-1677	85	14	tree	tree	NOUN
ajlm-1677	85	15	(	(	PUNCT
ajlm-1677	85	16	figure	figure	NOUN
ajlm-1677	85	17	1	1	NUM
ajlm-1677	85	18	)	)	PUNCT
ajlm-1677	85	19	,	,	PUNCT
ajlm-1677	85	20	which	which	PRON
ajlm-1677	85	21	showed	show	VERB
ajlm-1677	85	22	that	that	SCONJ
ajlm-1677	85	23	all	all	DET
ajlm-1677	85	24	the	the	DET
ajlm-1677	85	25	sequences	sequence	NOUN
ajlm-1677	85	26	were	be	AUX
ajlm-1677	85	27	hbv	hbv	NOUN
ajlm-1677	85	28	genotype	genotype	NOUN
ajlm-1677	85	29	e.	e.	PROPN
ajlm-1677	85	30	all	all	DET
ajlm-1677	85	31	the	the	DET
ajlm-1677	85	32	six	six	NUM
ajlm-1677	85	33	sequences	sequence	NOUN
ajlm-1677	85	34	clustered	cluster	VERB
ajlm-1677	85	35	with	with	ADP
ajlm-1677	85	36	hbv	hbv	NOUN
ajlm-1677	85	37	genotype	genotype	NOUN
ajlm-1677	85	38	e	e	NOUN
ajlm-1677	85	39	,	,	PUNCT
ajlm-1677	85	40	most	most	ADJ
ajlm-1677	85	41	of	of	ADP
ajlm-1677	85	42	which	which	PRON
ajlm-1677	85	43	were	be	AUX
ajlm-1677	85	44	from	from	ADP
ajlm-1677	85	45	the	the	DET
ajlm-1677	85	46	west	west	ADJ
ajlm-1677	85	47	african	african	ADJ
ajlm-1677	85	48	region	region	NOUN
ajlm-1677	85	49	.	.	PUNCT
ajlm-1677	86	1	figure	figure	VERB
ajlm-1677	86	2	1	1	NUM
ajlm-1677	86	3	:	:	PUNCT
ajlm-1677	86	4	phylogenetic	phylogenetic	ADJ
ajlm-1677	86	5	maximum	maximum	ADJ
ajlm-1677	86	6	likelihood	likelihood	NOUN
ajlm-1677	86	7	circular	circular	ADJ
ajlm-1677	86	8	consensus	consensus	NOUN
ajlm-1677	86	9	tree	tree	NOUN
ajlm-1677	86	10	with	with	ADP
ajlm-1677	86	11	branch	branch	NOUN
ajlm-1677	86	12	node	node	NOUN
ajlm-1677	86	13	statistics	statistic	NOUN
ajlm-1677	86	14	as	as	SCONJ
ajlm-1677	86	15	viewed	view	VERB
ajlm-1677	86	16	using	use	VERB
ajlm-1677	86	17	interactive	interactive	ADJ
ajlm-1677	86	18	tree	tree	NOUN
ajlm-1677	86	19	of	of	ADP
ajlm-1677	86	20	life	life	NOUN
ajlm-1677	86	21	(	(	PUNCT
ajlm-1677	86	22	https://itol.embl.de/tree/	https://itol.embl.de/tree/	PROPN
ajlm-1677	86	23	)	)	PUNCT
ajlm-1677	86	24	.	.	PUNCT
ajlm-1677	87	1	hepatitis	hepatitis	PROPN
ajlm-1677	87	2	b	b	PROPN
ajlm-1677	87	3	virus	virus	PROPN
ajlm-1677	87	4	drug	drug	NOUN
ajlm-1677	87	5	resistance	resistance	NOUN
ajlm-1677	87	6	report	report	NOUN
ajlm-1677	87	7	according	accord	VERB
ajlm-1677	87	8	to	to	ADP
ajlm-1677	87	9	the	the	DET
ajlm-1677	87	10	geno2pheno	geno2pheno	PROPN
ajlm-1677	87	11	(	(	PUNCT
ajlm-1677	87	12	hbv	hbv	NOUN
ajlm-1677	87	13	)	)	PUNCT
ajlm-1677	87	14	2.0	2.0	NUM
ajlm-1677	87	15	report	report	NOUN
ajlm-1677	87	16	,	,	PUNCT
ajlm-1677	87	17	all	all	DET
ajlm-1677	87	18	the	the	DET
ajlm-1677	87	19	six	six	NUM
ajlm-1677	87	20	hbv	hbv	NOUN
ajlm-1677	87	21	genotype	genotype	NOUN
ajlm-1677	87	22	e	e	NOUN
ajlm-1677	87	23	sequences	sequence	NOUN
ajlm-1677	87	24	were	be	AUX
ajlm-1677	87	25	susceptible	susceptible	ADJ
ajlm-1677	87	26	to	to	ADP
ajlm-1677	87	27	lamivudine	lamivudine	PROPN
ajlm-1677	87	28	,	,	PUNCT
ajlm-1677	87	29	adefovir	adefovir	PROPN
ajlm-1677	87	30	,	,	PUNCT
ajlm-1677	87	31	entecavir	entecavir	PROPN
ajlm-1677	87	32	,	,	PUNCT
ajlm-1677	87	33	tenofovir	tenofovir	NOUN
ajlm-1677	87	34	disoproxil	disoproxil	VERB
ajlm-1677	87	35	fumarate	fumarate	NOUN
ajlm-1677	87	36	,	,	PUNCT
ajlm-1677	87	37	and	and	CCONJ
ajlm-1677	87	38	telbivudine	telbivudine	NOUN
ajlm-1677	87	39	.	.	PUNCT
ajlm-1677	88	1	two	two	NUM
ajlm-1677	88	2	(	(	PUNCT
ajlm-1677	88	3	33.3	33.3	NUM
ajlm-1677	88	4	%	%	NOUN
ajlm-1677	88	5	)	)	PUNCT
ajlm-1677	88	6	of	of	ADP
ajlm-1677	88	7	the	the	DET
ajlm-1677	88	8	six	six	NUM
ajlm-1677	88	9	genotypes	genotype	NOUN
ajlm-1677	88	10	,	,	PUNCT
ajlm-1677	88	11	all	all	ADV
ajlm-1677	88	12	from	from	ADP
ajlm-1677	88	13	hbv	hbv	NOUN
ajlm-1677	88	14	-	-	PUNCT
ajlm-1677	88	15	mono	mono	NOUN
ajlm-1677	88	16	infected	infect	VERB
ajlm-1677	88	17	individuals	individual	NOUN
ajlm-1677	88	18	,	,	PUNCT
ajlm-1677	88	19	had	have	VERB
ajlm-1677	88	20	escape	escape	NOUN
ajlm-1677	88	21	mutations	mutation	NOUN
ajlm-1677	88	22	,	,	PUNCT
ajlm-1677	88	23	the	the	DET
ajlm-1677	88	24	sh2	sh2	NOUN
ajlm-1677	88	25	domain	domain	NOUN
ajlm-1677	88	26	-	-	PUNCT
ajlm-1677	88	27	containing	contain	VERB
ajlm-1677	88	28	adapter	adapter	NOUN
ajlm-1677	88	29	protein	protein	NOUN
ajlm-1677	88	30	b	b	PROPN
ajlm-1677	88	31	protein	protein	NOUN
ajlm-1677	88	32	of	of	ADP
ajlm-1677	88	33	the	the	DET
ajlm-1677	88	34	surface	surface	NOUN
ajlm-1677	88	35	-	-	PUNCT
ajlm-1677	88	36	gene	gene	NOUN
ajlm-1677	88	37	.	.	PUNCT
ajlm-1677	89	1	one	one	NUM
ajlm-1677	89	2	sample	sample	NOUN
ajlm-1677	89	3	had	have	VERB
ajlm-1677	89	4	l127r	l127r	NOUN
ajlm-1677	89	5	escape	escape	VERB
ajlm-1677	89	6	mutation	mutation	NOUN
ajlm-1677	89	7	while	while	SCONJ
ajlm-1677	89	8	the	the	DET
ajlm-1677	89	9	other	other	ADJ
ajlm-1677	89	10	had	have	AUX
ajlm-1677	89	11	g145a	g145a	ADV
ajlm-1677	89	12	at	at	ADP
ajlm-1677	89	13	a	a	DET
ajlm-1677	89	14	position	position	NOUN
ajlm-1677	89	15	first	first	ADV
ajlm-1677	89	16	described	describe	VERB
ajlm-1677	89	17	as	as	ADP
ajlm-1677	89	18	vaccine	vaccine	NOUN
ajlm-1677	89	19	escape	escape	NOUN
ajlm-1677	89	20	mutation	mutation	NOUN
ajlm-1677	89	21	.	.	PUNCT
ajlm-1677	90	1	these	these	DET
ajlm-1677	90	2	mutations	mutation	NOUN
ajlm-1677	90	3	are	be	AUX
ajlm-1677	90	4	amino	amino	NOUN
ajlm-1677	90	5	acid	acid	NOUN
ajlm-1677	90	6	substitutions	substitution	NOUN
ajlm-1677	90	7	within	within	ADP
ajlm-1677	90	8	the	the	DET
ajlm-1677	90	9	major	major	ADJ
ajlm-1677	90	10	hydrophilic	hydrophilic	ADJ
ajlm-1677	90	11	region	region	NOUN
ajlm-1677	90	12	called	call	VERB
ajlm-1677	90	13	the	the	DET
ajlm-1677	90	14	‘	'	PUNCT
ajlm-1677	90	15	a	a	PRON
ajlm-1677	90	16	’	'	PUNCT
ajlm-1677	90	17	determinant	determinant	ADJ
ajlm-1677	90	18	(	(	PUNCT
ajlm-1677	90	19	124–147	124–147	NUM
ajlm-1677	90	20	)	)	PUNCT
ajlm-1677	90	21	.	.	PUNCT
ajlm-1677	91	1	discussion	discussion	NOUN
ajlm-1677	91	2	our	our	PRON
ajlm-1677	91	3	findings	finding	NOUN
ajlm-1677	91	4	showed	show	VERB
ajlm-1677	91	5	a	a	DET
ajlm-1677	91	6	predominance	predominance	NOUN
ajlm-1677	91	7	of	of	ADP
ajlm-1677	91	8	genotype	genotype	NOUN
ajlm-1677	91	9	e	e	NOUN
ajlm-1677	91	10	consistent	consistent	ADJ
ajlm-1677	91	11	with	with	ADP
ajlm-1677	91	12	previous	previous	ADJ
ajlm-1677	91	13	studies	study	NOUN
ajlm-1677	91	14	from	from	ADP
ajlm-1677	91	15	nigeria	nigeria	PROPN
ajlm-1677	91	16	and	and	CCONJ
ajlm-1677	91	17	other	other	ADJ
ajlm-1677	91	18	west	west	NOUN
ajlm-1677	91	19	african	african	PROPN
ajlm-1677	92	1	regions.4,14,16,17,18,28,29,30	regions.4,14,16,17,18,28,29,30	PROPN
ajlm-1677	92	2	we	we	PRON
ajlm-1677	92	3	however	however	ADV
ajlm-1677	92	4	found	find	VERB
ajlm-1677	92	5	that	that	SCONJ
ajlm-1677	92	6	the	the	DET
ajlm-1677	92	7	genotypes	genotype	NOUN
ajlm-1677	92	8	had	have	VERB
ajlm-1677	92	9	a	a	DET
ajlm-1677	92	10	lower	low	ADJ
ajlm-1677	92	11	diversity	diversity	NOUN
ajlm-1677	92	12	compared	compare	VERB
ajlm-1677	92	13	to	to	ADP
ajlm-1677	92	14	a	a	DET
ajlm-1677	92	15	previous	previous	ADJ
ajlm-1677	92	16	report,14	report,14	ADV
ajlm-1677	92	17	although	although	SCONJ
ajlm-1677	92	18	other	other	ADJ
ajlm-1677	92	19	studies	study	NOUN
ajlm-1677	92	20	have	have	AUX
ajlm-1677	92	21	equally	equally	ADV
ajlm-1677	92	22	observed	observe	VERB
ajlm-1677	92	23	a	a	DET
ajlm-1677	92	24	low	low	ADJ
ajlm-1677	92	25	genetic	genetic	ADJ
ajlm-1677	92	26	diversity	diversity	NOUN
ajlm-1677	92	27	of	of	ADP
ajlm-1677	92	28	hbv	hbv	NOUN
ajlm-1677	92	29	genotype	genotype	NOUN
ajlm-1677	92	30	e	e	NOUN
ajlm-1677	92	31	in	in	ADP
ajlm-1677	92	32	west	west	PROPN
ajlm-1677	92	33	africa.18,31	africa.18,31	VERB
ajlm-1677	92	34	a	a	DET
ajlm-1677	92	35	possible	possible	ADJ
ajlm-1677	92	36	explanation	explanation	NOUN
ajlm-1677	92	37	may	may	AUX
ajlm-1677	92	38	be	be	AUX
ajlm-1677	92	39	due	due	ADJ
ajlm-1677	92	40	to	to	ADP
ajlm-1677	92	41	natural	natural	ADJ
ajlm-1677	92	42	selection	selection	NOUN
ajlm-1677	92	43	,	,	PUNCT
ajlm-1677	92	44	drug	drug	NOUN
ajlm-1677	92	45	pressure	pressure	NOUN
ajlm-1677	92	46	and	and	CCONJ
ajlm-1677	92	47	hyperendemicity	hyperendemicity	NOUN
ajlm-1677	92	48	of	of	ADP
ajlm-1677	92	49	hbv	hbv	NOUN
ajlm-1677	92	50	genotype	genotype	NOUN
ajlm-1677	92	51	e	e	NOUN
ajlm-1677	92	52	infection	infection	NOUN
ajlm-1677	92	53	in	in	ADP
ajlm-1677	92	54	other	other	ADJ
ajlm-1677	92	55	west	west	ADJ
ajlm-1677	92	56	african	african	ADJ
ajlm-1677	92	57	countries.28	countries.28	PROPN
ajlm-1677	92	58	the	the	DET
ajlm-1677	92	59	ease	ease	NOUN
ajlm-1677	92	60	of	of	ADP
ajlm-1677	92	61	transmission	transmission	NOUN
ajlm-1677	92	62	and	and	CCONJ
ajlm-1677	92	63	epidemiological	epidemiological	ADJ
ajlm-1677	92	64	pattern	pattern	NOUN
ajlm-1677	92	65	of	of	ADP
ajlm-1677	92	66	hbv	hbv	NOUN
ajlm-1677	92	67	have	have	AUX
ajlm-1677	92	68	been	be	AUX
ajlm-1677	92	69	linked	link	VERB
ajlm-1677	92	70	to	to	ADP
ajlm-1677	92	71	genotype	genotype	NOUN
ajlm-1677	92	72	variability	variability	NOUN
ajlm-1677	92	73	,	,	PUNCT
ajlm-1677	92	74	as	as	ADV
ajlm-1677	92	75	well	well	ADV
ajlm-1677	92	76	as	as	ADP
ajlm-1677	92	77	clinical	clinical	ADJ
ajlm-1677	92	78	virological	virological	ADJ
ajlm-1677	92	79	parameters	parameter	NOUN
ajlm-1677	92	80	.	.	PUNCT
ajlm-1677	93	1	the	the	DET
ajlm-1677	93	2	pathogenicity	pathogenicity	NOUN
ajlm-1677	93	3	of	of	ADP
ajlm-1677	93	4	hbv	hbv	NOUN
ajlm-1677	93	5	has	have	AUX
ajlm-1677	93	6	been	be	AUX
ajlm-1677	93	7	shown	show	VERB
ajlm-1677	93	8	to	to	PART
ajlm-1677	93	9	vary	vary	VERB
ajlm-1677	93	10	with	with	ADP
ajlm-1677	93	11	genotype	genotype	NOUN
ajlm-1677	93	12	and	and	CCONJ
ajlm-1677	93	13	certain	certain	ADJ
ajlm-1677	93	14	mutations	mutation	NOUN
ajlm-1677	93	15	have	have	AUX
ajlm-1677	93	16	been	be	AUX
ajlm-1677	93	17	associated	associate	VERB
ajlm-1677	93	18	with	with	ADP
ajlm-1677	93	19	genotype	genotype	NOUN
ajlm-1677	93	20	diversity	diversity	NOUN
ajlm-1677	93	21	that	that	PRON
ajlm-1677	93	22	influences	influence	VERB
ajlm-1677	93	23	disease	disease	NOUN
ajlm-1677	93	24	outcome	outcome	NOUN
ajlm-1677	93	25	,	,	PUNCT
ajlm-1677	93	26	hcc	hcc	PROPN
ajlm-1677	93	27	development	development	PROPN
ajlm-1677	93	28	,	,	PUNCT
ajlm-1677	93	29	diagnostic	diagnostic	ADJ
ajlm-1677	93	30	testing	testing	NOUN
ajlm-1677	93	31	and	and	CCONJ
ajlm-1677	93	32	treatment	treatment	NOUN
ajlm-1677	93	33	outcomes.28	outcomes.28	NOUN
ajlm-1677	93	34	studies	study	NOUN
ajlm-1677	93	35	have	have	AUX
ajlm-1677	93	36	shown	show	VERB
ajlm-1677	93	37	a	a	DET
ajlm-1677	93	38	higher	high	ADJ
ajlm-1677	93	39	severity	severity	NOUN
ajlm-1677	93	40	of	of	ADP
ajlm-1677	93	41	liver	liver	NOUN
ajlm-1677	93	42	disease	disease	NOUN
ajlm-1677	93	43	progression	progression	NOUN
ajlm-1677	93	44	and	and	CCONJ
ajlm-1677	93	45	hcc	hcc	PROPN
ajlm-1677	93	46	in	in	ADP
ajlm-1677	93	47	patients	patient	NOUN
ajlm-1677	93	48	infected	infect	VERB
ajlm-1677	93	49	with	with	ADP
ajlm-1677	93	50	c	c	PROPN
ajlm-1677	93	51	and	and	CCONJ
ajlm-1677	93	52	d	d	NOUN
ajlm-1677	93	53	genotypes	genotype	NOUN
ajlm-1677	93	54	than	than	ADP
ajlm-1677	93	55	those	those	PRON
ajlm-1677	93	56	infected	infect	VERB
ajlm-1677	93	57	with	with	ADP
ajlm-1677	93	58	a	a	DET
ajlm-1677	93	59	or	or	CCONJ
ajlm-1677	93	60	b	b	NOUN
ajlm-1677	93	61	genotypes.32,33	genotypes.32,33	NOUN
ajlm-1677	93	62	although	although	SCONJ
ajlm-1677	93	63	the	the	DET
ajlm-1677	93	64	clinical	clinical	ADJ
ajlm-1677	93	65	implications	implication	NOUN
ajlm-1677	93	66	of	of	ADP
ajlm-1677	93	67	genotype	genotype	NOUN
ajlm-1677	93	68	e	e	NOUN
ajlm-1677	93	69	,	,	PUNCT
ajlm-1677	93	70	the	the	DET
ajlm-1677	93	71	predominant	predominant	ADJ
ajlm-1677	93	72	genotype	genotype	NOUN
ajlm-1677	93	73	in	in	ADP
ajlm-1677	93	74	our	our	PRON
ajlm-1677	93	75	study	study	NOUN
ajlm-1677	93	76	,	,	PUNCT
ajlm-1677	93	77	have	have	AUX
ajlm-1677	93	78	not	not	PART
ajlm-1677	93	79	been	be	AUX
ajlm-1677	93	80	well	well	ADV
ajlm-1677	93	81	reported	report	VERB
ajlm-1677	93	82	,	,	PUNCT
ajlm-1677	93	83	it	it	PRON
ajlm-1677	93	84	is	be	AUX
ajlm-1677	93	85	speculated	speculate	VERB
ajlm-1677	93	86	that	that	SCONJ
ajlm-1677	93	87	patients	patient	NOUN
ajlm-1677	93	88	with	with	ADP
ajlm-1677	93	89	genotype	genotype	NOUN
ajlm-1677	93	90	e	e	NOUN
ajlm-1677	93	91	have	have	VERB
ajlm-1677	93	92	better	well	ADJ
ajlm-1677	93	93	liver	liver	NOUN
ajlm-1677	93	94	disease	disease	NOUN
ajlm-1677	93	95	prognosis	prognosis	NOUN
ajlm-1677	93	96	than	than	SCONJ
ajlm-1677	93	97	other	other	ADJ
ajlm-1677	93	98	genotypes.29	genotypes.29	PROPN
ajlm-1677	93	99	larger	large	ADJ
ajlm-1677	93	100	studies	study	NOUN
ajlm-1677	93	101	are	be	AUX
ajlm-1677	93	102	needed	need	VERB
ajlm-1677	93	103	to	to	PART
ajlm-1677	93	104	provide	provide	VERB
ajlm-1677	93	105	further	further	ADJ
ajlm-1677	93	106	evidence	evidence	NOUN
ajlm-1677	93	107	on	on	ADP
ajlm-1677	93	108	good	good	ADJ
ajlm-1677	93	109	clinical	clinical	ADJ
ajlm-1677	93	110	prognosis	prognosis	NOUN
ajlm-1677	93	111	for	for	ADP
ajlm-1677	93	112	patients	patient	NOUN
ajlm-1677	93	113	infected	infect	VERB
ajlm-1677	93	114	with	with	ADP
ajlm-1677	93	115	genotype	genotype	NOUN
ajlm-1677	93	116	e.	e.	PROPN
ajlm-1677	93	117	nonetheless	nonetheless	ADV
ajlm-1677	93	118	,	,	PUNCT
ajlm-1677	93	119	these	these	DET
ajlm-1677	93	120	findings	finding	NOUN
ajlm-1677	93	121	suggest	suggest	VERB
ajlm-1677	93	122	the	the	DET
ajlm-1677	93	123	need	need	NOUN
ajlm-1677	93	124	for	for	ADP
ajlm-1677	93	125	adoption	adoption	NOUN
ajlm-1677	93	126	of	of	ADP
ajlm-1677	93	127	individualised	individualised	ADJ
ajlm-1677	93	128	genotypic	genotypic	NOUN
ajlm-1677	93	129	testing	testing	NOUN
ajlm-1677	93	130	,	,	PUNCT
ajlm-1677	93	131	which	which	PRON
ajlm-1677	93	132	may	may	AUX
ajlm-1677	93	133	play	play	VERB
ajlm-1677	93	134	a	a	DET
ajlm-1677	93	135	key	key	ADJ
ajlm-1677	93	136	role	role	NOUN
ajlm-1677	93	137	in	in	ADP
ajlm-1677	93	138	guiding	guide	VERB
ajlm-1677	93	139	future	future	ADJ
ajlm-1677	93	140	treatment	treatment	NOUN
ajlm-1677	93	141	strategies	strategy	NOUN
ajlm-1677	93	142	to	to	PART
ajlm-1677	93	143	combat	combat	VERB
ajlm-1677	93	144	the	the	DET
ajlm-1677	93	145	hbv	hbv	NOUN
ajlm-1677	93	146	disease	disease	NOUN
ajlm-1677	93	147	.	.	PUNCT
ajlm-1677	94	1	in	in	ADP
ajlm-1677	94	2	the	the	DET
ajlm-1677	94	3	interim	interim	ADJ
ajlm-1677	94	4	,	,	PUNCT
ajlm-1677	94	5	early	early	ADJ
ajlm-1677	94	6	treatment	treatment	NOUN
ajlm-1677	94	7	is	be	AUX
ajlm-1677	94	8	warranted	warrant	VERB
ajlm-1677	94	9	to	to	PART
ajlm-1677	94	10	ensure	ensure	VERB
ajlm-1677	94	11	good	good	ADJ
ajlm-1677	94	12	hbv	hbv	NOUN
ajlm-1677	94	13	prognosis	prognosis	NOUN
ajlm-1677	94	14	.	.	PUNCT
ajlm-1677	95	1	as	as	SCONJ
ajlm-1677	95	2	reported	report	VERB
ajlm-1677	95	3	in	in	ADP
ajlm-1677	95	4	other	other	ADJ
ajlm-1677	95	5	studies	study	NOUN
ajlm-1677	95	6	,	,	PUNCT
ajlm-1677	95	7	we	we	PRON
ajlm-1677	95	8	did	do	AUX
ajlm-1677	95	9	not	not	PART
ajlm-1677	95	10	find	find	VERB
ajlm-1677	95	11	any	any	DET
ajlm-1677	95	12	tenofovir	tenofovir	NOUN
ajlm-1677	95	13	or	or	CCONJ
ajlm-1677	95	14	underlying	underlying	ADJ
ajlm-1677	95	15	lamivudine	lamivudine	NOUN
ajlm-1677	95	16	-	-	PUNCT
ajlm-1677	95	17	associated	associate	VERB
ajlm-1677	95	18	mutations	mutation	NOUN
ajlm-1677	95	19	including	include	VERB
ajlm-1677	95	20	the	the	DET
ajlm-1677	95	21	rta194	rta194	PROPN
ajlm-1677	95	22	t	t	PROPN
ajlm-1677	95	23	that	that	PRON
ajlm-1677	95	24	was	be	AUX
ajlm-1677	95	25	earlier	early	ADV
ajlm-1677	95	26	reported	report	VERB
ajlm-1677	95	27	to	to	PART
ajlm-1677	95	28	be	be	AUX
ajlm-1677	95	29	resistant	resistant	ADJ
ajlm-1677	95	30	to	to	ADP
ajlm-1677	95	31	tenofovir.34,35	tenofovir.34,35	NOUN
ajlm-1677	95	32	this	this	PRON
ajlm-1677	95	33	suggests	suggest	VERB
ajlm-1677	95	34	that	that	SCONJ
ajlm-1677	95	35	tenofovir	tenofovir	NOUN
ajlm-1677	95	36	-	-	PUNCT
ajlm-1677	95	37	containing	contain	VERB
ajlm-1677	95	38	and	and	CCONJ
ajlm-1677	95	39	monotherapy	monotherapy	NOUN
ajlm-1677	95	40	regimen	regiman	NOUN
ajlm-1677	95	41	is	be	AUX
ajlm-1677	95	42	still	still	ADV
ajlm-1677	95	43	effective	effective	ADJ
ajlm-1677	95	44	against	against	ADP
ajlm-1677	95	45	the	the	DET
ajlm-1677	95	46	virus	virus	NOUN
ajlm-1677	95	47	in	in	ADP
ajlm-1677	95	48	our	our	PRON
ajlm-1677	95	49	setting	setting	NOUN
ajlm-1677	95	50	.	.	PUNCT
ajlm-1677	96	1	however	however	ADV
ajlm-1677	96	2	,	,	PUNCT
ajlm-1677	96	3	we	we	PRON
ajlm-1677	96	4	observed	observe	VERB
ajlm-1677	96	5	vaccine	vaccine	NOUN
ajlm-1677	96	6	escape	escape	VERB
ajlm-1677	96	7	mutations	mutation	NOUN
ajlm-1677	96	8	(	(	PUNCT
ajlm-1677	96	9	l127r	l127r	NOUN
ajlm-1677	96	10	and	and	CCONJ
ajlm-1677	96	11	sg145a	sg145a	NUM
ajlm-1677	96	12	)	)	PUNCT
ajlm-1677	96	13	in	in	ADP
ajlm-1677	96	14	two	two	NUM
ajlm-1677	96	15	(	(	PUNCT
ajlm-1677	96	16	33.3	33.3	NUM
ajlm-1677	96	17	%	%	NOUN
ajlm-1677	96	18	)	)	PUNCT
ajlm-1677	96	19	of	of	ADP
ajlm-1677	96	20	the	the	DET
ajlm-1677	96	21	six	six	NUM
ajlm-1677	96	22	genotypes	genotype	NOUN
ajlm-1677	96	23	.	.	PUNCT
ajlm-1677	97	1	the	the	DET
ajlm-1677	97	2	finding	finding	NOUN
ajlm-1677	97	3	of	of	ADP
ajlm-1677	97	4	sg145a	sg145a	PROPN
ajlm-1677	97	5	is	be	AUX
ajlm-1677	97	6	consistent	consistent	ADJ
ajlm-1677	97	7	with	with	ADP
ajlm-1677	97	8	findings	finding	NOUN
ajlm-1677	97	9	from	from	ADP
ajlm-1677	97	10	nigeria,16	nigeria,16	ADJ
ajlm-1677	97	11	ghana36	ghana36	NOUN
ajlm-1677	97	12	and	and	CCONJ
ajlm-1677	97	13	gabon.37	gabon.37	VERB
ajlm-1677	97	14	these	these	DET
ajlm-1677	97	15	hbsag	hbsag	ADJ
ajlm-1677	97	16	vaccine	vaccine	NOUN
ajlm-1677	97	17	escape	escape	VERB
ajlm-1677	97	18	mutants	mutant	NOUN
ajlm-1677	97	19	may	may	AUX
ajlm-1677	97	20	have	have	AUX
ajlm-1677	97	21	arisen	arise	VERB
ajlm-1677	97	22	as	as	ADP
ajlm-1677	97	23	a	a	DET
ajlm-1677	97	24	result	result	NOUN
ajlm-1677	97	25	of	of	ADP
ajlm-1677	97	26	specific	specific	ADJ
ajlm-1677	97	27	selection	selection	NOUN
ajlm-1677	97	28	such	such	ADJ
ajlm-1677	97	29	as	as	ADP
ajlm-1677	97	30	the	the	DET
ajlm-1677	97	31	host	host	NOUN
ajlm-1677	97	32	immune	immune	ADJ
ajlm-1677	97	33	system	system	NOUN
ajlm-1677	97	34	due	due	ADP
ajlm-1677	97	35	to	to	ADP
ajlm-1677	97	36	vaccination	vaccination	NOUN
ajlm-1677	97	37	or	or	CCONJ
ajlm-1677	97	38	antiviral	antiviral	ADJ
ajlm-1677	97	39	selective	selective	ADJ
ajlm-1677	97	40	pressure	pressure	NOUN
ajlm-1677	97	41	that	that	PRON
ajlm-1677	97	42	truncates	truncate	VERB
ajlm-1677	97	43	the	the	DET
ajlm-1677	97	44	production	production	NOUN
ajlm-1677	97	45	of	of	ADP
ajlm-1677	97	46	hbsag	hbsag	NOUN
ajlm-1677	97	47	resulting	result	VERB
ajlm-1677	97	48	in	in	ADP
ajlm-1677	97	49	low	low	ADJ
ajlm-1677	97	50	plasma	plasma	NOUN
ajlm-1677	97	51	hbv	hbv	NOUN
ajlm-1677	97	52	dna	dna	PROPN
ajlm-1677	97	53	levels.38	levels.38	PROPN
ajlm-1677	97	54	although	although	SCONJ
ajlm-1677	97	55	we	we	PRON
ajlm-1677	97	56	did	do	AUX
ajlm-1677	97	57	not	not	PART
ajlm-1677	97	58	take	take	VERB
ajlm-1677	97	59	the	the	DET
ajlm-1677	97	60	history	history	NOUN
ajlm-1677	97	61	of	of	ADP
ajlm-1677	97	62	patients	patient	NOUN
ajlm-1677	97	63	’	'	PUNCT
ajlm-1677	97	64	vaccination	vaccination	NOUN
ajlm-1677	97	65	,	,	PUNCT
ajlm-1677	97	66	but	but	CCONJ
ajlm-1677	97	67	all	all	DET
ajlm-1677	97	68	the	the	DET
ajlm-1677	97	69	patients	patient	NOUN
ajlm-1677	97	70	were	be	AUX
ajlm-1677	97	71	on	on	ADP
ajlm-1677	97	72	antiviral	antiviral	ADJ
ajlm-1677	97	73	therapy	therapy	NOUN
ajlm-1677	97	74	(	(	PUNCT
ajlm-1677	97	75	≥	≥	NOUN
ajlm-1677	97	76	12	12	NUM
ajlm-1677	97	77	months	month	NOUN
ajlm-1677	97	78	)	)	PUNCT
ajlm-1677	97	79	,	,	PUNCT
ajlm-1677	97	80	including	include	VERB
ajlm-1677	97	81	mono	mono	NOUN
ajlm-1677	97	82	-	-	PUNCT
ajlm-1677	97	83	lamivudine	lamivudine	NOUN
ajlm-1677	97	84	or	or	CCONJ
ajlm-1677	97	85	lamivudine	lamivudine	NOUN
ajlm-1677	97	86	-	-	PUNCT
ajlm-1677	97	87	containing	contain	VERB
ajlm-1677	97	88	regimen	regiman	NOUN
ajlm-1677	97	89	before	before	ADP
ajlm-1677	97	90	switching	switch	VERB
ajlm-1677	97	91	to	to	ADP
ajlm-1677	97	92	tenofovir	tenofovir	NOUN
ajlm-1677	97	93	,	,	PUNCT
ajlm-1677	97	94	and	and	CCONJ
ajlm-1677	97	95	this	this	PRON
ajlm-1677	97	96	may	may	AUX
ajlm-1677	97	97	suggest	suggest	VERB
ajlm-1677	97	98	a	a	DET
ajlm-1677	97	99	possible	possible	ADJ
ajlm-1677	97	100	reason	reason	NOUN
ajlm-1677	97	101	for	for	ADP
ajlm-1677	97	102	emergence	emergence	NOUN
ajlm-1677	97	103	of	of	ADP
ajlm-1677	97	104	drug	drug	NOUN
ajlm-1677	97	105	-	-	PUNCT
ajlm-1677	97	106	associated	associate	VERB
ajlm-1677	97	107	potential	potential	ADJ
ajlm-1677	97	108	vaccine	vaccine	NOUN
ajlm-1677	97	109	-	-	PUNCT
ajlm-1677	97	110	escape	escape	NOUN
ajlm-1677	97	111	mutants	mutant	NOUN
ajlm-1677	97	112	(	(	PUNCT
ajlm-1677	97	113	sg145a	sg145a	PROPN
ajlm-1677	97	114	)	)	PUNCT
ajlm-1677	97	115	in	in	ADP
ajlm-1677	97	116	the	the	DET
ajlm-1677	97	117	study	study	NOUN
ajlm-1677	97	118	patients	patient	NOUN
ajlm-1677	97	119	.	.	PUNCT
ajlm-1677	98	1	similarly	similarly	ADV
ajlm-1677	98	2	,	,	PUNCT
ajlm-1677	98	3	mutations	mutation	NOUN
ajlm-1677	98	4	arising	arise	VERB
ajlm-1677	98	5	in	in	ADP
ajlm-1677	98	6	the	the	DET
ajlm-1677	98	7	s	s	X
ajlm-1677	98	8	orf	orf	PROPN
ajlm-1677	98	9	region	region	NOUN
ajlm-1677	98	10	because	because	SCONJ
ajlm-1677	98	11	of	of	ADP
ajlm-1677	98	12	inherent	inherent	ADJ
ajlm-1677	98	13	or	or	CCONJ
ajlm-1677	98	14	selective	selective	ADJ
ajlm-1677	98	15	pressure	pressure	NOUN
ajlm-1677	98	16	by	by	ADP
ajlm-1677	98	17	antiviral	antiviral	ADJ
ajlm-1677	98	18	drugs	drug	NOUN
ajlm-1677	98	19	can	can	AUX
ajlm-1677	98	20	end	end	VERB
ajlm-1677	98	21	up	up	ADP
ajlm-1677	98	22	in	in	ADP
ajlm-1677	98	23	the	the	DET
ajlm-1677	98	24	emergence	emergence	NOUN
ajlm-1677	98	25	of	of	ADP
ajlm-1677	98	26	virus	virus	NOUN
ajlm-1677	98	27	escape	escape	NOUN
ajlm-1677	98	28	mutants	mutant	NOUN
ajlm-1677	98	29	in	in	ADP
ajlm-1677	98	30	the	the	DET
ajlm-1677	98	31	adjacent	adjacent	ADJ
ajlm-1677	98	32	s	s	X
ajlm-1677	98	33	region	region	NOUN
ajlm-1677	98	34	with	with	ADP
ajlm-1677	98	35	subsequent	subsequent	ADJ
ajlm-1677	98	36	lack	lack	NOUN
ajlm-1677	98	37	of	of	ADP
ajlm-1677	98	38	response	response	NOUN
ajlm-1677	98	39	to	to	ADP
ajlm-1677	98	40	hbv	hbv	NOUN
ajlm-1677	98	41	vaccine	vaccine	NOUN
ajlm-1677	98	42	.	.	PUNCT
ajlm-1677	99	1	the	the	DET
ajlm-1677	99	2	presence	presence	NOUN
ajlm-1677	99	3	of	of	ADP
ajlm-1677	99	4	this	this	DET
ajlm-1677	99	5	mutant	mutant	NOUN
ajlm-1677	99	6	over	over	ADP
ajlm-1677	99	7	time	time	NOUN
ajlm-1677	99	8	could	could	AUX
ajlm-1677	99	9	lead	lead	VERB
ajlm-1677	99	10	to	to	ADP
ajlm-1677	99	11	partial	partial	ADJ
ajlm-1677	99	12	replicative	replicative	ADJ
ajlm-1677	99	13	capacity	capacity	NOUN
ajlm-1677	99	14	of	of	ADP
ajlm-1677	99	15	resistant	resistant	ADJ
ajlm-1677	99	16	hbv	hbv	NOUN
ajlm-1677	99	17	variant	variant	NOUN
ajlm-1677	99	18	,	,	PUNCT
ajlm-1677	99	19	and	and	CCONJ
ajlm-1677	99	20	lack	lack	NOUN
ajlm-1677	99	21	of	of	ADP
ajlm-1677	99	22	response	response	NOUN
ajlm-1677	99	23	to	to	ADP
ajlm-1677	99	24	hbv	hbv	NOUN
ajlm-1677	99	25	vaccine.39	vaccine.39	NOUN
ajlm-1677	99	26	this	this	DET
ajlm-1677	99	27	mutation	mutation	NOUN
ajlm-1677	99	28	may	may	AUX
ajlm-1677	99	29	be	be	AUX
ajlm-1677	99	30	due	due	ADJ
ajlm-1677	99	31	to	to	ADP
ajlm-1677	99	32	poor	poor	ADJ
ajlm-1677	99	33	adherence	adherence	NOUN
ajlm-1677	99	34	to	to	ADP
ajlm-1677	99	35	antiviral	antiviral	ADJ
ajlm-1677	99	36	therapy	therapy	NOUN
ajlm-1677	99	37	and	and	CCONJ
ajlm-1677	99	38	the	the	DET
ajlm-1677	99	39	use	use	NOUN
ajlm-1677	99	40	of	of	ADP
ajlm-1677	99	41	drugs	drug	NOUN
ajlm-1677	99	42	with	with	ADP
ajlm-1677	99	43	a	a	DET
ajlm-1677	99	44	low	low	ADJ
ajlm-1677	99	45	genetic	genetic	ADJ
ajlm-1677	99	46	barrier	barrier	NOUN
ajlm-1677	99	47	to	to	PART
ajlm-1677	99	48	resistance	resistance	NOUN
ajlm-1677	99	49	such	such	ADJ
ajlm-1677	99	50	as	as	ADP
ajlm-1677	99	51	lamivudine	lamivudine	NOUN
ajlm-1677	99	52	,	,	PUNCT
ajlm-1677	99	53	which	which	PRON
ajlm-1677	99	54	was	be	AUX
ajlm-1677	99	55	the	the	DET
ajlm-1677	99	56	major	major	ADJ
ajlm-1677	99	57	drug	drug	NOUN
ajlm-1677	99	58	used	use	VERB
ajlm-1677	99	59	in	in	ADP
ajlm-1677	99	60	nigeria	nigeria	PROPN
ajlm-1677	99	61	before	before	ADP
ajlm-1677	99	62	switching	switch	VERB
ajlm-1677	99	63	to	to	ADP
ajlm-1677	99	64	tenofovir	tenofovir	NOUN
ajlm-1677	99	65	among	among	ADP
ajlm-1677	99	66	hbv	hbv	NOUN
ajlm-1677	99	67	-	-	PUNCT
ajlm-1677	99	68	mono	mono	NOUN
ajlm-1677	99	69	infected	infected	ADJ
ajlm-1677	99	70	patients	patient	NOUN
ajlm-1677	99	71	.	.	PUNCT
ajlm-1677	100	1	this	this	DET
ajlm-1677	100	2	mutation	mutation	NOUN
ajlm-1677	100	3	sg145	sg145	PROPN
ajlm-1677	100	4	confers	confer	NOUN
ajlm-1677	100	5	immune	immune	ADJ
ajlm-1677	100	6	escape	escape	NOUN
ajlm-1677	100	7	competence	competence	NOUN
ajlm-1677	100	8	on	on	ADP
ajlm-1677	100	9	the	the	DET
ajlm-1677	100	10	virus,40,41	virus,40,41	ADJ
ajlm-1677	100	11	which	which	PRON
ajlm-1677	100	12	has	have	VERB
ajlm-1677	100	13	negative	negative	ADJ
ajlm-1677	100	14	impact	impact	NOUN
ajlm-1677	100	15	on	on	ADP
ajlm-1677	100	16	humoral	humoral	ADJ
ajlm-1677	100	17	immune	immune	ADJ
ajlm-1677	100	18	response	response	NOUN
ajlm-1677	100	19	to	to	ADP
ajlm-1677	100	20	hbv	hbv	NOUN
ajlm-1677	100	21	vaccine	vaccine	NOUN
ajlm-1677	100	22	.	.	PUNCT
ajlm-1677	101	1	however	however	ADV
ajlm-1677	101	2	,	,	PUNCT
ajlm-1677	101	3	a	a	DET
ajlm-1677	101	4	recent	recent	ADJ
ajlm-1677	101	5	study	study	NOUN
ajlm-1677	101	6	has	have	AUX
ajlm-1677	101	7	shown	show	VERB
ajlm-1677	101	8	that	that	SCONJ
ajlm-1677	101	9	the	the	DET
ajlm-1677	101	10	risk	risk	NOUN
ajlm-1677	101	11	of	of	ADP
ajlm-1677	101	12	transmission	transmission	NOUN
ajlm-1677	101	13	of	of	ADP
ajlm-1677	101	14	hbv	hbv	NOUN
ajlm-1677	101	15	infection	infection	NOUN
ajlm-1677	101	16	is	be	AUX
ajlm-1677	101	17	low	low	ADJ
ajlm-1677	101	18	in	in	ADP
ajlm-1677	101	19	a	a	DET
ajlm-1677	101	20	vaccinated	vaccinated	ADJ
ajlm-1677	101	21	individual.42	individual.42	NOUN
ajlm-1677	101	22	similarly	similarly	ADV
ajlm-1677	101	23	,	,	PUNCT
ajlm-1677	101	24	the	the	DET
ajlm-1677	101	25	presence	presence	NOUN
ajlm-1677	101	26	of	of	ADP
ajlm-1677	101	27	this	this	DET
ajlm-1677	101	28	mutation	mutation	NOUN
ajlm-1677	101	29	in	in	ADP
ajlm-1677	101	30	immune	immune	NOUN
ajlm-1677	101	31	-	-	PUNCT
ajlm-1677	101	32	compromised	compromise	VERB
ajlm-1677	101	33	patients	patient	NOUN
ajlm-1677	101	34	could	could	AUX
ajlm-1677	101	35	be	be	AUX
ajlm-1677	101	36	responsible	responsible	ADJ
ajlm-1677	101	37	for	for	ADP
ajlm-1677	101	38	hbv	hbv	NOUN
ajlm-1677	101	39	reactivation	reactivation	NOUN
ajlm-1677	101	40	among	among	ADP
ajlm-1677	101	41	persons	person	NOUN
ajlm-1677	101	42	previous	previous	ADJ
ajlm-1677	101	43	immune	immune	ADJ
ajlm-1677	101	44	to	to	ADP
ajlm-1677	101	45	hepatitus	hepatitus	PROPN
ajlm-1677	101	46	b	b	PROPN
ajlm-1677	101	47	surface	surface	NOUN
ajlm-1677	101	48	antigen	antigen	NOUN
ajlm-1677	101	49	antibodies	antibodie	VERB
ajlm-1677	101	50	,	,	PUNCT
ajlm-1677	101	51	suggesting	suggest	VERB
ajlm-1677	101	52	immune	immune	ADJ
ajlm-1677	101	53	escape	escape	NOUN
ajlm-1677	101	54	mutant.43	mutant.43	NOUN
ajlm-1677	101	55	also	also	ADV
ajlm-1677	101	56	,	,	PUNCT
ajlm-1677	101	57	this	this	DET
ajlm-1677	101	58	mutation	mutation	NOUN
ajlm-1677	101	59	among	among	ADP
ajlm-1677	101	60	others	other	NOUN
ajlm-1677	101	61	can	can	AUX
ajlm-1677	101	62	be	be	AUX
ajlm-1677	101	63	responsible	responsible	ADJ
ajlm-1677	101	64	for	for	ADP
ajlm-1677	101	65	virus	virus	NOUN
ajlm-1677	101	66	detection	detection	NOUN
ajlm-1677	101	67	failure	failure	NOUN
ajlm-1677	101	68	in	in	ADP
ajlm-1677	101	69	most	most	ADV
ajlm-1677	101	70	routine	routine	ADJ
ajlm-1677	101	71	screening	screening	NOUN
ajlm-1677	101	72	tests.44	tests.44	NOUN
ajlm-1677	101	73	this	this	PRON
ajlm-1677	101	74	is	be	AUX
ajlm-1677	101	75	because	because	SCONJ
ajlm-1677	101	76	an	an	DET
ajlm-1677	101	77	assay	assay	NOUN
ajlm-1677	101	78	used	use	VERB
ajlm-1677	101	79	for	for	ADP
ajlm-1677	101	80	hbv	hbv	NOUN
ajlm-1677	101	81	screening	screening	NOUN
ajlm-1677	101	82	may	may	AUX
ajlm-1677	101	83	give	give	VERB
ajlm-1677	101	84	false	false	ADJ
ajlm-1677	101	85	-	-	PUNCT
ajlm-1677	101	86	negative	negative	ADJ
ajlm-1677	101	87	results	result	NOUN
ajlm-1677	101	88	if	if	SCONJ
ajlm-1677	101	89	the	the	DET
ajlm-1677	101	90	test	test	NOUN
ajlm-1677	101	91	kit	kit	NOUN
ajlm-1677	101	92	was	be	AUX
ajlm-1677	101	93	not	not	PART
ajlm-1677	101	94	designed	design	VERB
ajlm-1677	101	95	to	to	PART
ajlm-1677	101	96	detect	detect	VERB
ajlm-1677	101	97	mutants	mutant	NOUN
ajlm-1677	101	98	in	in	ADP
ajlm-1677	101	99	the	the	DET
ajlm-1677	101	100	‘	'	PUNCT
ajlm-1677	101	101	a	a	DET
ajlm-1677	101	102	’	'	PUNCT
ajlm-1677	101	103	determinant	determinant	ADJ
ajlm-1677	101	104	.	.	PUNCT
ajlm-1677	102	1	this	this	PRON
ajlm-1677	102	2	is	be	AUX
ajlm-1677	102	3	common	common	ADJ
ajlm-1677	102	4	in	in	ADP
ajlm-1677	102	5	the	the	DET
ajlm-1677	102	6	clinical	clinical	ADJ
ajlm-1677	102	7	setting	setting	NOUN
ajlm-1677	102	8	where	where	SCONJ
ajlm-1677	102	9	the	the	DET
ajlm-1677	102	10	patients	patient	NOUN
ajlm-1677	102	11	have	have	VERB
ajlm-1677	102	12	hbsag	hbsag	ADJ
ajlm-1677	102	13	negative	negative	ADJ
ajlm-1677	102	14	result	result	NOUN
ajlm-1677	102	15	,	,	PUNCT
ajlm-1677	102	16	yet	yet	ADV
ajlm-1677	102	17	will	will	AUX
ajlm-1677	102	18	have	have	VERB
ajlm-1677	102	19	classical	classical	ADJ
ajlm-1677	102	20	symptoms	symptom	NOUN
ajlm-1677	102	21	and	and	CCONJ
ajlm-1677	102	22	,	,	PUNCT
ajlm-1677	102	23	if	if	SCONJ
ajlm-1677	102	24	tested	test	VERB
ajlm-1677	102	25	for	for	ADP
ajlm-1677	102	26	hbv	hbv	NOUN
ajlm-1677	102	27	dna	dna	PROPN
ajlm-1677	102	28	,	,	PUNCT
ajlm-1677	102	29	will	will	AUX
ajlm-1677	102	30	have	have	VERB
ajlm-1677	102	31	positive	positive	ADJ
ajlm-1677	102	32	high	high	ADJ
ajlm-1677	102	33	hbv	hbv	NOUN
ajlm-1677	102	34	dna	dna	PROPN
ajlm-1677	102	35	result	result	VERB
ajlm-1677	102	36	.	.	PUNCT
ajlm-1677	103	1	the	the	DET
ajlm-1677	103	2	detection	detection	NOUN
ajlm-1677	103	3	of	of	ADP
ajlm-1677	103	4	some	some	PRON
ajlm-1677	103	5	of	of	ADP
ajlm-1677	103	6	these	these	DET
ajlm-1677	103	7	emerging	emerge	VERB
ajlm-1677	103	8	mutants	mutant	NOUN
ajlm-1677	103	9	has	have	AUX
ajlm-1677	103	10	become	become	VERB
ajlm-1677	103	11	a	a	DET
ajlm-1677	103	12	major	major	ADJ
ajlm-1677	103	13	challenge	challenge	NOUN
ajlm-1677	103	14	to	to	ADP
ajlm-1677	103	15	commercially	commercially	ADV
ajlm-1677	103	16	available	available	ADJ
ajlm-1677	103	17	immunoassays	immunoassay	NOUN
ajlm-1677	103	18	.	.	PUNCT
ajlm-1677	104	1	the	the	DET
ajlm-1677	104	2	l127r	l127r	NOUN
ajlm-1677	104	3	escape	escape	NOUN
ajlm-1677	104	4	mutation	mutation	NOUN
ajlm-1677	104	5	in	in	ADP
ajlm-1677	104	6	the	the	DET
ajlm-1677	104	7	‘	'	PUNCT
ajlm-1677	104	8	a	a	DET
ajlm-1677	104	9	’	'	PUNCT
ajlm-1677	104	10	determinant	determinant	ADJ
ajlm-1677	104	11	region	region	NOUN
ajlm-1677	104	12	observed	observe	VERB
ajlm-1677	104	13	in	in	ADP
ajlm-1677	104	14	our	our	PRON
ajlm-1677	104	15	study	study	NOUN
ajlm-1677	104	16	has	have	AUX
ajlm-1677	104	17	been	be	AUX
ajlm-1677	104	18	associated	associate	VERB
ajlm-1677	104	19	with	with	ADP
ajlm-1677	104	20	hbv	hbv	PROPN
ajlm-1677	104	21	antigenicity	antigenicity	NOUN
ajlm-1677	104	22	,	,	PUNCT
ajlm-1677	104	23	diagnostics	diagnostic	NOUN
ajlm-1677	104	24	and	and	CCONJ
ajlm-1677	104	25	immunogenicity.45	immunogenicity.45	NOUN
ajlm-1677	104	26	overall	overall	ADJ
ajlm-1677	104	27	,	,	PUNCT
ajlm-1677	104	28	l127r	l127r	NOUN
ajlm-1677	104	29	mutation	mutation	NOUN
ajlm-1677	104	30	was	be	AUX
ajlm-1677	104	31	mostly	mostly	ADV
ajlm-1677	104	32	associated	associate	VERB
ajlm-1677	104	33	with	with	ADP
ajlm-1677	104	34	patients	patient	NOUN
ajlm-1677	104	35	who	who	PRON
ajlm-1677	104	36	had	have	AUX
ajlm-1677	104	37	experienced	experience	VERB
ajlm-1677	104	38	lamivudine	lamivudine	NOUN
ajlm-1677	104	39	treatment	treatment	NOUN
ajlm-1677	104	40	in	in	ADP
ajlm-1677	104	41	other	other	ADJ
ajlm-1677	104	42	african	african	ADJ
ajlm-1677	104	43	countries.36,37	countries.36,37	NOUN
ajlm-1677	104	44	the	the	DET
ajlm-1677	104	45	long	long	ADJ
ajlm-1677	104	46	-	-	PUNCT
ajlm-1677	104	47	term	term	NOUN
ajlm-1677	104	48	impact	impact	NOUN
ajlm-1677	104	49	of	of	ADP
ajlm-1677	104	50	hbsag	hbsag	ADJ
ajlm-1677	104	51	vaccine	vaccine	NOUN
ajlm-1677	104	52	escape	escape	VERB
ajlm-1677	104	53	mutations	mutation	NOUN
ajlm-1677	104	54	on	on	ADP
ajlm-1677	104	55	the	the	DET
ajlm-1677	104	56	natural	natural	ADJ
ajlm-1677	104	57	history	history	NOUN
ajlm-1677	104	58	of	of	ADP
ajlm-1677	104	59	chronic	chronic	ADJ
ajlm-1677	104	60	hbv	hbv	NOUN
ajlm-1677	104	61	remains	remain	VERB
ajlm-1677	104	62	unclear	unclear	ADJ
ajlm-1677	104	63	.	.	PUNCT
ajlm-1677	105	1	however	however	ADV
ajlm-1677	105	2	,	,	PUNCT
ajlm-1677	105	3	it	it	PRON
ajlm-1677	105	4	has	have	AUX
ajlm-1677	105	5	been	be	AUX
ajlm-1677	105	6	hypothesised	hypothesise	VERB
ajlm-1677	105	7	that	that	SCONJ
ajlm-1677	105	8	the	the	DET
ajlm-1677	105	9	presence	presence	NOUN
ajlm-1677	105	10	of	of	ADP
ajlm-1677	105	11	stop	stop	VERB
ajlm-1677	105	12	codons	codon	NOUN
ajlm-1677	105	13	may	may	AUX
ajlm-1677	105	14	favour	favour	VERB
ajlm-1677	105	15	the	the	DET
ajlm-1677	105	16	production	production	NOUN
ajlm-1677	105	17	of	of	ADP
ajlm-1677	105	18	a	a	DET
ajlm-1677	105	19	truncated	truncated	ADJ
ajlm-1677	105	20	hbsag	hbsag	NOUN
ajlm-1677	105	21	(	(	PUNCT
ajlm-1677	105	22	despite	despite	SCONJ
ajlm-1677	105	23	low	low	ADJ
ajlm-1677	105	24	serum	serum	NOUN
ajlm-1677	105	25	hbv	hbv	PROPN
ajlm-1677	105	26	dna	dna	PROPN
ajlm-1677	105	27	)	)	PUNCT
ajlm-1677	105	28	,	,	PUNCT
ajlm-1677	105	29	which	which	PRON
ajlm-1677	105	30	accumulates	accumulate	VERB
ajlm-1677	105	31	in	in	ADP
ajlm-1677	105	32	the	the	DET
ajlm-1677	105	33	endoplasmic	endoplasmic	ADJ
ajlm-1677	105	34	reticulum	reticulum	NOUN
ajlm-1677	105	35	and	and	CCONJ
ajlm-1677	105	36	induces	induce	VERB
ajlm-1677	105	37	oxidative	oxidative	ADJ
ajlm-1677	105	38	stress	stress	NOUN
ajlm-1677	105	39	to	to	PART
ajlm-1677	105	40	enhance	enhance	VERB
ajlm-1677	105	41	cell	cell	NOUN
ajlm-1677	105	42	proliferation.38	proliferation.38	NOUN
ajlm-1677	105	43	this	this	PRON
ajlm-1677	105	44	may	may	AUX
ajlm-1677	105	45	also	also	ADV
ajlm-1677	105	46	explain	explain	VERB
ajlm-1677	105	47	the	the	DET
ajlm-1677	105	48	transmission	transmission	NOUN
ajlm-1677	105	49	of	of	ADP
ajlm-1677	105	50	hbv	hbv	NOUN
ajlm-1677	105	51	genotype	genotype	NOUN
ajlm-1677	105	52	e	e	NOUN
ajlm-1677	105	53	infection	infection	NOUN
ajlm-1677	105	54	even	even	ADV
ajlm-1677	105	55	in	in	ADP
ajlm-1677	105	56	vaccinated	vaccinated	ADJ
ajlm-1677	105	57	individuals	individual	NOUN
ajlm-1677	105	58	.	.	PUNCT
ajlm-1677	106	1	studies	study	NOUN
ajlm-1677	106	2	on	on	ADP
ajlm-1677	106	3	the	the	DET
ajlm-1677	106	4	hbv	hbv	NOUN
ajlm-1677	106	5	genotypes	genotype	NOUN
ajlm-1677	106	6	,	,	PUNCT
ajlm-1677	106	7	immune	immune	ADJ
ajlm-1677	106	8	escape	escape	NOUN
ajlm-1677	106	9	and	and	CCONJ
ajlm-1677	106	10	antiviral	antiviral	ADJ
ajlm-1677	106	11	drug	drug	NOUN
ajlm-1677	106	12	resistance	resistance	NOUN
ajlm-1677	106	13	mutations	mutation	NOUN
ajlm-1677	106	14	in	in	ADP
ajlm-1677	106	15	nigeria	nigeria	PROPN
ajlm-1677	106	16	are	be	AUX
ajlm-1677	106	17	scarce	scarce	ADJ
ajlm-1677	106	18	.	.	PUNCT
ajlm-1677	107	1	this	this	PRON
ajlm-1677	107	2	is	be	AUX
ajlm-1677	107	3	the	the	DET
ajlm-1677	107	4	first	first	ADJ
ajlm-1677	107	5	published	publish	VERB
ajlm-1677	107	6	study	study	NOUN
ajlm-1677	107	7	,	,	PUNCT
ajlm-1677	107	8	to	to	ADP
ajlm-1677	107	9	the	the	DET
ajlm-1677	107	10	best	good	ADJ
ajlm-1677	107	11	of	of	ADP
ajlm-1677	107	12	our	our	PRON
ajlm-1677	107	13	knowledge	knowledge	NOUN
ajlm-1677	107	14	,	,	PUNCT
ajlm-1677	107	15	that	that	PRON
ajlm-1677	107	16	characterised	characterise	VERB
ajlm-1677	107	17	hbv	hbv	NOUN
ajlm-1677	107	18	genotypes	genotype	NOUN
ajlm-1677	107	19	and	and	CCONJ
ajlm-1677	107	20	drug	drug	NOUN
ajlm-1677	107	21	resistance	resistance	NOUN
ajlm-1677	107	22	in	in	ADP
ajlm-1677	107	23	chronic	chronic	ADJ
ajlm-1677	107	24	hepatitis	hepatitis	PROPN
ajlm-1677	107	25	b	b	PROPN
ajlm-1677	107	26	patients	patient	NOUN
ajlm-1677	107	27	(	(	PUNCT
ajlm-1677	107	28	hbv	hbv	PROPN
ajlm-1677	107	29	/	/	SYM
ajlm-1677	107	30	hiv	hiv	PROPN
ajlm-1677	107	31	co	co	VERB
ajlm-1677	107	32	-	-	VERB
ajlm-1677	107	33	infected	infected	ADJ
ajlm-1677	107	34	and	and	CCONJ
ajlm-1677	107	35	hbv	hbv	NOUN
ajlm-1677	107	36	-	-	PUNCT
ajlm-1677	107	37	mono	mono	NOUN
ajlm-1677	107	38	infected	infect	VERB
ajlm-1677	107	39	patients	patient	NOUN
ajlm-1677	107	40	)	)	PUNCT
ajlm-1677	107	41	on	on	ADP
ajlm-1677	107	42	long	long	ADJ
ajlm-1677	107	43	-	-	PUNCT
ajlm-1677	107	44	term	term	NOUN
ajlm-1677	107	45	antiviral	antiviral	ADJ
ajlm-1677	107	46	therapy	therapy	NOUN
ajlm-1677	107	47	(	(	PUNCT
ajlm-1677	107	48	tenofovir	tenofovir	PROPN
ajlm-1677	107	49	)	)	PUNCT
ajlm-1677	107	50	in	in	ADP
ajlm-1677	107	51	nigeria	nigeria	PROPN
ajlm-1677	107	52	.	.	PUNCT
ajlm-1677	108	1	however	however	ADV
ajlm-1677	108	2	,	,	PUNCT
ajlm-1677	108	3	one	one	NUM
ajlm-1677	108	4	recent	recent	ADJ
ajlm-1677	108	5	study	study	NOUN
ajlm-1677	108	6	assessed	assess	VERB
ajlm-1677	108	7	the	the	DET
ajlm-1677	108	8	effect	effect	NOUN
ajlm-1677	108	9	of	of	ADP
ajlm-1677	108	10	hbv	hbv	NOUN
ajlm-1677	108	11	mutations	mutation	NOUN
ajlm-1677	108	12	with	with	ADP
ajlm-1677	108	13	liver	liver	NOUN
ajlm-1677	108	14	severity	severity	NOUN
ajlm-1677	108	15	in	in	ADP
ajlm-1677	108	16	hiv	hiv	PROPN
ajlm-1677	108	17	/	/	SYM
ajlm-1677	108	18	hbv	hbv	PROPN
ajlm-1677	108	19	co	co	VERB
ajlm-1677	108	20	-	-	ADJ
ajlm-1677	108	21	infected	infected	ADJ
ajlm-1677	108	22	antiretroviral	antiretroviral	ADJ
ajlm-1677	108	23	therapy	therapy	NOUN
ajlm-1677	108	24	-	-	PUNCT
ajlm-1677	108	25	naïve	naïve	ADJ
ajlm-1677	108	26	patients	patient	NOUN
ajlm-1677	108	27	in	in	ADP
ajlm-1677	108	28	nigeria.27	nigeria.27	ADJ
ajlm-1677	108	29	in	in	ADP
ajlm-1677	108	30	this	this	DET
ajlm-1677	108	31	study	study	NOUN
ajlm-1677	108	32	,	,	PUNCT
ajlm-1677	108	33	hbv	hbv	NOUN
ajlm-1677	108	34	mutations	mutation	NOUN
ajlm-1677	108	35	were	be	AUX
ajlm-1677	108	36	independently	independently	ADV
ajlm-1677	108	37	associated	associate	VERB
ajlm-1677	108	38	with	with	ADP
ajlm-1677	108	39	liver	liver	NOUN
ajlm-1677	108	40	disease	disease	NOUN
ajlm-1677	108	41	severity	severity	NOUN
ajlm-1677	108	42	,	,	PUNCT
ajlm-1677	108	43	but	but	CCONJ
ajlm-1677	108	44	the	the	DET
ajlm-1677	108	45	effect	effect	NOUN
ajlm-1677	108	46	declined	decline	VERB
ajlm-1677	108	47	after	after	ADP
ajlm-1677	108	48	antiretroviral	antiretroviral	ADJ
ajlm-1677	108	49	therapy	therapy	NOUN
ajlm-1677	108	50	initiation	initiation	NOUN
ajlm-1677	108	51	.	.	PUNCT
ajlm-1677	109	1	our	our	PRON
ajlm-1677	109	2	study	study	NOUN
ajlm-1677	109	3	however	however	ADV
ajlm-1677	109	4	,	,	PUNCT
ajlm-1677	109	5	highlighted	highlight	VERB
ajlm-1677	109	6	the	the	DET
ajlm-1677	109	7	need	need	NOUN
ajlm-1677	109	8	to	to	PART
ajlm-1677	109	9	assess	assess	VERB
ajlm-1677	109	10	hbv	hbv	NOUN
ajlm-1677	109	11	mutations	mutation	NOUN
ajlm-1677	109	12	due	due	ADP
ajlm-1677	109	13	to	to	ADP
ajlm-1677	109	14	the	the	DET
ajlm-1677	109	15	potential	potential	ADJ
ajlm-1677	109	16	link	link	NOUN
ajlm-1677	109	17	with	with	ADP
ajlm-1677	109	18	disease	disease	NOUN
ajlm-1677	109	19	severity	severity	NOUN
ajlm-1677	109	20	.	.	PUNCT
ajlm-1677	110	1	limitations	limitation	NOUN
ajlm-1677	110	2	there	there	PRON
ajlm-1677	110	3	are	be	VERB
ajlm-1677	110	4	limitations	limitation	NOUN
ajlm-1677	110	5	to	to	ADP
ajlm-1677	110	6	this	this	DET
ajlm-1677	110	7	study	study	NOUN
ajlm-1677	110	8	that	that	PRON
ajlm-1677	110	9	need	need	VERB
ajlm-1677	110	10	to	to	PART
ajlm-1677	110	11	be	be	AUX
ajlm-1677	110	12	highlighted	highlight	VERB
ajlm-1677	110	13	.	.	PUNCT
ajlm-1677	111	1	it	it	PRON
ajlm-1677	111	2	is	be	AUX
ajlm-1677	111	3	a	a	DET
ajlm-1677	111	4	cross	cross	ADJ
ajlm-1677	111	5	-	-	ADJ
ajlm-1677	111	6	sectional	sectional	ADJ
ajlm-1677	111	7	study	study	NOUN
ajlm-1677	111	8	with	with	ADP
ajlm-1677	111	9	a	a	DET
ajlm-1677	111	10	small	small	ADJ
ajlm-1677	111	11	sample	sample	NOUN
ajlm-1677	111	12	size	size	NOUN
ajlm-1677	111	13	,	,	PUNCT
ajlm-1677	111	14	and	and	CCONJ
ajlm-1677	111	15	low	low	ADJ
ajlm-1677	111	16	amplification	amplification	NOUN
ajlm-1677	111	17	and	and	CCONJ
ajlm-1677	111	18	sequencing	sequencing	NOUN
ajlm-1677	111	19	rate	rate	NOUN
ajlm-1677	111	20	,	,	PUNCT
ajlm-1677	111	21	yielding	yield	VERB
ajlm-1677	111	22	only	only	ADV
ajlm-1677	111	23	20.0	20.0	NUM
ajlm-1677	111	24	%	%	NOUN
ajlm-1677	111	25	of	of	ADP
ajlm-1677	111	26	the	the	DET
ajlm-1677	111	27	intended	intend	VERB
ajlm-1677	111	28	samples	sample	NOUN
ajlm-1677	111	29	.	.	PUNCT
ajlm-1677	112	1	many	many	ADJ
ajlm-1677	112	2	factors	factor	NOUN
ajlm-1677	112	3	could	could	AUX
ajlm-1677	112	4	be	be	AUX
ajlm-1677	112	5	responsible	responsible	ADJ
ajlm-1677	112	6	for	for	ADP
ajlm-1677	112	7	this	this	PRON
ajlm-1677	112	8	.	.	PUNCT
ajlm-1677	113	1	for	for	ADP
ajlm-1677	113	2	example	example	NOUN
ajlm-1677	113	3	,	,	PUNCT
ajlm-1677	113	4	several	several	ADJ
ajlm-1677	113	5	freeze	freeze	NOUN
ajlm-1677	113	6	-	-	PUNCT
ajlm-1677	113	7	thawing	thaw	VERB
ajlm-1677	113	8	cycles	cycle	NOUN
ajlm-1677	113	9	and	and	CCONJ
ajlm-1677	113	10	poor	poor	ADJ
ajlm-1677	113	11	storage	storage	NOUN
ajlm-1677	113	12	due	due	ADP
ajlm-1677	113	13	to	to	ADP
ajlm-1677	113	14	frequent	frequent	ADJ
ajlm-1677	113	15	power	power	NOUN
ajlm-1677	113	16	outage	outage	NOUN
ajlm-1677	113	17	could	could	AUX
ajlm-1677	113	18	have	have	AUX
ajlm-1677	113	19	affected	affect	VERB
ajlm-1677	113	20	the	the	DET
ajlm-1677	113	21	sample	sample	NOUN
ajlm-1677	113	22	integrity	integrity	NOUN
ajlm-1677	113	23	,	,	PUNCT
ajlm-1677	113	24	resulting	result	VERB
ajlm-1677	113	25	in	in	ADP
ajlm-1677	113	26	decreased	decrease	VERB
ajlm-1677	113	27	hbv	hbv	NOUN
ajlm-1677	113	28	dna	dna	PROPN
ajlm-1677	113	29	quantity	quantity	NOUN
ajlm-1677	113	30	.	.	PUNCT
ajlm-1677	114	1	other	other	ADJ
ajlm-1677	114	2	causes	cause	NOUN
ajlm-1677	114	3	include	include	VERB
ajlm-1677	114	4	intrinsic	intrinsic	ADJ
ajlm-1677	114	5	reagent	reagent	ADJ
ajlm-1677	114	6	-	-	PUNCT
ajlm-1677	114	7	related	relate	VERB
ajlm-1677	114	8	issues	issue	NOUN
ajlm-1677	114	9	and	and	CCONJ
ajlm-1677	114	10	impact	impact	NOUN
ajlm-1677	114	11	of	of	ADP
ajlm-1677	114	12	hbv	hbv	NOUN
ajlm-1677	114	13	/	/	SYM
ajlm-1677	114	14	e	e	NOUN
ajlm-1677	114	15	on	on	ADP
ajlm-1677	114	16	the	the	DET
ajlm-1677	114	17	sensitivity	sensitivity	NOUN
ajlm-1677	114	18	of	of	ADP
ajlm-1677	114	19	hbsag	hbsag	ADJ
ajlm-1677	114	20	assays	assay	NOUN
ajlm-1677	114	21	due	due	ADP
ajlm-1677	114	22	to	to	ADP
ajlm-1677	114	23	surface	surface	VERB
ajlm-1677	114	24	antigen	antigen	ADJ
ajlm-1677	114	25	gene	gene	NOUN
ajlm-1677	114	26	mutations	mutation	NOUN
ajlm-1677	114	27	located	locate	VERB
ajlm-1677	114	28	outside	outside	ADP
ajlm-1677	114	29	the	the	DET
ajlm-1677	114	30	sequenced	sequence	VERB
ajlm-1677	114	31	region.46	region.46	NOUN
ajlm-1677	114	32	also	also	ADV
ajlm-1677	114	33	,	,	PUNCT
ajlm-1677	114	34	there	there	PRON
ajlm-1677	114	35	is	be	VERB
ajlm-1677	114	36	a	a	DET
ajlm-1677	114	37	growing	grow	VERB
ajlm-1677	114	38	concern	concern	NOUN
ajlm-1677	114	39	that	that	SCONJ
ajlm-1677	114	40	the	the	DET
ajlm-1677	114	41	accumulation	accumulation	NOUN
ajlm-1677	114	42	of	of	ADP
ajlm-1677	114	43	escape	escape	NOUN
ajlm-1677	114	44	mutations	mutation	NOUN
ajlm-1677	114	45	may	may	AUX
ajlm-1677	114	46	lead	lead	VERB
ajlm-1677	114	47	to	to	ADP
ajlm-1677	114	48	detection	detection	NOUN
ajlm-1677	114	49	failure	failure	NOUN
ajlm-1677	114	50	of	of	ADP
ajlm-1677	114	51	hbsag	hbsag	NOUN
ajlm-1677	114	52	using	use	VERB
ajlm-1677	114	53	the	the	DET
ajlm-1677	114	54	available	available	ADJ
ajlm-1677	114	55	commercial	commercial	ADJ
ajlm-1677	114	56	diagnostic	diagnostic	ADJ
ajlm-1677	114	57	assays	assay	NOUN
ajlm-1677	114	58	.	.	PUNCT
ajlm-1677	115	1	this	this	PRON
ajlm-1677	115	2	in	in	ADP
ajlm-1677	115	3	turn	turn	NOUN
ajlm-1677	115	4	may	may	AUX
ajlm-1677	115	5	lead	lead	VERB
ajlm-1677	115	6	to	to	ADP
ajlm-1677	115	7	a	a	DET
ajlm-1677	115	8	false	false	ADJ
ajlm-1677	115	9	-	-	PUNCT
ajlm-1677	115	10	negative	negative	ADJ
ajlm-1677	115	11	hbv	hbv	NOUN
ajlm-1677	115	12	result	result	NOUN
ajlm-1677	115	13	.	.	PUNCT
ajlm-1677	116	1	moreover	moreover	ADV
ajlm-1677	116	2	,	,	PUNCT
ajlm-1677	116	3	this	this	PRON
ajlm-1677	116	4	has	have	VERB
ajlm-1677	116	5	an	an	DET
ajlm-1677	116	6	impact	impact	NOUN
ajlm-1677	116	7	on	on	ADP
ajlm-1677	116	8	risk	risk	NOUN
ajlm-1677	116	9	of	of	ADP
ajlm-1677	116	10	transmission	transmission	NOUN
ajlm-1677	116	11	,	,	PUNCT
ajlm-1677	116	12	including	include	VERB
ajlm-1677	116	13	rendering	render	VERB
ajlm-1677	116	14	the	the	DET
ajlm-1677	116	15	vaccination	vaccination	NOUN
ajlm-1677	116	16	ineffective	ineffective	ADJ
ajlm-1677	116	17	due	due	ADJ
ajlm-1677	116	18	to	to	ADP
ajlm-1677	116	19	undiagnosed	undiagnosed	ADJ
ajlm-1677	116	20	mutant	mutant	ADJ
ajlm-1677	116	21	carriers	carrier	NOUN
ajlm-1677	116	22	.	.	PUNCT
ajlm-1677	117	1	conclusion	conclusion	NOUN
ajlm-1677	117	2	our	our	PRON
ajlm-1677	117	3	study	study	NOUN
ajlm-1677	117	4	confirmed	confirm	VERB
ajlm-1677	117	5	the	the	DET
ajlm-1677	117	6	dominance	dominance	NOUN
ajlm-1677	117	7	of	of	ADP
ajlm-1677	117	8	genotype	genotype	NOUN
ajlm-1677	117	9	e	e	NOUN
ajlm-1677	117	10	,	,	PUNCT
ajlm-1677	117	11	and	and	CCONJ
ajlm-1677	117	12	it	it	PRON
ajlm-1677	117	13	has	have	VERB
ajlm-1677	117	14	great	great	ADJ
ajlm-1677	117	15	public	public	ADJ
ajlm-1677	117	16	health	health	NOUN
ajlm-1677	117	17	significance	significance	NOUN
ajlm-1677	117	18	,	,	PUNCT
ajlm-1677	117	19	given	give	VERB
ajlm-1677	117	20	that	that	SCONJ
ajlm-1677	117	21	the	the	DET
ajlm-1677	117	22	protective	protective	ADJ
ajlm-1677	117	23	vaccine	vaccine	NOUN
ajlm-1677	117	24	currently	currently	ADV
ajlm-1677	117	25	in	in	ADP
ajlm-1677	117	26	use	use	NOUN
ajlm-1677	117	27	by	by	ADP
ajlm-1677	117	28	the	the	DET
ajlm-1677	117	29	national	national	ADJ
ajlm-1677	117	30	vaccination	vaccination	NOUN
ajlm-1677	117	31	programme	programme	NOUN
ajlm-1677	117	32	is	be	AUX
ajlm-1677	117	33	from	from	ADP
ajlm-1677	117	34	the	the	DET
ajlm-1677	117	35	hbv	hbv	NOUN
ajlm-1677	117	36	-	-	PUNCT
ajlm-1677	117	37	a2	a2	NOUN
ajlm-1677	117	38	strain	strain	NOUN
ajlm-1677	117	39	.	.	PUNCT
ajlm-1677	118	1	additionally	additionally	ADV
ajlm-1677	118	2	,	,	PUNCT
ajlm-1677	118	3	no	no	DET
ajlm-1677	118	4	patients	patient	NOUN
ajlm-1677	118	5	had	have	VERB
ajlm-1677	118	6	hbv	hbv	NOUN
ajlm-1677	118	7	drug	drug	NOUN
ajlm-1677	118	8	resistant	resistant	ADJ
ajlm-1677	118	9	mutations	mutation	NOUN
ajlm-1677	118	10	,	,	PUNCT
ajlm-1677	118	11	suggesting	suggest	VERB
ajlm-1677	118	12	that	that	SCONJ
ajlm-1677	118	13	the	the	DET
ajlm-1677	118	14	use	use	NOUN
ajlm-1677	118	15	of	of	ADP
ajlm-1677	118	16	tenofovir	tenofovir	NOUN
ajlm-1677	118	17	is	be	AUX
ajlm-1677	118	18	an	an	DET
ajlm-1677	118	19	effective	effective	ADJ
ajlm-1677	118	20	treatment	treatment	NOUN
ajlm-1677	118	21	in	in	ADP
ajlm-1677	118	22	the	the	DET
ajlm-1677	118	23	management	management	NOUN
ajlm-1677	118	24	of	of	ADP
ajlm-1677	118	25	hbv	hbv	NOUN
ajlm-1677	118	26	infection	infection	NOUN
ajlm-1677	118	27	in	in	ADP
ajlm-1677	118	28	both	both	CCONJ
ajlm-1677	118	29	chronic	chronic	ADJ
ajlm-1677	118	30	hbv	hbv	NOUN
ajlm-1677	118	31	/	/	SYM
ajlm-1677	118	32	hiv	hiv	PROPN
ajlm-1677	118	33	co	co	VERB
ajlm-1677	118	34	-	-	VERB
ajlm-1677	118	35	infected	infected	ADJ
ajlm-1677	118	36	and	and	CCONJ
ajlm-1677	118	37	hbv	hbv	NOUN
ajlm-1677	118	38	-	-	PUNCT
ajlm-1677	118	39	mono	mono	NOUN
ajlm-1677	118	40	infected	infect	VERB
ajlm-1677	118	41	patients	patient	NOUN
ajlm-1677	118	42	.	.	PUNCT
ajlm-1677	119	1	the	the	DET
ajlm-1677	119	2	study	study	NOUN
ajlm-1677	119	3	also	also	ADV
ajlm-1677	119	4	showed	show	VERB
ajlm-1677	119	5	the	the	DET
ajlm-1677	119	6	presence	presence	NOUN
ajlm-1677	119	7	of	of	ADP
ajlm-1677	119	8	mutation	mutation	NOUN
ajlm-1677	119	9	associated	associate	VERB
ajlm-1677	119	10	with	with	ADP
ajlm-1677	119	11	immune	immune	ADJ
ajlm-1677	119	12	escape	escape	NOUN
ajlm-1677	119	13	mutant	mutant	NOUN
ajlm-1677	119	14	in	in	ADP
ajlm-1677	119	15	chronic	chronic	ADJ
ajlm-1677	119	16	hbv	hbv	NOUN
ajlm-1677	119	17	-	-	PUNCT
ajlm-1677	119	18	infected	infect	VERB
ajlm-1677	119	19	patients	patient	NOUN
ajlm-1677	119	20	on	on	ADP
ajlm-1677	119	21	long	long	ADJ
ajlm-1677	119	22	-	-	PUNCT
ajlm-1677	119	23	term	term	NOUN
ajlm-1677	119	24	antiviral	antiviral	ADJ
ajlm-1677	119	25	therapy	therapy	NOUN
ajlm-1677	119	26	.	.	PUNCT
ajlm-1677	120	1	therefore	therefore	ADV
ajlm-1677	120	2	,	,	PUNCT
ajlm-1677	120	3	further	far	ADV
ajlm-1677	120	4	larger	large	ADJ
ajlm-1677	120	5	study	study	NOUN
ajlm-1677	120	6	is	be	AUX
ajlm-1677	120	7	required	require	VERB
ajlm-1677	120	8	to	to	PART
ajlm-1677	120	9	understand	understand	VERB
ajlm-1677	120	10	the	the	DET
ajlm-1677	120	11	dynamics	dynamic	NOUN
ajlm-1677	120	12	of	of	ADP
ajlm-1677	120	13	immune	immune	ADJ
ajlm-1677	120	14	escape	escape	NOUN
ajlm-1677	120	15	mutant	mutant	NOUN
ajlm-1677	120	16	on	on	ADP
ajlm-1677	120	17	hbv	hbv	NOUN
ajlm-1677	120	18	diagnosis	diagnosis	NOUN
ajlm-1677	120	19	,	,	PUNCT
ajlm-1677	120	20	and	and	CCONJ
ajlm-1677	120	21	impact	impact	NOUN
ajlm-1677	120	22	of	of	ADP
ajlm-1677	120	23	genotypes	genotype	NOUN
ajlm-1677	120	24	on	on	ADP
ajlm-1677	120	25	treatment	treatment	NOUN
ajlm-1677	120	26	outcomes	outcome	NOUN
ajlm-1677	120	27	.	.	PUNCT
ajlm-1677	121	1	acknowledgements	acknowledgement	NOUN
ajlm-1677	121	2	we	we	PRON
ajlm-1677	121	3	thank	thank	VERB
ajlm-1677	121	4	the	the	DET
ajlm-1677	121	5	patients	patient	NOUN
ajlm-1677	121	6	who	who	PRON
ajlm-1677	121	7	participated	participate	VERB
ajlm-1677	121	8	in	in	ADP
ajlm-1677	121	9	this	this	DET
ajlm-1677	121	10	study	study	NOUN
ajlm-1677	121	11	.	.	PUNCT
ajlm-1677	122	1	we	we	PRON
ajlm-1677	122	2	also	also	ADV
ajlm-1677	122	3	thank	thank	VERB
ajlm-1677	122	4	the	the	DET
ajlm-1677	122	5	staff	staff	NOUN
ajlm-1677	122	6	and	and	CCONJ
ajlm-1677	122	7	management	management	NOUN
ajlm-1677	122	8	of	of	ADP
ajlm-1677	122	9	jos	jos	PROPN
ajlm-1677	122	10	university	university	PROPN
ajlm-1677	122	11	teaching	teaching	NOUN
ajlm-1677	122	12	hospital	hospital	NOUN
ajlm-1677	122	13	,	,	PUNCT
ajlm-1677	122	14	faith	faith	NOUN
ajlm-1677	122	15	alive	alive	ADJ
ajlm-1677	122	16	foundation	foundation	NOUN
ajlm-1677	122	17	hospital	hospital	NOUN
ajlm-1677	122	18	,	,	PUNCT
ajlm-1677	122	19	bingham	bingham	PROPN
ajlm-1677	122	20	university	university	PROPN
ajlm-1677	122	21	teaching	teaching	NOUN
ajlm-1677	122	22	hospital	hospital	NOUN
ajlm-1677	122	23	,	,	PUNCT
ajlm-1677	122	24	and	and	CCONJ
ajlm-1677	122	25	plateau	plateau	NOUN
ajlm-1677	122	26	state	state	NOUN
ajlm-1677	122	27	specialist	specialist	NOUN
ajlm-1677	122	28	hospital	hospital	NOUN
ajlm-1677	122	29	for	for	ADP
ajlm-1677	122	30	their	their	PRON
ajlm-1677	122	31	support	support	NOUN
ajlm-1677	122	32	during	during	ADP
ajlm-1677	122	33	patients	patient	NOUN
ajlm-1677	122	34	’	'	PUNCT
ajlm-1677	122	35	enrolment	enrolment	NOUN
ajlm-1677	122	36	and	and	CCONJ
ajlm-1677	122	37	sample	sample	NOUN
ajlm-1677	122	38	collection	collection	NOUN
ajlm-1677	122	39	.	.	PUNCT
ajlm-1677	123	1	finally	finally	ADV
ajlm-1677	123	2	,	,	PUNCT
ajlm-1677	123	3	we	we	PRON
ajlm-1677	123	4	thank	thank	VERB
ajlm-1677	123	5	the	the	PRON
ajlm-1677	123	6	of	of	ADP
ajlm-1677	123	7	the	the	DET
ajlm-1677	123	8	management	management	NOUN
ajlm-1677	123	9	and	and	CCONJ
ajlm-1677	123	10	staff	staff	NOUN
ajlm-1677	123	11	of	of	ADP
ajlm-1677	123	12	center	center	NOUN
ajlm-1677	123	13	for	for	ADP
ajlm-1677	123	14	human	human	ADJ
ajlm-1677	123	15	virology	virology	NOUN
ajlm-1677	123	16	and	and	CCONJ
ajlm-1677	123	17	genomics	genomic	NOUN
ajlm-1677	123	18	,	,	PUNCT
ajlm-1677	123	19	and	and	CCONJ
ajlm-1677	123	20	nigeria	nigeria	PROPN
ajlm-1677	123	21	institute	institute	PROPN
ajlm-1677	123	22	of	of	ADP
ajlm-1677	123	23	medical	medical	ADJ
ajlm-1677	123	24	research	research	NOUN
ajlm-1677	123	25	,	,	PUNCT
ajlm-1677	123	26	lagos	lagos	PROPN
ajlm-1677	123	27	,	,	PUNCT
ajlm-1677	123	28	nigeria	nigeria	PROPN
ajlm-1677	123	29	,	,	PUNCT
ajlm-1677	123	30	for	for	ADP
ajlm-1677	123	31	providing	provide	VERB
ajlm-1677	123	32	the	the	DET
ajlm-1677	123	33	laboratory	laboratory	NOUN
ajlm-1677	123	34	space	space	NOUN
ajlm-1677	123	35	and	and	CCONJ
ajlm-1677	123	36	equipment	equipment	NOUN
ajlm-1677	123	37	during	during	ADP
ajlm-1677	123	38	the	the	DET
ajlm-1677	123	39	analysis	analysis	NOUN
ajlm-1677	123	40	.	.	PUNCT
ajlm-1677	124	1	competing	compete	VERB
ajlm-1677	124	2	interests	interest	NOUN
ajlm-1677	124	3	the	the	DET
ajlm-1677	124	4	authors	author	NOUN
ajlm-1677	124	5	declare	declare	VERB
ajlm-1677	124	6	that	that	SCONJ
ajlm-1677	124	7	they	they	PRON
ajlm-1677	124	8	have	have	VERB
ajlm-1677	124	9	no	no	DET
ajlm-1677	124	10	financial	financial	ADJ
ajlm-1677	124	11	or	or	CCONJ
ajlm-1677	124	12	personal	personal	ADJ
ajlm-1677	124	13	relationships	relationship	NOUN
ajlm-1677	124	14	that	that	PRON
ajlm-1677	124	15	may	may	AUX
ajlm-1677	124	16	have	have	AUX
ajlm-1677	124	17	inappropriately	inappropriately	ADV
ajlm-1677	124	18	influenced	influence	VERB
ajlm-1677	124	19	them	they	PRON
ajlm-1677	124	20	in	in	ADP
ajlm-1677	124	21	writing	write	VERB
ajlm-1677	124	22	this	this	DET
ajlm-1677	124	23	article	article	NOUN
ajlm-1677	124	24	.	.	PUNCT
ajlm-1677	125	1	authors	author	NOUN
ajlm-1677	125	2	’	'	PUNCT
ajlm-1677	125	3	contributions	contribution	VERB
ajlm-1677	125	4	j.a.-o	j.a.-o	NOUN
ajlm-1677	125	5	.	.	PUNCT
ajlm-1677	125	6	,	,	PUNCT
ajlm-1677	125	7	e.o	e.o	PROPN
ajlm-1677	125	8	.	.	PROPN
ajlm-1677	125	9	and	and	CCONJ
ajlm-1677	125	10	c.h	c.h	PROPN
ajlm-1677	125	11	.	.	PROPN
ajlm-1677	125	12	were	be	AUX
ajlm-1677	125	13	involved	involve	VERB
ajlm-1677	125	14	in	in	ADP
ajlm-1677	125	15	conceptualisation	conceptualisation	NOUN
ajlm-1677	125	16	,	,	PUNCT
ajlm-1677	125	17	methodology	methodology	NOUN
ajlm-1677	125	18	,	,	PUNCT
ajlm-1677	125	19	funding	funding	NOUN
ajlm-1677	125	20	acquisition	acquisition	NOUN
ajlm-1677	125	21	,	,	PUNCT
ajlm-1677	125	22	project	project	NOUN
ajlm-1677	125	23	administration	administration	NOUN
ajlm-1677	125	24	,	,	PUNCT
ajlm-1677	125	25	investigation	investigation	NOUN
ajlm-1677	125	26	,	,	PUNCT
ajlm-1677	125	27	writing	write	VERB
ajlm-1677	125	28	original	original	ADJ
ajlm-1677	125	29	draft	draft	NOUN
ajlm-1677	125	30	preparation	preparation	NOUN
ajlm-1677	125	31	and	and	CCONJ
ajlm-1677	125	32	supervision	supervision	NOUN
ajlm-1677	125	33	.	.	PUNCT
ajlm-1677	126	1	a.s.s	a.s.s	NOUN
ajlm-1677	126	2	.	.	PUNCT
ajlm-1677	127	1	and	and	CCONJ
ajlm-1677	127	2	o.a	o.a	PROPN
ajlm-1677	127	3	.	.	PROPN
ajlm-1677	127	4	assisted	assist	VERB
ajlm-1677	127	5	with	with	ADP
ajlm-1677	127	6	funding	funding	NOUN
ajlm-1677	127	7	acquisition	acquisition	NOUN
ajlm-1677	127	8	,	,	PUNCT
ajlm-1677	127	9	supervision	supervision	NOUN
ajlm-1677	127	10	,	,	PUNCT
ajlm-1677	127	11	project	project	NOUN
ajlm-1677	127	12	administration	administration	NOUN
ajlm-1677	127	13	,	,	PUNCT
ajlm-1677	127	14	resources	resource	NOUN
ajlm-1677	127	15	,	,	PUNCT
ajlm-1677	127	16	writing	writing	NOUN
ajlm-1677	127	17	,	,	PUNCT
ajlm-1677	127	18	reviewing	review	VERB
ajlm-1677	127	19	and	and	CCONJ
ajlm-1677	127	20	editing	editing	NOUN
ajlm-1677	127	21	.	.	PUNCT
ajlm-1677	128	1	h.o	h.o	INTJ
ajlm-1677	128	2	.	.	PROPN
ajlm-1677	128	3	and	and	CCONJ
ajlm-1677	128	4	c.o	c.o	PROPN
ajlm-1677	128	5	.	.	PROPN
ajlm-1677	128	6	performed	perform	VERB
ajlm-1677	128	7	data	datum	NOUN
ajlm-1677	128	8	curation	curation	NOUN
ajlm-1677	128	9	,	,	PUNCT
ajlm-1677	128	10	assisted	assist	VERB
ajlm-1677	128	11	with	with	ADP
ajlm-1677	128	12	software	software	NOUN
ajlm-1677	128	13	and	and	CCONJ
ajlm-1677	128	14	contributed	contribute	VERB
ajlm-1677	128	15	to	to	ADP
ajlm-1677	128	16	the	the	DET
ajlm-1677	128	17	formal	formal	ADJ
ajlm-1677	128	18	analysis	analysis	NOUN
ajlm-1677	128	19	,	,	PUNCT
ajlm-1677	128	20	validation	validation	NOUN
ajlm-1677	128	21	,	,	PUNCT
ajlm-1677	128	22	preparation	preparation	NOUN
ajlm-1677	128	23	of	of	ADP
ajlm-1677	128	24	the	the	DET
ajlm-1677	128	25	original	original	ADJ
ajlm-1677	128	26	draft	draft	NOUN
ajlm-1677	128	27	and	and	CCONJ
ajlm-1677	128	28	validation	validation	NOUN
ajlm-1677	128	29	.	.	PUNCT
ajlm-1677	129	1	p.m.d	p.m.d	PROPN
ajlm-1677	129	2	.	.	PROPN
ajlm-1677	129	3	,	,	PUNCT
ajlm-1677	129	4	p.o	p.o	PROPN
ajlm-1677	129	5	.	.	PROPN
ajlm-1677	129	6	and	and	CCONJ
ajlm-1677	129	7	m.d	m.d	PROPN
ajlm-1677	129	8	.	.	PROPN
ajlm-1677	129	9	were	be	AUX
ajlm-1677	129	10	responsible	responsible	ADJ
ajlm-1677	129	11	for	for	ADP
ajlm-1677	129	12	investigation	investigation	NOUN
ajlm-1677	129	13	,	,	PUNCT
ajlm-1677	129	14	project	project	NOUN
ajlm-1677	129	15	administration	administration	NOUN
ajlm-1677	129	16	,	,	PUNCT
ajlm-1677	129	17	resources	resource	NOUN
ajlm-1677	129	18	,	,	PUNCT
ajlm-1677	129	19	writing	writing	NOUN
ajlm-1677	129	20	,	,	PUNCT
ajlm-1677	129	21	reviewing	review	VERB
ajlm-1677	129	22	and	and	CCONJ
ajlm-1677	129	23	editing	editing	NOUN
ajlm-1677	129	24	.	.	PUNCT
ajlm-1677	130	1	all	all	DET
ajlm-1677	130	2	authors	author	NOUN
ajlm-1677	130	3	discussed	discuss	VERB
ajlm-1677	130	4	the	the	DET
ajlm-1677	130	5	results	result	NOUN
ajlm-1677	130	6	,	,	PUNCT
ajlm-1677	130	7	contributed	contribute	VERB
ajlm-1677	130	8	to	to	ADP
ajlm-1677	130	9	and	and	CCONJ
ajlm-1677	130	10	approved	approve	VERB
ajlm-1677	130	11	the	the	DET
ajlm-1677	130	12	final	final	ADJ
ajlm-1677	130	13	manuscript	manuscript	NOUN
ajlm-1677	130	14	.	.	PUNCT
ajlm-1677	131	1	sources	source	NOUN
ajlm-1677	131	2	of	of	ADP
ajlm-1677	131	3	support	support	NOUN
ajlm-1677	131	4	research	research	NOUN
ajlm-1677	131	5	reported	report	VERB
ajlm-1677	131	6	in	in	ADP
ajlm-1677	131	7	this	this	DET
ajlm-1677	131	8	publication	publication	NOUN
ajlm-1677	131	9	was	be	AUX
ajlm-1677	131	10	partly	partly	ADV
ajlm-1677	131	11	supported	support	VERB
ajlm-1677	131	12	by	by	ADP
ajlm-1677	131	13	the	the	DET
ajlm-1677	131	14	fogarty	fogarty	PROPN
ajlm-1677	131	15	international	international	PROPN
ajlm-1677	131	16	center	center	PROPN
ajlm-1677	131	17	and	and	CCONJ
ajlm-1677	131	18	national	national	PROPN
ajlm-1677	131	19	institute	institute	PROPN
ajlm-1677	131	20	of	of	ADP
ajlm-1677	131	21	mental	mental	ADJ
ajlm-1677	131	22	health	health	NOUN
ajlm-1677	131	23	,	,	PUNCT
ajlm-1677	131	24	of	of	ADP
ajlm-1677	131	25	the	the	DET
ajlm-1677	131	26	united	united	PROPN
ajlm-1677	131	27	states	states	PROPN
ajlm-1677	131	28	national	national	PROPN
ajlm-1677	131	29	institutes	institutes	PROPN
ajlm-1677	131	30	of	of	ADP
ajlm-1677	131	31	health	health	PROPN
ajlm-1677	131	32	under	under	ADP
ajlm-1677	131	33	award	award	NOUN
ajlm-1677	131	34	number	number	NOUN
ajlm-1677	131	35	d43	d43	PROPN
ajlm-1677	131	36	tw010543	tw010543	PROPN
ajlm-1677	131	37	.	.	PUNCT
ajlm-1677	132	1	data	datum	NOUN
ajlm-1677	132	2	availability	availability	NOUN
ajlm-1677	132	3	the	the	DET
ajlm-1677	132	4	data	data	NOUN
ajlm-1677	132	5	sets	set	NOUN
ajlm-1677	132	6	generated	generate	VERB
ajlm-1677	132	7	with	with	ADP
ajlm-1677	132	8	unique	unique	ADJ
ajlm-1677	132	9	identifiers	identifier	NOUN
ajlm-1677	132	10	and	and	CCONJ
ajlm-1677	132	11	analysed	analyse	VERB
ajlm-1677	132	12	during	during	ADP
ajlm-1677	132	13	the	the	DET
ajlm-1677	132	14	study	study	NOUN
ajlm-1677	132	15	are	be	AUX
ajlm-1677	132	16	available	available	ADJ
ajlm-1677	132	17	on	on	ADP
ajlm-1677	132	18	request	request	NOUN
ajlm-1677	132	19	from	from	ADP
ajlm-1677	132	20	the	the	DET
ajlm-1677	132	21	corresponding	corresponding	ADJ
ajlm-1677	132	22	author	author	NOUN
ajlm-1677	132	23	,	,	PUNCT
ajlm-1677	132	24	j.a.-o	j.a.-o	NOUN
ajlm-1677	132	25	.	.	PUNCT
ajlm-1677	132	26	,	,	PUNCT
ajlm-1677	132	27	but	but	CCONJ
ajlm-1677	132	28	are	be	AUX
ajlm-1677	132	29	not	not	PART
ajlm-1677	132	30	publicly	publicly	ADV
ajlm-1677	132	31	available	available	ADJ
ajlm-1677	132	32	.	.	PUNCT
ajlm-1677	133	1	disclaimer	disclaimer	VERB
ajlm-1677	133	2	the	the	DET
ajlm-1677	133	3	content	content	NOUN
ajlm-1677	133	4	is	be	AUX
ajlm-1677	133	5	solely	solely	ADV
ajlm-1677	133	6	the	the	DET
ajlm-1677	133	7	responsibility	responsibility	NOUN
ajlm-1677	133	8	of	of	ADP
ajlm-1677	133	9	the	the	DET
ajlm-1677	133	10	authors	author	NOUN
ajlm-1677	133	11	and	and	CCONJ
ajlm-1677	133	12	does	do	AUX
ajlm-1677	133	13	not	not	PART
ajlm-1677	133	14	necessarily	necessarily	ADV
ajlm-1677	133	15	represent	represent	VERB
ajlm-1677	133	16	the	the	DET
ajlm-1677	133	17	official	official	ADJ
ajlm-1677	133	18	views	view	NOUN
ajlm-1677	133	19	of	of	ADP
ajlm-1677	133	20	the	the	DET
ajlm-1677	133	21	national	national	PROPN
ajlm-1677	133	22	institutes	institutes	PROPN
ajlm-1677	133	23	of	of	ADP
ajlm-1677	133	24	health	health	NOUN
ajlm-1677	133	25	.	.	PUNCT
ajlm-1677	134	1	references	reference	NOUN
ajlm-1677	134	2	stanaway	stanaway	VERB
ajlm-1677	134	3	jd	jd	PROPN
ajlm-1677	134	4	,	,	PUNCT
ajlm-1677	134	5	flaxman	flaxman	NOUN
ajlm-1677	134	6	ad	ad	NOUN
ajlm-1677	134	7	,	,	PUNCT
ajlm-1677	134	8	naghavi	naghavi	NOUN
ajlm-1677	134	9	m	m	PROPN
ajlm-1677	134	10	,	,	PUNCT
ajlm-1677	134	11	et	et	PROPN
ajlm-1677	134	12	al	al	PROPN
ajlm-1677	134	13	.	.	PUNCT
ajlm-1677	135	1	the	the	DET
ajlm-1677	135	2	global	global	ADJ
ajlm-1677	135	3	burden	burden	NOUN
ajlm-1677	135	4	of	of	ADP
ajlm-1677	135	5	viral	viral	ADJ
ajlm-1677	135	6	hepatitis	hepatitis	NOUN
ajlm-1677	135	7	from	from	ADP
ajlm-1677	135	8	1990	1990	NUM
ajlm-1677	135	9	to	to	ADP
ajlm-1677	135	10	2013	2013	NUM
ajlm-1677	135	11	:	:	PUNCT
ajlm-1677	135	12	findings	finding	NOUN
ajlm-1677	135	13	from	from	ADP
ajlm-1677	135	14	the	the	DET
ajlm-1677	135	15	global	global	ADJ
ajlm-1677	135	16	burden	burden	NOUN
ajlm-1677	135	17	of	of	ADP
ajlm-1677	135	18	disease	disease	NOUN
ajlm-1677	135	19	study	study	NOUN
ajlm-1677	135	20	2013	2013	NUM
ajlm-1677	135	21	.	.	PUNCT
ajlm-1677	136	1	lancet	lancet	NOUN
ajlm-1677	136	2	.	.	PUNCT
ajlm-1677	137	1	2016;388(10049):1081–1088	2016;388(10049):1081–1088	NOUN
ajlm-1677	137	2	.	.	PUNCT
ajlm-1677	138	1	https://doi.org/10.1016/s0140-6736(16)30579-7	https://doi.org/10.1016/s0140-6736(16)30579-7	PROPN
ajlm-1677	138	2	who	who	PRON
ajlm-1677	138	3	.	.	PUNCT
ajlm-1677	139	1	hepatitis	hepatitis	PROPN
ajlm-1677	139	2	b	b	PROPN
ajlm-1677	140	1	fact	fact	NOUN
ajlm-1677	140	2	sheet	sheet	NOUN
ajlm-1677	140	3	.	.	PUNCT
ajlm-1677	141	1	geneva	geneva	PROPN
ajlm-1677	141	2	:	:	PUNCT
ajlm-1677	141	3	world	world	PROPN
ajlm-1677	141	4	health	health	PROPN
ajlm-1677	141	5	organization	organization	NOUN
ajlm-1677	141	6	(	(	PUNCT
ajlm-1677	141	7	editor	editor	NOUN
ajlm-1677	141	8	)	)	PUNCT
ajlm-1677	141	9	;	;	PUNCT
ajlm-1677	141	10	2017	2017	NUM
ajlm-1677	141	11	.	.	PUNCT
ajlm-1677	142	1	hou	hou	PROPN
ajlm-1677	142	2	j	j	PROPN
ajlm-1677	142	3	,	,	PUNCT
ajlm-1677	142	4	liu	liu	PROPN
ajlm-1677	142	5	z	z	PROPN
ajlm-1677	142	6	,	,	PUNCT
ajlm-1677	142	7	gu	gu	PROPN
ajlm-1677	142	8	f.	f.	PROPN
ajlm-1677	142	9	epidemiology	epidemiology	PROPN
ajlm-1677	142	10	and	and	CCONJ
ajlm-1677	142	11	prevention	prevention	NOUN
ajlm-1677	142	12	of	of	ADP
ajlm-1677	142	13	hepatitis	hepatitis	PROPN
ajlm-1677	142	14	b	b	PROPN
ajlm-1677	142	15	virus	virus	NOUN
ajlm-1677	142	16	infection	infection	NOUN
ajlm-1677	142	17	.	.	PUNCT
ajlm-1677	143	1	int	int	PROPN
ajlm-1677	143	2	j	j	PROPN
ajlm-1677	143	3	med	med	PROPN
ajlm-1677	143	4	sci	sci	PROPN
ajlm-1677	143	5	.	.	PUNCT
ajlm-1677	144	1	2005;2(1):50–57	2005;2(1):50–57	NUM
ajlm-1677	144	2	.	.	PUNCT
ajlm-1677	145	1	https://doi.org/10.7150/ijms.2.50	https://doi.org/10.7150/ijms.2.50	PROPN
ajlm-1677	145	2	kramvis	kramvis	PROPN
ajlm-1677	145	3	a	a	PRON
ajlm-1677	145	4	,	,	PUNCT
ajlm-1677	146	1	kew	kew	PROPN
ajlm-1677	146	2	mc	mc	PROPN
ajlm-1677	146	3	.	.	PROPN
ajlm-1677	146	4	epidemiology	epidemiology	NOUN
ajlm-1677	146	5	of	of	ADP
ajlm-1677	146	6	hepatitis	hepatitis	PROPN
ajlm-1677	146	7	b	b	PROPN
ajlm-1677	146	8	virus	virus	NOUN
ajlm-1677	146	9	in	in	ADP
ajlm-1677	146	10	africa	africa	PROPN
ajlm-1677	146	11	,	,	PUNCT
ajlm-1677	146	12	its	its	PRON
ajlm-1677	146	13	genotypes	genotype	NOUN
ajlm-1677	146	14	and	and	CCONJ
ajlm-1677	146	15	clinical	clinical	ADJ
ajlm-1677	146	16	associations	association	NOUN
ajlm-1677	146	17	of	of	ADP
ajlm-1677	146	18	genotypes	genotype	NOUN
ajlm-1677	146	19	.	.	PUNCT
ajlm-1677	147	1	hepatol	hepatol	ADJ
ajlm-1677	147	2	res	re	NOUN
ajlm-1677	147	3	.	.	PUNCT
ajlm-1677	148	1	2007;37(s1):s9	2007;37(s1):s9	NUM
ajlm-1677	148	2	–	–	PUNCT
ajlm-1677	148	3	s19	s19	NOUN
ajlm-1677	148	4	.	.	PUNCT
ajlm-1677	148	5	https://doi.org/10.1111/j.1872-034x.2007.00098.x	https://doi.org/10.1111/j.1872-034x.2007.00098.x	PROPN
ajlm-1677	148	6	schweitzer	schweitzer	PROPN
ajlm-1677	148	7	a	a	PROPN
ajlm-1677	148	8	,	,	PUNCT
ajlm-1677	148	9	horn	horn	PROPN
ajlm-1677	148	10	j	j	PROPN
ajlm-1677	148	11	,	,	PUNCT
ajlm-1677	148	12	mikolajczyk	mikolajczyk	ADJ
ajlm-1677	148	13	rt	rt	PROPN
ajlm-1677	148	14	,	,	PUNCT
ajlm-1677	148	15	krause	krause	PROPN
ajlm-1677	148	16	g	g	PROPN
ajlm-1677	148	17	,	,	PUNCT
ajlm-1677	148	18	ott	ott	PROPN
ajlm-1677	148	19	jj	jj	PROPN
ajlm-1677	148	20	.	.	PROPN
ajlm-1677	149	1	estimations	estimation	NOUN
ajlm-1677	149	2	of	of	ADP
ajlm-1677	149	3	worldwide	worldwide	ADJ
ajlm-1677	149	4	prevalence	prevalence	NOUN
ajlm-1677	149	5	of	of	ADP
ajlm-1677	149	6	chronic	chronic	ADJ
ajlm-1677	149	7	hepatitis	hepatitis	PROPN
ajlm-1677	149	8	b	b	PROPN
ajlm-1677	149	9	virus	virus	NOUN
ajlm-1677	149	10	infection	infection	NOUN
ajlm-1677	149	11	:	:	PUNCT
ajlm-1677	149	12	a	a	DET
ajlm-1677	149	13	systematic	systematic	ADJ
ajlm-1677	149	14	review	review	NOUN
ajlm-1677	149	15	of	of	ADP
ajlm-1677	149	16	data	datum	NOUN
ajlm-1677	149	17	published	publish	VERB
ajlm-1677	149	18	between	between	ADP
ajlm-1677	149	19	1965	1965	NUM
ajlm-1677	149	20	and	and	CCONJ
ajlm-1677	149	21	2013	2013	NUM
ajlm-1677	149	22	.	.	PUNCT
ajlm-1677	150	1	lancet	lancet	NOUN
ajlm-1677	150	2	.	.	PUNCT
ajlm-1677	151	1	2015;386(10003):1546–1555	2015;386(10003):1546–1555	NUM
ajlm-1677	151	2	.	.	PUNCT
ajlm-1677	152	1	https://doi.org/10.1016/s0140-6736(15)61412-x	https://doi.org/10.1016/s0140-6736(15)61412-x	PROPN
ajlm-1677	152	2	kim	kim	PROPN
ajlm-1677	152	3	bk	bk	PROPN
ajlm-1677	152	4	,	,	PUNCT
ajlm-1677	152	5	han	han	PROPN
ajlm-1677	152	6	kh	kh	PROPN
ajlm-1677	152	7	,	,	PUNCT
ajlm-1677	152	8	ahn	ahn	PROPN
ajlm-1677	152	9	sh	sh	PROPN
ajlm-1677	152	10	.	.	PROPN
ajlm-1677	152	11	prevention	prevention	NOUN
ajlm-1677	152	12	of	of	ADP
ajlm-1677	152	13	hepatocellular	hepatocellular	ADJ
ajlm-1677	152	14	carcinoma	carcinoma	NOUN
ajlm-1677	152	15	in	in	ADP
ajlm-1677	152	16	patients	patient	NOUN
ajlm-1677	152	17	with	with	ADP
ajlm-1677	152	18	chronic	chronic	ADJ
ajlm-1677	152	19	hepatitis	hepatitis	PROPN
ajlm-1677	152	20	b	b	PROPN
ajlm-1677	152	21	virus	virus	NOUN
ajlm-1677	152	22	infection	infection	NOUN
ajlm-1677	152	23	.	.	PUNCT
ajlm-1677	153	1	oncology	oncology	NOUN
ajlm-1677	153	2	.	.	PUNCT
ajlm-1677	154	1	2011;81(suppl	2011;81(suppl	PROPN
ajlm-1677	154	2	.	.	PUNCT
ajlm-1677	155	1	1):41–49	1):41–49	NUM
ajlm-1677	155	2	.	.	PUNCT
ajlm-1677	156	1	https://doi.org/10.1159/000333258	https://doi.org/10.1159/000333258	PROPN
ajlm-1677	156	2	olayinka	olayinka	PROPN
ajlm-1677	156	3	ta	ta	PROPN
ajlm-1677	156	4	,	,	PUNCT
ajlm-1677	156	5	oyemakinde	oyemakinde	ADP
ajlm-1677	156	6	a	a	PRON
ajlm-1677	156	7	,	,	PUNCT
ajlm-1677	156	8	balogun	balogun	VERB
ajlm-1677	156	9	sm	sm	PROPN
ajlm-1677	156	10	,	,	PUNCT
ajlm-1677	156	11	et	et	PROPN
ajlm-1677	156	12	al	al	PROPN
ajlm-1677	156	13	.	.	PROPN
ajlm-1677	157	1	seroprevalence	seroprevalence	NOUN
ajlm-1677	157	2	of	of	ADP
ajlm-1677	157	3	hepatitis	hepatitis	PROPN
ajlm-1677	157	4	b	b	PROPN
ajlm-1677	157	5	infection	infection	NOUN
ajlm-1677	157	6	in	in	ADP
ajlm-1677	157	7	nigeria	nigeria	PROPN
ajlm-1677	157	8	:	:	PUNCT
ajlm-1677	157	9	a	a	DET
ajlm-1677	157	10	national	national	ADJ
ajlm-1677	157	11	survey	survey	NOUN
ajlm-1677	157	12	.	.	PUNCT
ajlm-1677	158	1	am	be	AUX
ajlm-1677	158	2	j	j	PROPN
ajlm-1677	158	3	trop	trop	X
ajlm-1677	158	4	med	med	PROPN
ajlm-1677	158	5	hyg	hyg	PROPN
ajlm-1677	158	6	.	.	PUNCT
ajlm-1677	159	1	2016;95(4):902–907	2016;95(4):902–907	NUM
ajlm-1677	159	2	.	.	PUNCT
ajlm-1677	160	1	https://doi.org/10.4269/ajtmh.15-0874	https://doi.org/10.4269/ajtmh.15-0874	PROPN
ajlm-1677	160	2	akindigh	akindigh	PROPN
ajlm-1677	160	3	mt	mt	PROPN
ajlm-1677	160	4	,	,	PUNCT
ajlm-1677	160	5	abba	abba	PROPN
ajlm-1677	160	6	oj	oj	PROPN
ajlm-1677	160	7	,	,	PUNCT
ajlm-1677	160	8	robert	robert	PROPN
ajlm-1677	160	9	oc	oc	PROPN
ajlm-1677	160	10	,	,	PUNCT
ajlm-1677	160	11	okojokwu	okojokwu	PROPN
ajlm-1677	160	12	jo	jo	PROPN
ajlm-1677	160	13	,	,	PUNCT
ajlm-1677	160	14	okechalu	okechalu	PROPN
ajlm-1677	160	15	nj	nj	PROPN
ajlm-1677	160	16	,	,	PUNCT
ajlm-1677	160	17	anejo	anejo	PROPN
ajlm-1677	160	18	-	-	PUNCT
ajlm-1677	160	19	okopi	okopi	NOUN
ajlm-1677	160	20	aj	aj	PROPN
ajlm-1677	160	21	.	.	PROPN
ajlm-1677	160	22	seroprevalence	seroprevalence	NOUN
ajlm-1677	160	23	of	of	ADP
ajlm-1677	160	24	hepatitis	hepatitis	PROPN
ajlm-1677	160	25	b	b	PROPN
ajlm-1677	160	26	virus	virus	PROPN
ajlm-1677	160	27	co	co	NOUN
ajlm-1677	160	28	-	-	NOUN
ajlm-1677	160	29	infection	infection	NOUN
ajlm-1677	160	30	among	among	ADP
ajlm-1677	160	31	hiv-1	hiv-1	ADJ
ajlm-1677	160	32	-	-	ADJ
ajlm-1677	160	33	positive	positive	ADJ
ajlm-1677	160	34	patients	patient	NOUN
ajlm-1677	160	35	in	in	ADP
ajlm-1677	160	36	north	north	NOUN
ajlm-1677	160	37	-	-	PUNCT
ajlm-1677	160	38	central	central	NOUN
ajlm-1677	160	39	nigeria	nigeria	PROPN
ajlm-1677	160	40	:	:	PUNCT
ajlm-1677	160	41	the	the	DET
ajlm-1677	160	42	urgent	urgent	ADJ
ajlm-1677	160	43	need	need	NOUN
ajlm-1677	160	44	for	for	ADP
ajlm-1677	160	45	surveillance	surveillance	NOUN
ajlm-1677	160	46	.	.	PUNCT
ajlm-1677	161	1	afr	afr	PROPN
ajlm-1677	161	2	j	j	PROPN
ajlm-1677	161	3	lab	lab	PROPN
ajlm-1677	161	4	med	med	PROPN
ajlm-1677	161	5	.	.	PUNCT
ajlm-1677	162	1	2019;8(1):622	2019;8(1):622	X
ajlm-1677	162	2	.	.	PUNCT
ajlm-1677	162	3	https://doi.org/10.4102/ajlm.v8i1.622	https://doi.org/10.4102/ajlm.v8i1.622	PROPN
ajlm-1677	162	4	musa	musa	PROPN
ajlm-1677	162	5	b	b	PROPN
ajlm-1677	162	6	,	,	PUNCT
ajlm-1677	162	7	bussell	bussell	PROPN
ajlm-1677	162	8	s	s	NOUN
ajlm-1677	162	9	,	,	PUNCT
ajlm-1677	162	10	borodo	borodo	PROPN
ajlm-1677	162	11	mm	mm	PROPN
ajlm-1677	162	12	,	,	PUNCT
ajlm-1677	162	13	samaila	samaila	PROPN
ajlm-1677	162	14	aa	aa	PROPN
ajlm-1677	162	15	,	,	PUNCT
ajlm-1677	162	16	femi	femi	PROPN
ajlm-1677	162	17	ol	ol	PROPN
ajlm-1677	162	18	.	.	PUNCT
ajlm-1677	163	1	prevalence	prevalence	NOUN
ajlm-1677	163	2	of	of	ADP
ajlm-1677	163	3	hepatitis	hepatitis	PROPN
ajlm-1677	163	4	b	b	PROPN
ajlm-1677	163	5	virus	virus	NOUN
ajlm-1677	163	6	infection	infection	NOUN
ajlm-1677	163	7	in	in	ADP
ajlm-1677	163	8	nigeria	nigeria	PROPN
ajlm-1677	163	9	,	,	PUNCT
ajlm-1677	163	10	2000	2000	NUM
ajlm-1677	163	11	-	-	SYM
ajlm-1677	163	12	2013	2013	NUM
ajlm-1677	163	13	:	:	PUNCT
ajlm-1677	163	14	a	a	DET
ajlm-1677	163	15	systematic	systematic	ADJ
ajlm-1677	163	16	review	review	NOUN
ajlm-1677	163	17	and	and	CCONJ
ajlm-1677	163	18	meta	meta	ADJ
ajlm-1677	163	19	-	-	PUNCT
ajlm-1677	163	20	analysis	analysis	NOUN
ajlm-1677	163	21	.	.	PUNCT
ajlm-1677	164	1	niger	niger	PROPN
ajlm-1677	164	2	j	j	PROPN
ajlm-1677	164	3	clin	clin	PROPN
ajlm-1677	164	4	pract	pract	PROPN
ajlm-1677	164	5	.	.	PUNCT
ajlm-1677	165	1	2015;18(2):163–172	2015;18(2):163–172	X
ajlm-1677	165	2	.	.	PUNCT
ajlm-1677	166	1	https://doi.org/10.4103/1119-3077.151035	https://doi.org/10.4103/1119-3077.151035	PROPN
ajlm-1677	166	2	croagh	croagh	PROPN
ajlm-1677	166	3	cm	cm	PROPN
ajlm-1677	166	4	,	,	PUNCT
ajlm-1677	166	5	desmond	desmond	PROPN
ajlm-1677	166	6	pv	pv	PROPN
ajlm-1677	166	7	,	,	PUNCT
ajlm-1677	166	8	bell	bell	PROPN
ajlm-1677	166	9	sj	sj	PROPN
ajlm-1677	166	10	.	.	PUNCT
ajlm-1677	166	11	genotypes	genotype	NOUN
ajlm-1677	166	12	and	and	CCONJ
ajlm-1677	166	13	viral	viral	ADJ
ajlm-1677	166	14	variants	variant	NOUN
ajlm-1677	166	15	in	in	ADP
ajlm-1677	166	16	chronic	chronic	ADJ
ajlm-1677	166	17	hepatitis	hepatitis	PROPN
ajlm-1677	166	18	b	b	PROPN
ajlm-1677	166	19	:	:	PUNCT
ajlm-1677	166	20	a	a	DET
ajlm-1677	166	21	review	review	NOUN
ajlm-1677	166	22	of	of	ADP
ajlm-1677	166	23	epidemiology	epidemiology	NOUN
ajlm-1677	166	24	and	and	CCONJ
ajlm-1677	166	25	clinical	clinical	ADJ
ajlm-1677	166	26	relevance	relevance	NOUN
ajlm-1677	166	27	.	.	PUNCT
ajlm-1677	167	1	world	world	NOUN
ajlm-1677	167	2	j	j	PROPN
ajlm-1677	167	3	hepatol	hepatol	ADV
ajlm-1677	167	4	.	.	PUNCT
ajlm-1677	168	1	2015;7(3):289–303	2015;7(3):289–303	X
ajlm-1677	168	2	.	.	PUNCT
ajlm-1677	169	1	https://doi.org/10.4254/wjh.v7.i3.289	https://doi.org/10.4254/wjh.v7.i3.289	PROPN
ajlm-1677	169	2	yu	yu	PROPN
ajlm-1677	169	3	h	h	PROPN
ajlm-1677	169	4	,	,	PUNCT
ajlm-1677	169	5	yuan	yuan	PROPN
ajlm-1677	169	6	q	q	PROPN
ajlm-1677	169	7	,	,	PUNCT
ajlm-1677	169	8	ge	ge	PROPN
ajlm-1677	169	9	sx	sx	PROPN
ajlm-1677	169	10	,	,	PUNCT
ajlm-1677	169	11	et	et	PROPN
ajlm-1677	169	12	al	al	PROPN
ajlm-1677	169	13	.	.	PROPN
ajlm-1677	170	1	molecular	molecular	ADJ
ajlm-1677	170	2	and	and	CCONJ
ajlm-1677	170	3	phylogenetic	phylogenetic	ADJ
ajlm-1677	170	4	analyses	analysis	NOUN
ajlm-1677	170	5	suggest	suggest	VERB
ajlm-1677	170	6	an	an	DET
ajlm-1677	170	7	additional	additional	ADJ
ajlm-1677	170	8	hepatitis	hepatitis	PROPN
ajlm-1677	170	9	b	b	PROPN
ajlm-1677	170	10	virus	virus	NOUN
ajlm-1677	170	11	genotype	genotype	NOUN
ajlm-1677	170	12	‘	'	PUNCT
ajlm-1677	170	13	i	i	PRON
ajlm-1677	170	14	’	'	PUNCT
ajlm-1677	170	15	.	.	PUNCT
ajlm-1677	171	1	plos	plos	PROPN
ajlm-1677	171	2	one	one	NUM
ajlm-1677	171	3	.	.	PUNCT
ajlm-1677	172	1	2010;5(2):e9297	2010;5(2):e9297	NOUN
ajlm-1677	172	2	.	.	PUNCT
ajlm-1677	173	1	https://doi.org/10.1371/journal.pone.0009297	https://doi.org/10.1371/journal.pone.0009297	PRON
ajlm-1677	173	2	tatematsu	tatematsu	NOUN
ajlm-1677	173	3	k	k	PROPN
ajlm-1677	173	4	,	,	PUNCT
ajlm-1677	173	5	tanaka	tanaka	PROPN
ajlm-1677	173	6	y	y	PROPN
ajlm-1677	173	7	,	,	PUNCT
ajlm-1677	173	8	kurbanov	kurbanov	PROPN
ajlm-1677	173	9	f	f	PROPN
ajlm-1677	173	10	,	,	PUNCT
ajlm-1677	173	11	et	et	PROPN
ajlm-1677	173	12	al	al	PROPN
ajlm-1677	173	13	.	.	PUNCT
ajlm-1677	174	1	a	a	DET
ajlm-1677	174	2	genetic	genetic	ADJ
ajlm-1677	174	3	variant	variant	NOUN
ajlm-1677	174	4	of	of	ADP
ajlm-1677	174	5	hepatitis	hepatitis	PROPN
ajlm-1677	174	6	b	b	PROPN
ajlm-1677	174	7	virus	virus	NOUN
ajlm-1677	174	8	divergent	divergent	ADJ
ajlm-1677	174	9	from	from	ADP
ajlm-1677	174	10	known	know	VERB
ajlm-1677	174	11	human	human	ADJ
ajlm-1677	174	12	and	and	CCONJ
ajlm-1677	174	13	ape	ape	NOUN
ajlm-1677	174	14	genotypes	genotype	NOUN
ajlm-1677	174	15	isolated	isolate	VERB
ajlm-1677	174	16	from	from	ADP
ajlm-1677	174	17	a	a	DET
ajlm-1677	174	18	japanese	japanese	ADJ
ajlm-1677	174	19	patient	patient	NOUN
ajlm-1677	174	20	and	and	CCONJ
ajlm-1677	174	21	provisionally	provisionally	ADV
ajlm-1677	174	22	assigned	assign	VERB
ajlm-1677	174	23	to	to	ADP
ajlm-1677	174	24	new	new	ADJ
ajlm-1677	174	25	genotype	genotype	NOUN
ajlm-1677	174	26	j.	j.	PROPN
ajlm-1677	174	27	j	j	PROPN
ajlm-1677	174	28	virol	virol	PROPN
ajlm-1677	174	29	.	.	PUNCT
ajlm-1677	175	1	2009;83(20):10538–10547	2009;83(20):10538–10547	X
ajlm-1677	175	2	.	.	PUNCT
ajlm-1677	176	1	https://doi.org/10.1128/jvi.00462-09	https://doi.org/10.1128/jvi.00462-09	PRON
ajlm-1677	176	2	yousif	yousif	PROPN
ajlm-1677	176	3	m	m	PROPN
ajlm-1677	176	4	,	,	PUNCT
ajlm-1677	176	5	mudawi	mudawi	PROPN
ajlm-1677	176	6	h	h	NOUN
ajlm-1677	176	7	,	,	PUNCT
ajlm-1677	176	8	bakhiet	bakhiet	PROPN
ajlm-1677	176	9	s	s	PROPN
ajlm-1677	176	10	,	,	PUNCT
ajlm-1677	176	11	glebe	glebe	NOUN
ajlm-1677	176	12	d	d	NOUN
ajlm-1677	176	13	,	,	PUNCT
ajlm-1677	176	14	kramvis	kramvis	ADJ
ajlm-1677	176	15	a.	a.	PROPN
ajlm-1677	176	16	molecular	molecular	ADJ
ajlm-1677	176	17	characterization	characterization	NOUN
ajlm-1677	176	18	of	of	ADP
ajlm-1677	176	19	hepatitis	hepatitis	PROPN
ajlm-1677	176	20	b	b	PROPN
ajlm-1677	176	21	virus	virus	NOUN
ajlm-1677	176	22	in	in	ADP
ajlm-1677	176	23	liver	liver	NOUN
ajlm-1677	176	24	disease	disease	NOUN
ajlm-1677	176	25	patients	patient	NOUN
ajlm-1677	176	26	and	and	CCONJ
ajlm-1677	176	27	asymptomatic	asymptomatic	ADJ
ajlm-1677	176	28	carriers	carrier	NOUN
ajlm-1677	176	29	of	of	ADP
ajlm-1677	176	30	the	the	DET
ajlm-1677	176	31	virus	virus	NOUN
ajlm-1677	176	32	in	in	ADP
ajlm-1677	176	33	sudan	sudan	PROPN
ajlm-1677	176	34	.	.	PUNCT
ajlm-1677	177	1	bmc	bmc	PROPN
ajlm-1677	177	2	infect	infect	PROPN
ajlm-1677	177	3	dis	dis	PROPN
ajlm-1677	177	4	.	.	PUNCT
ajlm-1677	178	1	2013;13:328	2013;13:328	X
ajlm-1677	178	2	.	.	PUNCT
ajlm-1677	179	1	https://doi.org/10.1186/1471-2334-13-328	https://doi.org/10.1186/1471-2334-13-328	PROPN
ajlm-1677	179	2	forbi	forbi	PROPN
ajlm-1677	179	3	jc	jc	PROPN
ajlm-1677	179	4	,	,	PUNCT
ajlm-1677	179	5	ben	ben	PROPN
ajlm-1677	179	6	-	-	PUNCT
ajlm-1677	179	7	ayed	aye	VERB
ajlm-1677	179	8	y	y	PROPN
ajlm-1677	179	9	,	,	PUNCT
ajlm-1677	179	10	xia	xia	PROPN
ajlm-1677	179	11	gl	gl	PROPN
ajlm-1677	179	12	,	,	PUNCT
ajlm-1677	179	13	et	et	PROPN
ajlm-1677	179	14	al	al	PROPN
ajlm-1677	179	15	.	.	PUNCT
ajlm-1677	180	1	disparate	disparate	ADJ
ajlm-1677	180	2	distribution	distribution	NOUN
ajlm-1677	180	3	of	of	ADP
ajlm-1677	180	4	hepatitis	hepatitis	PROPN
ajlm-1677	180	5	b	b	PROPN
ajlm-1677	180	6	virus	virus	NOUN
ajlm-1677	180	7	genotypes	genotype	NOUN
ajlm-1677	180	8	in	in	ADP
ajlm-1677	180	9	four	four	NUM
ajlm-1677	180	10	sub	sub	ADJ
ajlm-1677	180	11	-	-	ADJ
ajlm-1677	180	12	saharan	saharan	ADJ
ajlm-1677	180	13	african	african	ADJ
ajlm-1677	180	14	countries	country	NOUN
ajlm-1677	180	15	.	.	PUNCT
ajlm-1677	181	1	j	j	PROPN
ajlm-1677	181	2	clin	clin	PROPN
ajlm-1677	181	3	virol	virol	PROPN
ajlm-1677	181	4	.	.	PUNCT
ajlm-1677	182	1	2013;58(1):59–66	2013;58(1):59–66	X
ajlm-1677	182	2	.	.	PUNCT
ajlm-1677	183	1	https://doi.org/10.1016/j.jcv.2013.06.028	https://doi.org/10.1016/j.jcv.2013.06.028	PROPN
ajlm-1677	183	2	ayodele	ayodele	PROPN
ajlm-1677	183	3	mbo	mbo	PROPN
ajlm-1677	183	4	,	,	PUNCT
ajlm-1677	183	5	ogugbue	ogugbue	PROPN
ajlm-1677	183	6	cj	cj	PROPN
ajlm-1677	183	7	,	,	PUNCT
ajlm-1677	183	8	frank	frank	ADJ
ajlm-1677	183	9	-	-	PUNCT
ajlm-1677	183	10	peterside	peterside	NOUN
ajlm-1677	183	11	n	n	CCONJ
ajlm-1677	183	12	,	,	PUNCT
ajlm-1677	183	13	tatfeng	tatfeng	PROPN
ajlm-1677	183	14	ym	ym	PROPN
ajlm-1677	183	15	.	.	PUNCT
ajlm-1677	184	1	prevalent	prevalent	PROPN
ajlm-1677	184	2	hepatitis	hepatitis	PROPN
ajlm-1677	184	3	b	b	PROPN
ajlm-1677	184	4	virus	virus	NOUN
ajlm-1677	184	5	genotypes	genotype	NOUN
ajlm-1677	184	6	circulating	circulate	VERB
ajlm-1677	184	7	among	among	ADP
ajlm-1677	184	8	hiv	hiv	PROPN
ajlm-1677	184	9	co	co	VERB
ajlm-1677	184	10	-	-	ADJ
ajlm-1677	184	11	infected	infected	ADJ
ajlm-1677	184	12	patients	patient	NOUN
ajlm-1677	184	13	in	in	ADP
ajlm-1677	184	14	an	an	DET
ajlm-1677	184	15	urban	urban	ADJ
ajlm-1677	184	16	city	city	NOUN
ajlm-1677	184	17	,	,	PUNCT
ajlm-1677	184	18	south	south	ADJ
ajlm-1677	184	19	-	-	PUNCT
ajlm-1677	184	20	south	south	NOUN
ajlm-1677	184	21	nigeria	nigeria	PROPN
ajlm-1677	184	22	.	.	PUNCT
ajlm-1677	185	1	j	j	PROPN
ajlm-1677	185	2	aids	aids	PROPN
ajlm-1677	185	3	clin	clin	PROPN
ajlm-1677	185	4	res	re	NOUN
ajlm-1677	185	5	.	.	PUNCT
ajlm-1677	186	1	2019;10:5	2019;10:5	X
ajlm-1677	186	2	.	.	PUNCT
ajlm-1677	187	1	faleye	faleye	NOUN
ajlm-1677	187	2	cot	cot	NOUN
ajlm-1677	187	3	,	,	PUNCT
ajlm-1677	187	4	adewumi	adewumi	PROPN
ajlm-1677	187	5	om	om	PROPN
ajlm-1677	187	6	,	,	PUNCT
ajlm-1677	187	7	ifeorah	ifeorah	PROPN
ajlm-1677	187	8	mi	mi	PROPN
ajlm-1677	187	9	,	,	PUNCT
ajlm-1677	187	10	et	et	PROPN
ajlm-1677	187	11	al	al	PROPN
ajlm-1677	187	12	.	.	PUNCT
ajlm-1677	188	1	detection	detection	NOUN
ajlm-1677	188	2	of	of	ADP
ajlm-1677	188	3	hepatitis	hepatitis	PROPN
ajlm-1677	188	4	b	b	PROPN
ajlm-1677	188	5	virus	virus	NOUN
ajlm-1677	188	6	isolates	isolate	VERB
ajlm-1677	188	7	with	with	ADP
ajlm-1677	188	8	mutations	mutation	NOUN
ajlm-1677	188	9	associated	associate	VERB
ajlm-1677	188	10	with	with	ADP
ajlm-1677	188	11	immune	immune	ADJ
ajlm-1677	188	12	escape	escape	NOUN
ajlm-1677	188	13	mutants	mutant	NOUN
ajlm-1677	188	14	among	among	ADP
ajlm-1677	188	15	pregnant	pregnant	ADJ
ajlm-1677	188	16	women	woman	NOUN
ajlm-1677	188	17	in	in	ADP
ajlm-1677	188	18	ibadan	ibadan	PROPN
ajlm-1677	188	19	,	,	PUNCT
ajlm-1677	188	20	southwestern	southwestern	PROPN
ajlm-1677	188	21	nigeria	nigeria	PROPN
ajlm-1677	188	22	.	.	PUNCT
ajlm-1677	189	1	springerplus	springerplus	PROPN
ajlm-1677	189	2	.	.	PUNCT
ajlm-1677	189	3	2015;4:43	2015;4:43	PROPN
ajlm-1677	189	4	.	.	PUNCT
ajlm-1677	189	5	https://doi.org/10.1186/s40064-015-0813-1	https://doi.org/10.1186/s40064-015-0813-1	X
ajlm-1677	190	1	ahmad	ahmad	PROPN
ajlm-1677	190	2	ae	ae	PROPN
ajlm-1677	190	3	,	,	PUNCT
ajlm-1677	190	4	bakari	bakari	PROPN
ajlm-1677	190	5	ag	ag	PROPN
ajlm-1677	190	6	,	,	PUNCT
ajlm-1677	190	7	olayinka	olayinka	NOUN
ajlm-1677	190	8	at	at	ADP
ajlm-1677	190	9	.	.	PUNCT
ajlm-1677	190	10	pattern	pattern	NOUN
ajlm-1677	190	11	of	of	ADP
ajlm-1677	190	12	prevalent	prevalent	ADJ
ajlm-1677	190	13	hepatitis	hepatitis	PROPN
ajlm-1677	190	14	b	b	PROPN
ajlm-1677	190	15	virus	virus	NOUN
ajlm-1677	190	16	genotypes	genotype	NOUN
ajlm-1677	190	17	in	in	ADP
ajlm-1677	190	18	zaria	zaria	PROPN
ajlm-1677	190	19	,	,	PUNCT
ajlm-1677	190	20	nigeria	nigeria	PROPN
ajlm-1677	190	21	.	.	PUNCT
ajlm-1677	191	1	niger	niger	PROPN
ajlm-1677	191	2	postgrad	postgrad	NOUN
ajlm-1677	191	3	med	me	VERB
ajlm-1677	191	4	.	.	PUNCT
ajlm-1677	192	1	2019;26(2):80–86	2019;26(2):80–86	NUM
ajlm-1677	192	2	.	.	PUNCT
ajlm-1677	193	1	https://doi.org/10.4103/npmj.npmj_59_19	https://doi.org/10.4103/npmj.npmj_59_19	PROPN
ajlm-1677	193	2	assih	assih	PROPN
ajlm-1677	193	3	m	m	PROPN
ajlm-1677	193	4	,	,	PUNCT
ajlm-1677	193	5	ouattara	ouattara	PROPN
ajlm-1677	193	6	ka	ka	PROPN
ajlm-1677	193	7	,	,	PUNCT
ajlm-1677	193	8	diarra	diarra	PROPN
ajlm-1677	193	9	b	b	PROPN
ajlm-1677	193	10	,	,	PUNCT
ajlm-1677	193	11	et	et	PROPN
ajlm-1677	193	12	al	al	PROPN
ajlm-1677	193	13	.	.	PUNCT
ajlm-1677	194	1	genetic	genetic	ADJ
ajlm-1677	194	2	diversity	diversity	NOUN
ajlm-1677	194	3	of	of	ADP
ajlm-1677	194	4	hepatitis	hepatitis	NOUN
ajlm-1677	194	5	viruses	virus	NOUN
ajlm-1677	194	6	in	in	ADP
ajlm-1677	194	7	west	west	ADJ
ajlm-1677	194	8	-	-	PUNCT
ajlm-1677	194	9	african	african	ADJ
ajlm-1677	194	10	countries	country	NOUN
ajlm-1677	194	11	from	from	ADP
ajlm-1677	194	12	1996	1996	NUM
ajlm-1677	194	13	to	to	ADP
ajlm-1677	194	14	2018	2018	NUM
ajlm-1677	194	15	.	.	PUNCT
ajlm-1677	195	1	world	world	PROPN
ajlm-1677	195	2	j	j	PROPN
ajlm-1677	195	3	hepatol	hepatol	ADV
ajlm-1677	195	4	.	.	PUNCT
ajlm-1677	196	1	2018;10(11):807–821	2018;10(11):807–821	X
ajlm-1677	196	2	.	.	PUNCT
ajlm-1677	197	1	https://doi.org/10.4254/wjh.v10.i11.807	https://doi.org/10.4254/wjh.v10.i11.807	PROPN
ajlm-1677	197	2	de	de	X
ajlm-1677	197	3	clercq	clercq	PROPN
ajlm-1677	197	4	e	e	NOUN
ajlm-1677	197	5	,	,	PUNCT
ajlm-1677	197	6	ferir	ferir	NOUN
ajlm-1677	197	7	g	g	NOUN
ajlm-1677	197	8	,	,	PUNCT
ajlm-1677	197	9	kaptein	kaptein	PROPN
ajlm-1677	197	10	s	s	PART
ajlm-1677	197	11	,	,	PUNCT
ajlm-1677	197	12	neyts	neyts	PROPN
ajlm-1677	197	13	j.	j.	PROPN
ajlm-1677	197	14	antiviral	antiviral	PROPN
ajlm-1677	197	15	treatment	treatment	NOUN
ajlm-1677	197	16	of	of	ADP
ajlm-1677	197	17	chronic	chronic	ADJ
ajlm-1677	197	18	hepatitis	hepatitis	PROPN
ajlm-1677	197	19	b	b	PROPN
ajlm-1677	197	20	virus	virus	NOUN
ajlm-1677	197	21	(	(	PUNCT
ajlm-1677	197	22	hbv	hbv	NOUN
ajlm-1677	197	23	)	)	PUNCT
ajlm-1677	197	24	infections	infection	NOUN
ajlm-1677	197	25	.	.	PUNCT
ajlm-1677	198	1	viruses	virus	NOUN
ajlm-1677	198	2	.	.	PUNCT
ajlm-1677	199	1	2010;2(6):1279–1305	2010;2(6):1279–1305	X
ajlm-1677	199	2	.	.	PUNCT
ajlm-1677	200	1	https://doi.org/10.3390/v2061279	https://doi.org/10.3390/v2061279	PROPN
ajlm-1677	200	2	mokaya	mokaya	PROPN
ajlm-1677	200	3	j	j	PROPN
ajlm-1677	200	4	,	,	PUNCT
ajlm-1677	200	5	mcnaughton	mcnaughton	PROPN
ajlm-1677	200	6	al	al	PROPN
ajlm-1677	200	7	,	,	PUNCT
ajlm-1677	200	8	hadley	hadley	PROPN
ajlm-1677	200	9	mj	mj	PROPN
ajlm-1677	200	10	,	,	PUNCT
ajlm-1677	200	11	et	et	PROPN
ajlm-1677	200	12	al	al	PROPN
ajlm-1677	200	13	.	.	PUNCT
ajlm-1677	201	1	a	a	DET
ajlm-1677	201	2	systematic	systematic	ADJ
ajlm-1677	201	3	review	review	NOUN
ajlm-1677	201	4	of	of	ADP
ajlm-1677	201	5	hepatitis	hepatitis	PROPN
ajlm-1677	201	6	b	b	PROPN
ajlm-1677	201	7	virus	virus	NOUN
ajlm-1677	201	8	(	(	PUNCT
ajlm-1677	201	9	hbv	hbv	NOUN
ajlm-1677	201	10	)	)	PUNCT
ajlm-1677	201	11	drug	drug	NOUN
ajlm-1677	201	12	and	and	CCONJ
ajlm-1677	201	13	vaccine	vaccine	NOUN
ajlm-1677	201	14	escape	escape	VERB
ajlm-1677	201	15	mutations	mutation	NOUN
ajlm-1677	201	16	in	in	ADP
ajlm-1677	201	17	africa	africa	PROPN
ajlm-1677	201	18	:	:	PUNCT
ajlm-1677	201	19	a	a	DET
ajlm-1677	201	20	call	call	NOUN
ajlm-1677	201	21	for	for	ADP
ajlm-1677	201	22	urgent	urgent	ADJ
ajlm-1677	201	23	action	action	NOUN
ajlm-1677	201	24	.	.	PUNCT
ajlm-1677	202	1	plos	plos	PROPN
ajlm-1677	202	2	negl	negl	PROPN
ajlm-1677	202	3	trop	trop	X
ajlm-1677	202	4	dis	dis	PROPN
ajlm-1677	202	5	.	.	PUNCT
ajlm-1677	203	1	2018;12(8):e0006629	2018;12(8):e0006629	NUM
ajlm-1677	203	2	.	.	PUNCT
ajlm-1677	204	1	https://doi.org/10.1371/journal.pntd.0006629	https://doi.org/10.1371/journal.pntd.0006629	PROPN
ajlm-1677	204	2	locarnini	locarnini	PROPN
ajlm-1677	204	3	s	s	PROPN
ajlm-1677	204	4	,	,	PUNCT
ajlm-1677	204	5	mason	mason	PROPN
ajlm-1677	204	6	ws	ws	PROPN
ajlm-1677	204	7	.	.	PUNCT
ajlm-1677	205	1	cellular	cellular	ADJ
ajlm-1677	205	2	and	and	CCONJ
ajlm-1677	205	3	virological	virological	ADJ
ajlm-1677	205	4	mechanisms	mechanism	NOUN
ajlm-1677	205	5	of	of	ADP
ajlm-1677	205	6	hbv	hbv	NOUN
ajlm-1677	205	7	drug	drug	NOUN
ajlm-1677	205	8	resistance	resistance	NOUN
ajlm-1677	205	9	.	.	PUNCT
ajlm-1677	206	1	j	j	PROPN
ajlm-1677	206	2	hepatol	hepatol	ADJ
ajlm-1677	206	3	.	.	PUNCT
ajlm-1677	207	1	2006;44(2):422–431	2006;44(2):422–431	X
ajlm-1677	207	2	.	.	PUNCT
ajlm-1677	208	1	https://doi.org/10.1016/j.jhep.2005.11.036	https://doi.org/10.1016/j.jhep.2005.11.036	NOUN
ajlm-1677	208	2	sayan	sayan	PROPN
ajlm-1677	208	3	m	m	PROPN
ajlm-1677	208	4	,	,	PUNCT
ajlm-1677	208	5	akhan	akhan	PROPN
ajlm-1677	208	6	sc	sc	PROPN
ajlm-1677	208	7	,	,	PUNCT
ajlm-1677	208	8	meric	meric	PROPN
ajlm-1677	208	9	m.	m.	PROPN
ajlm-1677	208	10	naturally	naturally	ADV
ajlm-1677	208	11	occurring	occur	VERB
ajlm-1677	208	12	amino	amino	NOUN
ajlm-1677	208	13	-	-	PUNCT
ajlm-1677	208	14	acid	acid	NOUN
ajlm-1677	208	15	substitutions	substitution	NOUN
ajlm-1677	208	16	to	to	ADP
ajlm-1677	208	17	nucleos(t)ide	nucleos(t)ide	VERB
ajlm-1677	208	18	analogues	analogue	NOUN
ajlm-1677	208	19	in	in	ADP
ajlm-1677	208	20	treatment	treatment	NOUN
ajlm-1677	208	21	naïve	naïve	ADJ
ajlm-1677	208	22	turkish	turkish	ADJ
ajlm-1677	208	23	patients	patient	NOUN
ajlm-1677	208	24	with	with	ADP
ajlm-1677	208	25	chronic	chronic	ADJ
ajlm-1677	208	26	hepatitis	hepatitis	PROPN
ajlm-1677	208	27	b.	b.	PROPN
ajlm-1677	208	28	j	j	PROPN
ajlm-1677	208	29	viral	viral	ADJ
ajlm-1677	208	30	hepat	hepat	NOUN
ajlm-1677	208	31	.	.	PUNCT
ajlm-1677	209	1	2010;17(1):23–27	2010;17(1):23–27	X
ajlm-1677	209	2	.	.	PUNCT
ajlm-1677	210	1	https://doi.org/10.1111/j.1365-2893.2009.01149.x	https://doi.org/10.1111/j.1365-2893.2009.01149.x	PROPN
ajlm-1677	210	2	chook	chook	PROPN
ajlm-1677	210	3	jb	jb	PROPN
ajlm-1677	210	4	,	,	PUNCT
ajlm-1677	210	5	teo	teo	PROPN
ajlm-1677	210	6	lw	lw	PROPN
ajlm-1677	210	7	,	,	PUNCT
ajlm-1677	210	8	ngeow	ngeow	PROPN
ajlm-1677	210	9	fy	fy	PROPN
ajlm-1677	210	10	,	,	PUNCT
ajlm-1677	210	11	et	et	PROPN
ajlm-1677	210	12	al	al	PROPN
ajlm-1677	210	13	.	.	PUNCT
ajlm-1677	211	1	universal	universal	ADJ
ajlm-1677	211	2	primers	primer	NOUN
ajlm-1677	211	3	for	for	ADP
ajlm-1677	211	4	detection	detection	NOUN
ajlm-1677	211	5	and	and	CCONJ
ajlm-1677	211	6	sequencing	sequencing	NOUN
ajlm-1677	211	7	of	of	ADP
ajlm-1677	211	8	hepatitis	hepatitis	PROPN
ajlm-1677	211	9	b	b	PROPN
ajlm-1677	211	10	virus	virus	NOUN
ajlm-1677	211	11	genomes	genome	VERB
ajlm-1677	211	12	across	across	ADP
ajlm-1677	211	13	genotypes	genotype	NOUN
ajlm-1677	211	14	a	a	PRON
ajlm-1677	211	15	to	to	ADP
ajlm-1677	211	16	g.	g.	PROPN
ajlm-1677	211	17	j	j	PROPN
ajlm-1677	211	18	clin	clin	PROPN
ajlm-1677	211	19	microbiol	microbiol	PROPN
ajlm-1677	211	20	.	.	PUNCT
ajlm-1677	212	1	2015;53(6):1831–1835	2015;53(6):1831–1835	PROPN
ajlm-1677	212	2	.	.	PUNCT
ajlm-1677	213	1	https://doi.org/10.1128/jcm.03449-14	https://doi.org/10.1128/jcm.03449-14	PROPN
ajlm-1677	213	2	kumar	kumar	PROPN
ajlm-1677	213	3	s	s	PROPN
ajlm-1677	213	4	,	,	PUNCT
ajlm-1677	213	5	stecher	stecher	NOUN
ajlm-1677	213	6	g	g	PROPN
ajlm-1677	213	7	,	,	PUNCT
ajlm-1677	213	8	li	li	PROPN
ajlm-1677	213	9	m	m	PROPN
ajlm-1677	213	10	,	,	PUNCT
ajlm-1677	213	11	knyaz	knyaz	VERB
ajlm-1677	213	12	c	c	PROPN
ajlm-1677	213	13	,	,	PUNCT
ajlm-1677	213	14	tamura	tamura	PROPN
ajlm-1677	213	15	k.	k.	PROPN
ajlm-1677	213	16	mega	mega	PROPN
ajlm-1677	214	1	x	x	X
ajlm-1677	214	2	:	:	PUNCT
ajlm-1677	214	3	molecular	molecular	ADJ
ajlm-1677	214	4	evolutionary	evolutionary	ADJ
ajlm-1677	214	5	genetics	genetic	NOUN
ajlm-1677	214	6	analysis	analysis	NOUN
ajlm-1677	214	7	across	across	ADP
ajlm-1677	214	8	computing	computing	NOUN
ajlm-1677	214	9	platforms	platform	NOUN
ajlm-1677	214	10	.	.	PUNCT
ajlm-1677	215	1	mol	mol	ADP
ajlm-1677	215	2	biol	biol	PROPN
ajlm-1677	215	3	evol	evol	NOUN
ajlm-1677	215	4	.	.	PUNCT
ajlm-1677	216	1	2018;35(6):1547–1549	2018;35(6):1547–1549	NUM
ajlm-1677	216	2	.	.	PUNCT
ajlm-1677	216	3	https://doi.org/10.1093/molbev/msy096	https://doi.org/10.1093/molbev/msy096	PROPN
ajlm-1677	216	4	edgar	edgar	PROPN
ajlm-1677	216	5	rc	rc	PROPN
ajlm-1677	216	6	.	.	PROPN
ajlm-1677	216	7	muscle	muscle	PROPN
ajlm-1677	216	8	:	:	PUNCT
ajlm-1677	216	9	a	a	DET
ajlm-1677	216	10	multiple	multiple	ADJ
ajlm-1677	216	11	sequence	sequence	NOUN
ajlm-1677	216	12	alignment	alignment	NOUN
ajlm-1677	216	13	method	method	NOUN
ajlm-1677	216	14	with	with	ADP
ajlm-1677	216	15	reduced	reduce	VERB
ajlm-1677	216	16	time	time	NOUN
ajlm-1677	216	17	and	and	CCONJ
ajlm-1677	216	18	space	space	NOUN
ajlm-1677	216	19	complexity	complexity	NOUN
ajlm-1677	216	20	.	.	PUNCT
ajlm-1677	217	1	bmc	bmc	ADJ
ajlm-1677	217	2	bioinformatics	bioinformatic	NOUN
ajlm-1677	217	3	.	.	PUNCT
ajlm-1677	218	1	2004;5:113	2004;5:113	PROPN
ajlm-1677	218	2	.	.	PUNCT
ajlm-1677	219	1	hall	hall	PROPN
ajlm-1677	219	2	ta	ta	PROPN
ajlm-1677	219	3	.	.	PUNCT
ajlm-1677	220	1	bioedit	bioedit	NOUN
ajlm-1677	220	2	:	:	PUNCT
ajlm-1677	220	3	a	a	DET
ajlm-1677	220	4	user	user	NOUN
ajlm-1677	220	5	-	-	PUNCT
ajlm-1677	220	6	friendly	friendly	ADJ
ajlm-1677	220	7	biological	biological	ADJ
ajlm-1677	220	8	sequence	sequence	NOUN
ajlm-1677	220	9	alignment	alignment	NOUN
ajlm-1677	220	10	editor	editor	NOUN
ajlm-1677	220	11	and	and	CCONJ
ajlm-1677	220	12	analysis	analysis	NOUN
ajlm-1677	220	13	program	program	NOUN
ajlm-1677	220	14	for	for	ADP
ajlm-1677	220	15	windows	window	NOUN
ajlm-1677	220	16	95/98	95/98	NUM
ajlm-1677	220	17	/	/	SYM
ajlm-1677	220	18	nt	nt	NOUN
ajlm-1677	220	19	.	.	PUNCT
ajlm-1677	221	1	nucleic	nucleic	ADJ
ajlm-1677	221	2	acids	acid	NOUN
ajlm-1677	221	3	symp	symp	NOUN
ajlm-1677	221	4	.	.	PUNCT
ajlm-1677	222	1	1999;41:95–98	1999;41:95–98	NUM
ajlm-1677	222	2	.	.	PUNCT
ajlm-1677	223	1	neumann	neumann	PROPN
ajlm-1677	223	2	-	-	PUNCT
ajlm-1677	223	3	fraune	fraune	PROPN
ajlm-1677	223	4	m	m	NOUN
ajlm-1677	223	5	,	,	PUNCT
ajlm-1677	223	6	beggel	beggel	NOUN
ajlm-1677	223	7	b	b	NOUN
ajlm-1677	223	8	,	,	PUNCT
ajlm-1677	223	9	kaiser	kaiser	PROPN
ajlm-1677	223	10	r	r	PROPN
ajlm-1677	223	11	,	,	PUNCT
ajlm-1677	223	12	obermeier	obermeier	NOUN
ajlm-1677	223	13	m.	m.	NOUN
ajlm-1677	223	14	hepatitis	hepatitis	PROPN
ajlm-1677	223	15	b	b	PROPN
ajlm-1677	223	16	virus	virus	PROPN
ajlm-1677	223	17	drug	drug	NOUN
ajlm-1677	223	18	resistance	resistance	NOUN
ajlm-1677	223	19	tools	tool	NOUN
ajlm-1677	223	20	:	:	PUNCT
ajlm-1677	223	21	one	one	NUM
ajlm-1677	223	22	sequence	sequence	NOUN
ajlm-1677	223	23	,	,	PUNCT
ajlm-1677	223	24	two	two	NUM
ajlm-1677	223	25	predictions	prediction	NOUN
ajlm-1677	223	26	.	.	PUNCT
ajlm-1677	224	1	intervirology	intervirology	NOUN
ajlm-1677	224	2	.	.	PUNCT
ajlm-1677	225	1	2014;57(3–4):232–236	2014;57(3–4):232–236	NUM
ajlm-1677	225	2	.	.	PUNCT
ajlm-1677	226	1	https://doi.org/10.1159/000361076	https://doi.org/10.1159/000361076	PROPN
ajlm-1677	226	2	grant	grant	PROPN
ajlm-1677	226	3	j	j	PROPN
ajlm-1677	226	4	,	,	PUNCT
ajlm-1677	226	5	agbaji	agbaji	PROPN
ajlm-1677	226	6	o	o	NOUN
ajlm-1677	226	7	,	,	PUNCT
ajlm-1677	226	8	hawkins	hawkins	PROPN
ajlm-1677	226	9	c	c	PROPN
ajlm-1677	226	10	,	,	PUNCT
ajlm-1677	226	11	et	et	PROPN
ajlm-1677	226	12	al	al	PROPN
ajlm-1677	226	13	.	.	PUNCT
ajlm-1677	227	1	hepatitis	hepatitis	PROPN
ajlm-1677	227	2	b	b	PROPN
ajlm-1677	227	3	virus	virus	NOUN
ajlm-1677	227	4	sequencing	sequence	VERB
ajlm-1677	227	5	and	and	CCONJ
ajlm-1677	227	6	liver	liver	NOUN
ajlm-1677	227	7	fibrosis	fibrosis	NOUN
ajlm-1677	227	8	evaluation	evaluation	NOUN
ajlm-1677	227	9	in	in	ADP
ajlm-1677	227	10	hiv	hiv	PROPN
ajlm-1677	227	11	/	/	SYM
ajlm-1677	227	12	hbv	hbv	PROPN
ajlm-1677	227	13	co	co	VERB
ajlm-1677	227	14	-	-	ADJ
ajlm-1677	227	15	infected	infected	ADJ
ajlm-1677	227	16	nigerians	nigerians	PROPN
ajlm-1677	227	17	.	.	PUNCT
ajlm-1677	228	1	trop	trop	PROPN
ajlm-1677	228	2	med	med	PROPN
ajlm-1677	228	3	int	int	PROPN
ajlm-1677	228	4	health	health	NOUN
ajlm-1677	228	5	.	.	PUNCT
ajlm-1677	229	1	2017;22(6):744–754	2017;22(6):744–754	NUM
ajlm-1677	229	2	.	.	PUNCT
ajlm-1677	230	1	https://doi.org/10.1111/tmi.12873	https://doi.org/10.1111/tmi.12873	PROPN
ajlm-1677	230	2	mulders	mulders	PROPN
ajlm-1677	230	3	mn	mn	PROPN
ajlm-1677	230	4	,	,	PUNCT
ajlm-1677	230	5	venard	venard	NOUN
ajlm-1677	230	6	v	v	NOUN
ajlm-1677	230	7	,	,	PUNCT
ajlm-1677	230	8	njayou	njayou	PROPN
ajlm-1677	230	9	me	i	PRON
ajlm-1677	230	10	,	,	PUNCT
ajlm-1677	230	11	et	et	PROPN
ajlm-1677	230	12	al	al	PROPN
ajlm-1677	230	13	.	.	PROPN
ajlm-1677	230	14	low	low	ADJ
ajlm-1677	230	15	genetic	genetic	ADJ
ajlm-1677	230	16	diversity	diversity	NOUN
ajlm-1677	230	17	despite	despite	SCONJ
ajlm-1677	230	18	hyperendemicity	hyperendemicity	NOUN
ajlm-1677	230	19	of	of	ADP
ajlm-1677	230	20	hepatitis	hepatitis	PROPN
ajlm-1677	230	21	b	b	PROPN
ajlm-1677	230	22	virus	virus	NOUN
ajlm-1677	230	23	genotype	genotype	NOUN
ajlm-1677	230	24	e	e	NOUN
ajlm-1677	230	25	throughout	throughout	ADP
ajlm-1677	230	26	west	west	PROPN
ajlm-1677	230	27	africa	africa	PROPN
ajlm-1677	230	28	.	.	PUNCT
ajlm-1677	231	1	j	j	PROPN
ajlm-1677	231	2	infect	infect	VERB
ajlm-1677	231	3	dis	dis	PROPN
ajlm-1677	231	4	.	.	PUNCT
ajlm-1677	232	1	2004;190(2):400–408	2004;190(2):400–408	NUM
ajlm-1677	232	2	.	.	PUNCT
ajlm-1677	232	3	https://doi.org/10.1086/421502	https://doi.org/10.1086/421502	PROPN
ajlm-1677	233	1	fujiwara	fujiwara	PROPN
ajlm-1677	233	2	k	k	PROPN
ajlm-1677	233	3	,	,	PUNCT
ajlm-1677	233	4	tanaka	tanaka	PROPN
ajlm-1677	233	5	y	y	PROPN
ajlm-1677	233	6	,	,	PUNCT
ajlm-1677	233	7	orito	orito	ADJ
ajlm-1677	233	8	e	e	NOUN
ajlm-1677	233	9	,	,	PUNCT
ajlm-1677	233	10	et	et	PROPN
ajlm-1677	233	11	al	al	PROPN
ajlm-1677	233	12	.	.	PUNCT
ajlm-1677	234	1	distribution	distribution	NOUN
ajlm-1677	234	2	of	of	ADP
ajlm-1677	234	3	hbv	hbv	NOUN
ajlm-1677	234	4	genotypes	genotype	NOUN
ajlm-1677	234	5	among	among	ADP
ajlm-1677	234	6	hbv	hbv	NOUN
ajlm-1677	234	7	carriers	carrier	NOUN
ajlm-1677	234	8	in	in	ADP
ajlm-1677	234	9	benin	benin	PROPN
ajlm-1677	234	10	:	:	PUNCT
ajlm-1677	234	11	phylogenetic	phylogenetic	ADJ
ajlm-1677	234	12	analysis	analysis	NOUN
ajlm-1677	234	13	and	and	CCONJ
ajlm-1677	234	14	virological	virological	ADJ
ajlm-1677	234	15	characteristics	characteristic	NOUN
ajlm-1677	234	16	of	of	ADP
ajlm-1677	234	17	hbv	hbv	NOUN
ajlm-1677	234	18	genotype	genotype	PROPN
ajlm-1677	234	19	e.	e.	PROPN
ajlm-1677	234	20	world	world	PROPN
ajlm-1677	234	21	j	j	PROPN
ajlm-1677	234	22	gastroenterol	gastroenterol	PROPN
ajlm-1677	234	23	.	.	PUNCT
ajlm-1677	235	1	2005;11(41):6410–6415	2005;11(41):6410–6415	X
ajlm-1677	235	2	.	.	PUNCT
ajlm-1677	236	1	https://doi.org/10.3748/wjg.v11.i41.6410	https://doi.org/10.3748/wjg.v11.i41.6410	PROPN
ajlm-1677	236	2	dongdem	dongdem	PROPN
ajlm-1677	236	3	za	za	PROPN
ajlm-1677	236	4	,	,	PUNCT
ajlm-1677	236	5	dzodzomenyo	dzodzomenyo	PROPN
ajlm-1677	236	6	m	m	PROPN
ajlm-1677	236	7	,	,	PUNCT
ajlm-1677	236	8	adjei	adjei	VERB
ajlm-1677	236	9	aa	aa	PROPN
ajlm-1677	236	10	,	,	PUNCT
ajlm-1677	236	11	et	et	PROPN
ajlm-1677	236	12	al	al	PROPN
ajlm-1677	236	13	.	.	PUNCT
ajlm-1677	237	1	hepatitis	hepatitis	PROPN
ajlm-1677	237	2	b	b	PROPN
ajlm-1677	237	3	virus	virus	NOUN
ajlm-1677	237	4	genotypes	genotype	NOUN
ajlm-1677	237	5	among	among	ADP
ajlm-1677	237	6	chronic	chronic	ADJ
ajlm-1677	237	7	hepatitis	hepatitis	NOUN
ajlm-1677	237	8	b	b	PROPN
ajlm-1677	237	9	patients	patient	NOUN
ajlm-1677	237	10	reporting	report	VERB
ajlm-1677	237	11	at	at	ADP
ajlm-1677	237	12	korle	korle	NOUN
ajlm-1677	237	13	-	-	PUNCT
ajlm-1677	237	14	bu	bu	NOUN
ajlm-1677	237	15	teaching	teaching	NOUN
ajlm-1677	237	16	hospital	hospital	NOUN
ajlm-1677	237	17	,	,	PUNCT
ajlm-1677	237	18	accra	accra	PROPN
ajlm-1677	237	19	,	,	PUNCT
ajlm-1677	237	20	ghana	ghana	PROPN
ajlm-1677	237	21	.	.	PUNCT
ajlm-1677	238	1	pan	pan	PROPN
ajlm-1677	238	2	afr	afr	PROPN
ajlm-1677	238	3	med	med	PROPN
ajlm-1677	238	4	j.	j.	PROPN
ajlm-1677	238	5	2016;25(suppl	2016;25(suppl	PROPN
ajlm-1677	238	6	1):5	1):5	PROPN
ajlm-1677	238	7	.	.	PUNCT
ajlm-1677	239	1	https://doi.org/10.11604/pamj.supp.2016.25.1.6170	https://doi.org/10.11604/pamj.supp.2016.25.1.6170	PROPN
ajlm-1677	239	2	shi	shi	PROPN
ajlm-1677	239	3	y	y	PROPN
ajlm-1677	239	4	-	-	PUNCT
ajlm-1677	239	5	h.	h.	NOUN
ajlm-1677	239	6	correlation	correlation	NOUN
ajlm-1677	239	7	between	between	ADP
ajlm-1677	239	8	hepatitis	hepatitis	PROPN
ajlm-1677	239	9	b	b	PROPN
ajlm-1677	239	10	virus	virus	NOUN
ajlm-1677	239	11	genotypes	genotype	NOUN
ajlm-1677	239	12	and	and	CCONJ
ajlm-1677	239	13	clinical	clinical	ADJ
ajlm-1677	239	14	outcomes	outcome	NOUN
ajlm-1677	239	15	.	.	PUNCT
ajlm-1677	240	1	jpn	jpn	PROPN
ajlm-1677	240	2	j	j	PROPN
ajlm-1677	240	3	infect	infect	PROPN
ajlm-1677	240	4	dis	dis	PROPN
ajlm-1677	240	5	.	.	PUNCT
ajlm-1677	241	1	2012;65(6):476–478	2012;65(6):476–478	X
ajlm-1677	241	2	.	.	PUNCT
ajlm-1677	241	3	https://doi.org/10.7883/yoken.65.476	https://doi.org/10.7883/yoken.65.476	PROPN
ajlm-1677	241	4	kramvis	kramvis	PROPN
ajlm-1677	241	5	a.	a.	PROPN
ajlm-1677	241	6	clinical	clinical	ADJ
ajlm-1677	241	7	implications	implication	NOUN
ajlm-1677	241	8	of	of	ADP
ajlm-1677	241	9	hepatitis	hepatitis	PROPN
ajlm-1677	241	10	b	b	PROPN
ajlm-1677	241	11	virus	virus	NOUN
ajlm-1677	241	12	genotypes	genotype	NOUN
ajlm-1677	241	13	and	and	CCONJ
ajlm-1677	241	14	hbeag	hbeag	NOUN
ajlm-1677	241	15	in	in	ADP
ajlm-1677	241	16	pediatrics	pediatric	NOUN
ajlm-1677	241	17	.	.	PUNCT
ajlm-1677	242	1	rev	rev	PROPN
ajlm-1677	242	2	med	med	PROPN
ajlm-1677	242	3	virol	virol	NOUN
ajlm-1677	242	4	.	.	PUNCT
ajlm-1677	243	1	2016;26(4):285–303	2016;26(4):285–303	X
ajlm-1677	243	2	.	.	PUNCT
ajlm-1677	244	1	https://doi.org/10.1002/rmv.1885	https://doi.org/10.1002/rmv.1885	VERB
ajlm-1677	244	2	sunbul	sunbul	NOUN
ajlm-1677	244	3	m.	m.	NOUN
ajlm-1677	244	4	hepatitis	hepatitis	PROPN
ajlm-1677	244	5	b	b	PROPN
ajlm-1677	244	6	virus	virus	NOUN
ajlm-1677	244	7	genotypes	genotype	NOUN
ajlm-1677	244	8	:	:	PUNCT
ajlm-1677	244	9	global	global	ADJ
ajlm-1677	244	10	distribution	distribution	NOUN
ajlm-1677	244	11	and	and	CCONJ
ajlm-1677	244	12	clinical	clinical	ADJ
ajlm-1677	244	13	importance	importance	NOUN
ajlm-1677	244	14	.	.	PUNCT
ajlm-1677	245	1	world	world	PROPN
ajlm-1677	245	2	j	j	PROPN
ajlm-1677	245	3	gastroenterol	gastroenterol	PROPN
ajlm-1677	245	4	.	.	PUNCT
ajlm-1677	246	1	2014;20(18):5427–5434	2014;20(18):5427–5434	NUM
ajlm-1677	246	2	.	.	PUNCT
ajlm-1677	247	1	https://doi.org/10.3748/wjg.v20.i18.5427	https://doi.org/10.3748/wjg.v20.i18.5427	NUM
ajlm-1677	247	2	amini	amini	PROPN
ajlm-1677	247	3	-	-	PUNCT
ajlm-1677	247	4	bavil	bavil	ADJ
ajlm-1677	247	5	-	-	PUNCT
ajlm-1677	247	6	olyaee	olyaee	ADJ
ajlm-1677	247	7	s	s	PROPN
ajlm-1677	247	8	,	,	PUNCT
ajlm-1677	247	9	herbers	herbers	PROPN
ajlm-1677	247	10	u	u	PROPN
ajlm-1677	247	11	,	,	PUNCT
ajlm-1677	247	12	sheldon	sheldon	PROPN
ajlm-1677	247	13	j	j	PROPN
ajlm-1677	247	14	,	,	PUNCT
ajlm-1677	247	15	luedde	luedde	VERB
ajlm-1677	247	16	t	t	PROPN
ajlm-1677	247	17	,	,	PUNCT
ajlm-1677	247	18	trautwein	trautwein	ADV
ajlm-1677	248	1	c	c	X
ajlm-1677	248	2	,	,	PUNCT
ajlm-1677	248	3	tacke	tacke	PROPN
ajlm-1677	248	4	f.	f.	PROPN
ajlm-1677	249	1	the	the	DET
ajlm-1677	249	2	rta194	rta194	PROPN
ajlm-1677	249	3	t	t	PROPN
ajlm-1677	249	4	polymerase	polymerase	NOUN
ajlm-1677	249	5	mutation	mutation	NOUN
ajlm-1677	249	6	impacts	impact	VERB
ajlm-1677	249	7	viral	viral	ADJ
ajlm-1677	249	8	replication	replication	NOUN
ajlm-1677	249	9	and	and	CCONJ
ajlm-1677	249	10	susceptibility	susceptibility	NOUN
ajlm-1677	249	11	to	to	ADP
ajlm-1677	249	12	tenofovir	tenofovir	NOUN
ajlm-1677	249	13	in	in	ADP
ajlm-1677	249	14	hepatitis	hepatitis	PROPN
ajlm-1677	249	15	b	b	PROPN
ajlm-1677	249	16	e	e	X
ajlm-1677	249	17	antigen	antigen	NOUN
ajlm-1677	249	18	-	-	PUNCT
ajlm-1677	249	19	positive	positive	ADJ
ajlm-1677	249	20	and	and	CCONJ
ajlm-1677	249	21	hepatitis	hepatitis	NOUN
ajlm-1677	249	22	b	b	PROPN
ajlm-1677	249	23	e	e	X
ajlm-1677	249	24	antigen	antigen	NOUN
ajlm-1677	249	25	-	-	PUNCT
ajlm-1677	249	26	negative	negative	ADJ
ajlm-1677	249	27	hepatitis	hepatitis	PROPN
ajlm-1677	249	28	b	b	PROPN
ajlm-1677	249	29	virus	virus	NOUN
ajlm-1677	249	30	strains	strain	VERB
ajlm-1677	249	31	.	.	PUNCT
ajlm-1677	250	1	hepatology	hepatology	NOUN
ajlm-1677	250	2	.	.	PUNCT
ajlm-1677	251	1	2009;49(4):1158–1165	2009;49(4):1158–1165	NUM
ajlm-1677	251	2	.	.	PUNCT
ajlm-1677	252	1	https://doi.org/10.1002/hep.22790	https://doi.org/10.1002/hep.22790	NOUN
ajlm-1677	252	2	mahmood	mahmood	PROPN
ajlm-1677	252	3	m	m	PROPN
ajlm-1677	252	4	,	,	PUNCT
ajlm-1677	252	5	anwar	anwar	PROPN
ajlm-1677	252	6	ma	ma	PROPN
ajlm-1677	252	7	.	.	PROPN
ajlm-1677	252	8	analysis	analysis	NOUN
ajlm-1677	252	9	of	of	ADP
ajlm-1677	252	10	resistant	resistant	ADJ
ajlm-1677	252	11	mutations	mutation	NOUN
ajlm-1677	252	12	in	in	ADP
ajlm-1677	252	13	reverse	reverse	ADJ
ajlm-1677	252	14	transcriptase	transcriptase	NOUN
ajlm-1677	252	15	domain	domain	NOUN
ajlm-1677	252	16	of	of	ADP
ajlm-1677	252	17	hepatitis	hepatitis	PROPN
ajlm-1677	252	18	b	b	PROPN
ajlm-1677	252	19	virus	virus	NOUN
ajlm-1677	252	20	from	from	ADP
ajlm-1677	252	21	patients	patient	NOUN
ajlm-1677	252	22	from	from	ADP
ajlm-1677	252	23	islamabad	islamabad	PROPN
ajlm-1677	252	24	,	,	PUNCT
ajlm-1677	252	25	pakistan	pakistan	PROPN
ajlm-1677	252	26	.	.	PUNCT
ajlm-1677	253	1	j	j	PROPN
ajlm-1677	253	2	unexplored	unexplored	ADJ
ajlm-1677	253	3	med	med	PROPN
ajlm-1677	253	4	data	data	PROPN
ajlm-1677	253	5	.	.	PUNCT
ajlm-1677	254	1	2017;2:60–64	2017;2:60–64	NUM
ajlm-1677	254	2	.	.	PROPN
ajlm-1677	255	1	https://doi.org/10.20517/2572-8180.2017.13	https://doi.org/10.20517/2572-8180.2017.13	PROPN
ajlm-1677	255	2	liu	liu	PROPN
ajlm-1677	255	3	y	y	PROPN
ajlm-1677	255	4	,	,	PUNCT
ajlm-1677	255	5	wang	wang	PROPN
ajlm-1677	255	6	cm	cm	PROPN
ajlm-1677	255	7	,	,	PUNCT
ajlm-1677	255	8	cheng	cheng	PROPN
ajlm-1677	255	9	j	j	PROPN
ajlm-1677	255	10	,	,	PUNCT
ajlm-1677	255	11	et	et	PROPN
ajlm-1677	255	12	al	al	PROPN
ajlm-1677	255	13	.	.	PUNCT
ajlm-1677	256	1	hepatitis	hepatitis	PROPN
ajlm-1677	256	2	b	b	PROPN
ajlm-1677	256	3	virus	virus	NOUN
ajlm-1677	256	4	in	in	ADP
ajlm-1677	256	5	tenofovir	tenofovir	ADV
ajlm-1677	256	6	-	-	PUNCT
ajlm-1677	256	7	naive	naive	ADJ
ajlm-1677	256	8	chinese	chinese	ADJ
ajlm-1677	256	9	patients	patient	NOUN
ajlm-1677	256	10	with	with	ADP
ajlm-1677	256	11	chronic	chronic	ADJ
ajlm-1677	256	12	hepatitis	hepatitis	PROPN
ajlm-1677	256	13	b	b	PROPN
ajlm-1677	256	14	contains	contain	VERB
ajlm-1677	256	15	no	no	DET
ajlm-1677	256	16	mutation	mutation	NOUN
ajlm-1677	256	17	of	of	ADP
ajlm-1677	256	18	rta194	rta194	PROPN
ajlm-1677	256	19	t	t	PROPN
ajlm-1677	256	20	conferring	confer	VERB
ajlm-1677	256	21	a	a	DET
ajlm-1677	256	22	reduced	reduce	VERB
ajlm-1677	256	23	tenofovir	tenofovir	NOUN
ajlm-1677	256	24	susceptibility	susceptibility	NOUN
ajlm-1677	256	25	.	.	PUNCT
ajlm-1677	257	1	chin	chin	PROPN
ajlm-1677	257	2	med	med	PROPN
ajlm-1677	257	3	j	j	PROPN
ajlm-1677	257	4	(	(	PUNCT
ajlm-1677	257	5	engl	engl	PROPN
ajlm-1677	257	6	)	)	PUNCT
ajlm-1677	257	7	.	.	PUNCT
ajlm-1677	258	1	2009;122:1585–1586	2009;122:1585–1586	X
ajlm-1677	258	2	.	.	PUNCT
ajlm-1677	258	3	malagnino	malagnino	PROPN
ajlm-1677	258	4	v	v	PROPN
ajlm-1677	258	5	,	,	PUNCT
ajlm-1677	258	6	salpini	salpini	ADJ
ajlm-1677	258	7	r	r	NOUN
ajlm-1677	258	8	,	,	PUNCT
ajlm-1677	258	9	maffongelli	maffongelli	NOUN
ajlm-1677	258	10	g	g	PROPN
ajlm-1677	258	11	,	,	PUNCT
ajlm-1677	258	12	et	et	PROPN
ajlm-1677	258	13	al	al	PROPN
ajlm-1677	258	14	.	.	PROPN
ajlm-1677	258	15	high	high	ADJ
ajlm-1677	258	16	rates	rate	NOUN
ajlm-1677	258	17	of	of	ADP
ajlm-1677	258	18	chronic	chronic	ADJ
ajlm-1677	258	19	hbv	hbv	NOUN
ajlm-1677	258	20	genotype	genotype	NOUN
ajlm-1677	258	21	e	e	NOUN
ajlm-1677	258	22	infection	infection	NOUN
ajlm-1677	258	23	in	in	ADP
ajlm-1677	258	24	a	a	DET
ajlm-1677	258	25	group	group	NOUN
ajlm-1677	258	26	of	of	ADP
ajlm-1677	258	27	migrants	migrant	NOUN
ajlm-1677	258	28	in	in	ADP
ajlm-1677	258	29	italy	italy	PROPN
ajlm-1677	258	30	from	from	ADP
ajlm-1677	258	31	west	west	PROPN
ajlm-1677	258	32	africa	africa	PROPN
ajlm-1677	258	33	:	:	PUNCT
ajlm-1677	258	34	virological	virological	ADJ
ajlm-1677	258	35	characteristics	characteristic	NOUN
ajlm-1677	258	36	associated	associate	VERB
ajlm-1677	258	37	with	with	ADP
ajlm-1677	258	38	poor	poor	ADJ
ajlm-1677	258	39	immune	immune	ADJ
ajlm-1677	258	40	clearance	clearance	NOUN
ajlm-1677	258	41	.	.	PUNCT
ajlm-1677	259	1	plos	plos	PROPN
ajlm-1677	259	2	one	one	NUM
ajlm-1677	259	3	.	.	PUNCT
ajlm-1677	260	1	2018;13(3):e0195045	2018;13(3):e0195045	NUM
ajlm-1677	260	2	.	.	PUNCT
ajlm-1677	260	3	https://doi.org/10.1371/journal.pone.0195045	https://doi.org/10.1371/journal.pone.0195045	ADJ
ajlm-1677	260	4	bivigou	bivigou	NOUN
ajlm-1677	260	5	-	-	PUNCT
ajlm-1677	260	6	mboumba	mboumba	NOUN
ajlm-1677	260	7	b	b	NOUN
ajlm-1677	260	8	,	,	PUNCT
ajlm-1677	260	9	francois	francois	PROPN
ajlm-1677	260	10	-	-	PUNCT
ajlm-1677	260	11	souquiere	souquiere	PROPN
ajlm-1677	260	12	s	s	PROPN
ajlm-1677	260	13	,	,	PUNCT
ajlm-1677	260	14	deleplancque	deleplancque	ADJ
ajlm-1677	260	15	l	l	NOUN
ajlm-1677	260	16	,	,	PUNCT
ajlm-1677	260	17	et	et	PROPN
ajlm-1677	260	18	al	al	PROPN
ajlm-1677	260	19	.	.	PROPN
ajlm-1677	260	20	broad	broad	ADJ
ajlm-1677	260	21	range	range	NOUN
ajlm-1677	260	22	of	of	ADP
ajlm-1677	260	23	hepatitis	hepatitis	PROPN
ajlm-1677	260	24	b	b	PROPN
ajlm-1677	260	25	virus	virus	NOUN
ajlm-1677	260	26	(	(	PUNCT
ajlm-1677	260	27	hbv	hbv	NOUN
ajlm-1677	260	28	)	)	PUNCT
ajlm-1677	260	29	patterns	pattern	NOUN
ajlm-1677	260	30	,	,	PUNCT
ajlm-1677	260	31	dual	dual	ADJ
ajlm-1677	260	32	circulation	circulation	NOUN
ajlm-1677	260	33	of	of	ADP
ajlm-1677	260	34	quasi	quasi	ADJ
ajlm-1677	260	35	-	-	ADJ
ajlm-1677	260	36	subgenotype	subgenotype	ADJ
ajlm-1677	260	37	a3	a3	NOUN
ajlm-1677	260	38	and	and	CCONJ
ajlm-1677	260	39	hbv	hbv	NOUN
ajlm-1677	260	40	/	/	SYM
ajlm-1677	260	41	e	e	NOUN
ajlm-1677	260	42	and	and	CCONJ
ajlm-1677	260	43	heterogeneous	heterogeneous	ADJ
ajlm-1677	260	44	hbv	hbv	NOUN
ajlm-1677	260	45	mutations	mutation	NOUN
ajlm-1677	260	46	in	in	ADP
ajlm-1677	260	47	hiv	hiv	PROPN
ajlm-1677	260	48	-	-	PUNCT
ajlm-1677	260	49	positive	positive	ADJ
ajlm-1677	260	50	patients	patient	NOUN
ajlm-1677	260	51	in	in	ADP
ajlm-1677	260	52	gabon	gabon	PROPN
ajlm-1677	260	53	.	.	PUNCT
ajlm-1677	261	1	plos	plos	PROPN
ajlm-1677	261	2	one	one	NUM
ajlm-1677	261	3	.	.	PUNCT
ajlm-1677	262	1	2016;11(1):e0143869	2016;11(1):e0143869	NUM
ajlm-1677	262	2	.	.	PUNCT
ajlm-1677	263	1	https://doi.org/10.1371/journal.pone.0143869	https://doi.org/10.1371/journal.pone.0143869	PROPN
ajlm-1677	263	2	perazzo	perazzo	PROPN
ajlm-1677	263	3	p	p	X
ajlm-1677	263	4	,	,	PUNCT
ajlm-1677	263	5	eguibar	eguibar	NOUN
ajlm-1677	263	6	n	n	CCONJ
ajlm-1677	263	7	,	,	PUNCT
ajlm-1677	263	8	gonzã¡lez	gonzã¡lez	PROPN
ajlm-1677	263	9	rh	rh	PROPN
ajlm-1677	263	10	,	,	PUNCT
ajlm-1677	263	11	nusblat	nusblat	ADJ
ajlm-1677	263	12	ad	ad	NOUN
ajlm-1677	263	13	,	,	PUNCT
ajlm-1677	263	14	cuestas	cuesta	NOUN
ajlm-1677	263	15	ml	ml	NOUN
ajlm-1677	263	16	.	.	PUNCT
ajlm-1677	264	1	hepatitis	hepatitis	PROPN
ajlm-1677	264	2	b	b	PROPN
ajlm-1677	264	3	virus	virus	NOUN
ajlm-1677	264	4	(	(	PUNCT
ajlm-1677	264	5	hbv	hbv	NOUN
ajlm-1677	264	6	)	)	PUNCT
ajlm-1677	264	7	and	and	CCONJ
ajlm-1677	264	8	s	s	NOUN
ajlm-1677	264	9	-	-	PUNCT
ajlm-1677	264	10	escape	escape	NOUN
ajlm-1677	264	11	perazzo	perazzo	PROPN
ajlm-1677	264	12	p	p	PROPN
ajlm-1677	264	13	mutants	mutant	NOUN
ajlm-1677	264	14	:	:	PUNCT
ajlm-1677	264	15	from	from	ADP
ajlm-1677	264	16	the	the	DET
ajlm-1677	264	17	beginning	beginning	NOUN
ajlm-1677	264	18	until	until	ADP
ajlm-1677	264	19	now	now	ADV
ajlm-1677	264	20	.	.	PUNCT
ajlm-1677	265	1	j	j	PROPN
ajlm-1677	265	2	hum	hum	PROPN
ajlm-1677	265	3	virol	virol	PROPN
ajlm-1677	265	4	retrovirol	retrovirol	PROPN
ajlm-1677	265	5	.	.	PUNCT
ajlm-1677	266	1	2015;2(3):00046	2015;2(3):00046	NUM
ajlm-1677	266	2	.	.	PUNCT
ajlm-1677	267	1	https://doi.org/10.15406/jhvrv.2015.02.00046	https://doi.org/10.15406/jhvrv.2015.02.00046	VERB
ajlm-1677	267	2	caligiuri	caligiuri	NOUN
ajlm-1677	267	3	p	p	PROPN
ajlm-1677	267	4	,	,	PUNCT
ajlm-1677	267	5	cerruti	cerruti	PROPN
ajlm-1677	267	6	r	r	NOUN
ajlm-1677	267	7	,	,	PUNCT
ajlm-1677	267	8	icardi	icardi	PROPN
ajlm-1677	267	9	g	g	PROPN
ajlm-1677	267	10	,	,	PUNCT
ajlm-1677	267	11	bruzzone	bruzzone	PROPN
ajlm-1677	267	12	b.	b.	PROPN
ajlm-1677	267	13	overview	overview	NOUN
ajlm-1677	267	14	of	of	ADP
ajlm-1677	267	15	hepatitis	hepatitis	PROPN
ajlm-1677	267	16	b	b	PROPN
ajlm-1677	267	17	virus	virus	NOUN
ajlm-1677	267	18	mutations	mutation	NOUN
ajlm-1677	267	19	and	and	CCONJ
ajlm-1677	267	20	their	their	PRON
ajlm-1677	267	21	implications	implication	NOUN
ajlm-1677	267	22	in	in	ADP
ajlm-1677	267	23	the	the	DET
ajlm-1677	267	24	management	management	NOUN
ajlm-1677	267	25	of	of	ADP
ajlm-1677	267	26	infection	infection	NOUN
ajlm-1677	267	27	.	.	PUNCT
ajlm-1677	268	1	world	world	PROPN
ajlm-1677	268	2	j	j	PROPN
ajlm-1677	268	3	gastroenterol	gastroenterol	PROPN
ajlm-1677	268	4	.	.	PUNCT
ajlm-1677	269	1	2016;22(1):145–154	2016;22(1):145–154	NOUN
ajlm-1677	269	2	.	.	PUNCT
ajlm-1677	270	1	https://doi.org/10.3748/wjg.v22.i1.145	https://doi.org/10.3748/wjg.v22.i1.145	PROPN
ajlm-1677	270	2	sheldon	sheldon	PROPN
ajlm-1677	270	3	j	j	PROPN
ajlm-1677	270	4	,	,	PUNCT
ajlm-1677	270	5	ramos	ramos	PROPN
ajlm-1677	270	6	b	b	PROPN
ajlm-1677	270	7	,	,	PUNCT
ajlm-1677	270	8	garcia	garcia	PROPN
ajlm-1677	270	9	-	-	PUNCT
ajlm-1677	270	10	samaniego	samaniego	PROPN
ajlm-1677	270	11	j	j	PROPN
ajlm-1677	270	12	,	,	PUNCT
ajlm-1677	270	13	et	et	PROPN
ajlm-1677	270	14	al	al	PROPN
ajlm-1677	270	15	.	.	PROPN
ajlm-1677	270	16	selection	selection	NOUN
ajlm-1677	270	17	of	of	ADP
ajlm-1677	270	18	hepatitis	hepatitis	PROPN
ajlm-1677	270	19	b	b	PROPN
ajlm-1677	270	20	virus	virus	NOUN
ajlm-1677	270	21	(	(	PUNCT
ajlm-1677	270	22	hbv	hbv	NOUN
ajlm-1677	270	23	)	)	PUNCT
ajlm-1677	270	24	vaccine	vaccine	NOUN
ajlm-1677	270	25	escape	escape	VERB
ajlm-1677	270	26	mutants	mutant	NOUN
ajlm-1677	270	27	in	in	ADP
ajlm-1677	270	28	hbv	hbv	NOUN
ajlm-1677	270	29	-	-	PUNCT
ajlm-1677	270	30	infected	infect	VERB
ajlm-1677	270	31	and	and	CCONJ
ajlm-1677	270	32	hbv	hbv	NOUN
ajlm-1677	270	33	/	/	SYM
ajlm-1677	270	34	hiv	hiv	PROPN
ajlm-1677	270	35	-	-	PUNCT
ajlm-1677	270	36	coinfected	coinfecte	VERB
ajlm-1677	270	37	patients	patient	NOUN
ajlm-1677	270	38	failing	fail	VERB
ajlm-1677	270	39	antiretroviral	antiretroviral	ADJ
ajlm-1677	270	40	drugs	drug	NOUN
ajlm-1677	270	41	with	with	ADP
ajlm-1677	270	42	anti	anti	ADJ
ajlm-1677	270	43	-	-	ADJ
ajlm-1677	270	44	hbv	hbv	ADJ
ajlm-1677	270	45	activity	activity	NOUN
ajlm-1677	270	46	.	.	PUNCT
ajlm-1677	271	1	j	j	PROPN
ajlm-1677	271	2	acquir	acquir	PROPN
ajlm-1677	271	3	immune	immune	VERB
ajlm-1677	271	4	defic	defic	ADJ
ajlm-1677	271	5	syndr	syndr	NOUN
ajlm-1677	271	6	.	.	PUNCT
ajlm-1677	272	1	2007;46(3):279–282	2007;46(3):279–282	NUM
ajlm-1677	272	2	.	.	PUNCT
ajlm-1677	273	1	https://doi.org/10.1097/qai.0b013e318154bd89	https://doi.org/10.1097/qai.0b013e318154bd89	ADP
ajlm-1677	273	2	salpini	salpini	PROPN
ajlm-1677	273	3	r	r	PROPN
ajlm-1677	273	4	,	,	PUNCT
ajlm-1677	273	5	colagrossi	colagrossi	ADJ
ajlm-1677	273	6	l	l	NOUN
ajlm-1677	273	7	,	,	PUNCT
ajlm-1677	273	8	bellocchi	bellocchi	PROPN
ajlm-1677	273	9	mc	mc	PROPN
ajlm-1677	273	10	,	,	PUNCT
ajlm-1677	273	11	et	et	PROPN
ajlm-1677	273	12	al	al	PROPN
ajlm-1677	273	13	.	.	PUNCT
ajlm-1677	274	1	hepatitis	hepatitis	PROPN
ajlm-1677	274	2	b	b	PROPN
ajlm-1677	274	3	surface	surface	NOUN
ajlm-1677	274	4	antigen	antigen	ADJ
ajlm-1677	274	5	genetic	genetic	ADJ
ajlm-1677	274	6	elements	element	NOUN
ajlm-1677	274	7	critical	critical	ADJ
ajlm-1677	274	8	for	for	ADP
ajlm-1677	274	9	immune	immune	ADJ
ajlm-1677	274	10	escape	escape	NOUN
ajlm-1677	274	11	correlate	correlate	ADJ
ajlm-1677	274	12	with	with	ADP
ajlm-1677	274	13	hepatitis	hepatitis	PROPN
ajlm-1677	274	14	b	b	PROPN
ajlm-1677	274	15	virus	virus	NOUN
ajlm-1677	274	16	reactivation	reactivation	NOUN
ajlm-1677	274	17	upon	upon	SCONJ
ajlm-1677	274	18	immunosuppression	immunosuppression	NOUN
ajlm-1677	274	19	.	.	PUNCT
ajlm-1677	275	1	hepatology	hepatology	NOUN
ajlm-1677	275	2	.	.	PUNCT
ajlm-1677	276	1	2015;61(3):823–833	2015;61(3):823–833	X
ajlm-1677	276	2	.	.	PUNCT
ajlm-1677	277	1	https://doi.org/10.1002/hep.27604	https://doi.org/10.1002/hep.27604	PROPN
ajlm-1677	277	2	cao	cao	PROPN
ajlm-1677	277	3	gw	gw	PROPN
ajlm-1677	277	4	.	.	PUNCT
ajlm-1677	278	1	clinical	clinical	ADJ
ajlm-1677	278	2	relevance	relevance	NOUN
ajlm-1677	278	3	and	and	CCONJ
ajlm-1677	278	4	public	public	ADJ
ajlm-1677	278	5	health	health	NOUN
ajlm-1677	278	6	significance	significance	NOUN
ajlm-1677	278	7	of	of	ADP
ajlm-1677	278	8	hepatitis	hepatitis	PROPN
ajlm-1677	278	9	b	b	PROPN
ajlm-1677	278	10	virus	virus	NOUN
ajlm-1677	278	11	genomic	genomic	NOUN
ajlm-1677	278	12	variations	variation	NOUN
ajlm-1677	278	13	.	.	PUNCT
ajlm-1677	279	1	world	world	PROPN
ajlm-1677	279	2	j	j	PROPN
ajlm-1677	279	3	gastroenterol	gastroenterol	PROPN
ajlm-1677	279	4	.	.	PUNCT
ajlm-1677	280	1	2009;15(46):5761–5769	2009;15(46):5761–5769	NOUN
ajlm-1677	280	2	.	.	PUNCT
ajlm-1677	281	1	https://doi.org/10.3748/wjg.15.5761	https://doi.org/10.3748/wjg.15.5761	PROPN
ajlm-1677	281	2	zeid	zeid	PROPN
ajlm-1677	281	3	wma	wma	PROPN
ajlm-1677	281	4	,	,	PUNCT
ajlm-1677	281	5	ramadan	ramadan	PROPN
ajlm-1677	281	6	di	di	PROPN
ajlm-1677	281	7	,	,	PUNCT
ajlm-1677	281	8	shemis	shemis	PROPN
ajlm-1677	281	9	ma	ma	PROPN
ajlm-1677	281	10	.	.	PROPN
ajlm-1677	281	11	prevalence	prevalence	NOUN
ajlm-1677	281	12	of	of	ADP
ajlm-1677	281	13	mutations	mutation	NOUN
ajlm-1677	281	14	within	within	ADP
ajlm-1677	281	15	major	major	ADJ
ajlm-1677	281	16	hydrophilic	hydrophilic	ADJ
ajlm-1677	281	17	region	region	NOUN
ajlm-1677	281	18	of	of	ADP
ajlm-1677	281	19	hepatitis	hepatitis	PROPN
ajlm-1677	281	20	b	b	PROPN
ajlm-1677	281	21	virus	virus	NOUN
ajlm-1677	281	22	and	and	CCONJ
ajlm-1677	281	23	their	their	PRON
ajlm-1677	281	24	correlation	correlation	NOUN
ajlm-1677	281	25	with	with	ADP
ajlm-1677	281	26	genotypes	genotype	NOUN
ajlm-1677	281	27	among	among	ADP
ajlm-1677	281	28	chronically	chronically	ADV
ajlm-1677	281	29	infected	infected	ADJ
ajlm-1677	281	30	patients	patient	NOUN
ajlm-1677	281	31	in	in	ADP
ajlm-1677	281	32	egypt	egypt	PROPN
ajlm-1677	281	33	.	.	PUNCT
ajlm-1677	282	1	arab	arab	PROPN
ajlm-1677	282	2	j	j	PROPN
ajlm-1677	282	3	gastroenterol	gastroenterol	PROPN
ajlm-1677	282	4	.	.	PUNCT
ajlm-1677	283	1	2016;17(1):34–40	2016;17(1):34–40	X
ajlm-1677	283	2	.	.	PUNCT
ajlm-1677	283	3	https://doi.org/10.1016/j.ajg.2016.03.001	https://doi.org/10.1016/j.ajg.2016.03.001	VERB
ajlm-1677	283	4	launay	launay	NOUN
ajlm-1677	283	5	o	o	NOUN
ajlm-1677	283	6	,	,	PUNCT
ajlm-1677	283	7	masurel	masurel	PROPN
ajlm-1677	283	8	j	j	PROPN
ajlm-1677	283	9	,	,	PUNCT
ajlm-1677	283	10	rosenberg	rosenberg	PROPN
ajlm-1677	283	11	ra	ra	PROPN
ajlm-1677	283	12	,	,	PUNCT
ajlm-1677	283	13	et	et	PROPN
ajlm-1677	283	14	al	al	PROPN
ajlm-1677	283	15	.	.	PROPN
ajlm-1677	283	16	high	high	ADJ
ajlm-1677	283	17	levels	level	NOUN
ajlm-1677	283	18	of	of	ADP
ajlm-1677	283	19	serum	serum	PROPN
ajlm-1677	283	20	hepatitis	hepatitis	PROPN
ajlm-1677	283	21	b	b	PROPN
ajlm-1677	283	22	virus	virus	NOUN
ajlm-1677	283	23	dna	dna	PROPN
ajlm-1677	283	24	in	in	ADP
ajlm-1677	283	25	patients	patient	NOUN
ajlm-1677	283	26	with	with	ADP
ajlm-1677	283	27	‘	'	PUNCT
ajlm-1677	283	28	anti	anti	ADJ
ajlm-1677	283	29	-	-	ADJ
ajlm-1677	283	30	hbc	hbc	ADJ
ajlm-1677	283	31	alone	alone	ADV
ajlm-1677	283	32	’	'	PUNCT
ajlm-1677	283	33	:	:	PUNCT
ajlm-1677	283	34	role	role	NOUN
ajlm-1677	283	35	of	of	ADP
ajlm-1677	283	36	hbsag	hbsag	ADJ
ajlm-1677	283	37	mutants	mutant	NOUN
ajlm-1677	283	38	.	.	PUNCT
ajlm-1677	284	1	j	j	PROPN
ajlm-1677	284	2	viral	viral	ADJ
ajlm-1677	284	3	hepat	hepat	NOUN
ajlm-1677	284	4	.	.	PUNCT
ajlm-1677	285	1	2011;8(10):721–729	2011;8(10):721–729	NUM
ajlm-1677	285	2	.	.	PUNCT
ajlm-1677	286	1	https://doi.org/10.1111/j.1365-2893.2011.01482.x	https://doi.org/10.1111/j.1365-2893.2011.01482.x	PROPN